European Journal of Medicinal Chemistry 145 (2018) 634–648

Contents lists available at ScienceDirect

European Journal of Medicinal Chemistry

journal homepage: http://www.elsevier.com/locate/ejmech

Research paper

A focused fragment library targeting the antibiotic resistance enzyme - Oxacillinase-48: Synthesis, structural evaluation and inhibitor design

Sundus Akhter [a, 1], Bjarte Aarmo Lund [b, 1], Aya Ismael [a], Manuel Langer [a], Johan Isaksson [a], Tony Christopeit [b], Hanna-Kirsti S. Leiros [b, **], Annette Bayer [a, *]

[a] Department of Chemistry, Faculty of Science and Technology, UiT- The Arctic University of Norway, N-9037 Tromsø, Norway
[b] The Norwegian Structural Biology Centre (NorStruct), Department of Chemistry, Faculty of Science and Technology, UiT-The Arctic University of Norway, N-9037 Tromsø, Norway

ARTICLE INFO

Article history:
Received 6 July 2017
Received in revised form
24 December 2017
Accepted 26 December 2017
Available online 30 December 2017

Keywords:
Crystal structure
Inhibition properties
Benzoic acid derivatives
Serine-β-lactamase inhibitors
Fragments
Structure-guided drug design

ABSTRACT

β-Lactam antibiotics are of utmost importance when treating bacterial infections in the medical community. However, currently their utility is threatened by the emergence and spread of β-lactam resistance. The most prevalent resistance mechanism to β-lactam antibiotics is expression of β-lactamase enzymes. One way to overcome resistance caused by β-lactamases, is the development of β-lactamase inhibitors and today several β-lactamase inhibitors e.g. avibactam, are approved in the clinic. Our focus is the oxacillinase-48 (OXA-48), an enzyme reported to spread rapidly across the world and commonly identified in *Escherichia coli* and *Klebsiella pneumoniae*. To guide inhibitor design, we used diversely substituted 3-aryl and 3-heteroaryl benzoic acids to probe the active site of OXA-48 for useful enzyme-inhibitor interactions. In the presented study, a focused fragment library containing 49 3-substituted benzoic acid derivatives were synthesised and biochemically characterized. Based on crystallographic data from 33 fragment-enzyme complexes, the fragments could be classified into R^1 or R^2 binders by their overall binding conformation in relation to the binding of the R^1 and R^2 side groups of imipenem. Moreover, binding interactions attractive for future inhibitor design were found and their usefulness explored by the rational design and evaluation of merged inhibitors from orthogonally binding fragments. The best inhibitors among the resulting 3,5-disubstituted benzoic acids showed inhibitory potential in the low micromolar range ($IC_{50} = 2.9\ \mu M$). For these inhibitors, the complex X-ray structures revealed non-covalent binding to Arg250, Arg214 and Tyr211 in the active site and the interactions observed with the mono-substituted fragments were also identified in the merged structures.

1. Introduction

Years of overuse of antibiotics have selected for antibiotic resistant strains [1], and today medical personnel are frequently forced to administer last-resort antibiotics. However, the number of cases where last-resort antibiotics fail in treatment are increasing [2] and deaths due to antibiotic resistant infections are expected to surpass cancer deaths by 2050 [3]. Bacterial resistance towards clinically important β-lactam antibiotics [4] like penicillins, cephalosporins and carbapenems originates most often from the occurrence of β-lactam-hydrolysing enzymes – the β-lactamases.

The β-lactamase enzymes are of ancient origin [5] and today over 2600 enzymes spanning four classes of β-lactamases are known [6–8]. β-Lactamases are grouped into two super families based on the enzyme mechanism for β-lactam hydrolysis: the serine dependent β-lactamases (SBLs; Amber class A, C, and D) and metallo-β-lactamases (MBLs; Amber class B) [7,9]. SBLs are characterized by a serine residue in the active site, while MBLs require a metal co-factor, usually one or two zinc ions, for enzyme activity. This work focuses on the class D SBLs – also called oxacillinases (OXAs) – and in particular on the oxacillinase-48 (OXA-48).

Abbreviations: DMSO, dimethyl sulfoxide; OXA, oxacillinase; IC_{50}, half maximal inhibitory concentration; LE, ligand efficiency; MBL, metallo-β-lactamase; NMR, nuclear magnetic resonance; SBL, serine-β-lactamase; SPR, surface plasmon resonance.

* Corresponding author.
** Corresponding author.
E-mail addresses: hanna-kirsti.leiros@uit.no (H.-K.S. Leiros), annette.bayer@uit.no (A. Bayer).

[1] These authors have contributed equally to this work.

https://doi.org/10.1016/j.ejmech.2017.12.085
0223-5234/

The class D SBLs are characterized by a hydrophobic environment in the active site, that facilitates the carboxylation of a lysine residue. The *N*-carboxylated lysine plays a critical role in the substrate hydrolysis [10]. Originally, the OXAs were believed to have a limited substrate profile only hydrolysing penicillins, but with the emergence of carbapenem-hydrolysing OXA variants, e.g. OXA-23, OXA-24 and OXA-48, their clinical relevance has increased [11]. OXA-48 was reported for the first time in 2001 and has since then spread rapidly across the world [11]. It is commonly identified in *Escherichia coli* and *Klebsiella pneumoniae.*

One strategy to circumvent resistance in β-lactamase producing pathogens is the use of β-lactamases inhibitors [4,12] in combination with the β-lactam antibiotic. Inhibitors of class A SBLs like clavulanic acid, sulbactam and tazobactam became clinically available from the 1980s [13], but only a few class D β-lactamases are inhibited by these β-lactamase inhibitors e.g. OXA-2 and OXA-18 [14]. In 2015, a new SBL inhibitor, avibactam, targeting class A, C and some class D SBLs, including OXA-48, was approved by the FDA for treatment of complicated urinary tract and intra-abdominal infections [15]. However, the inhibition level of different class D β-lactamases by avibactam varies [16,17]. With the first reports of resistance to avibactam published [18], one can speculate that it will only be a matter of time before class D β-lactamases show resistance to avibactam as well.

The development of new OXA inhibitors, either with a different enzyme-inhibition profile compared to existing inhibitors, or as alternative when resistance to existing inhibitors arises, is of importance. We have previously reported a fragment-based screening approach to identify weak inhibitors of OXA-48 [19]. The most interesting hit was 3-(pyridin-4-yl)benzoic acid **1** with an IC_{50} of 250 μM and a ligand efficiency (LE) of 0.32. Crystallographic data from enzyme-fragment complexes indicated two overlapping binding conformations of the fragment. Merging of the two conformations of **1** into one molecule **2** (Fig. 1) gave a 10-fold increase in binding affinity improving the IC_{50} from 250 μM to 18 μM [19].

In this study, we describe the use of small mono-substituted fragments - analogues of fragment **1** - as probes to explore the OXA-48 binding site. The aim was to identify fragment-enzyme interactions in the two alternate binding pockets of the active site of OXA-48, which could be of general interest for the design of OXA-48 inhibitors. We wanted to exploit the ability of small fragments to efficiently explore the binding pocket as they are less restricted by size and more flexible compared to more elaborated inhibitors. Moreover, the smaller fragments generally have the advantage of being more easily prepared making the discovery process more work-efficient. Furthermore, we wanted to translate the knowledge gained into the rational design of di-substituted inhibitors related to compound **2** circumventing the laborious preparation of a large library of elaborated inhibitors.

Towards this goal, we prepared a focused fragment library containing 3-aryl benzoic acids decorated with a wide range of polar groups and a number of 3-heteroaryl benzoic acid derivatives. In total 49 fragments were tested for inhibitory activity against OXA-48 and the binding conformations of 33 fragment-enzyme complexes were analyzed by X-ray crystallography. Based on the structural information, fragments could be classified according to their preferred binding pocket and useful fragment-enzyme interactions e.g. hydrogen bonds were identified. Moreover, several new orthogonally binding fragments were found leading to the design of symmetrically and unsymmetrically di-substituted inhibitors with improved IC_{50} in the low micromolar range. The structural data from enzyme-inhibitor complexes was compared with enzyme-fragment complexes.

2. Results and discussion

2.1. Synthesis

2.1.1. Synthesis of 3-substituted benzoic acids

A fragment library containing 49 3-substituted benzoic acid analogues **3a**–**35** was prepared (Table 1). The fragments generally fulfilled the demands of libraries for fragment-based ligand design (MW < 300, clogP < 3, hydrogen bond acceptor/donors < 3) [20]. For the synthesis, a strategy based on the Suzuki-Miyaura (SM) cross-coupling reaction to join two sp^2–hybridized carbons was employed [21]. Two alternate coupling strategies were successful starting with either 3-bromobenzoic acid (Table 1, strategy A) or 3-carboxyphenylboronic acid pinacol ester (Table 1, strategy B) as starting materials allowing for the utilisation of a wide range of aryl boronic acids or aryl bromides to introduce diversity in the library.

Many of the required aryl boronic acids and bromides were commercial available, while the aryl bromides used as starting materials for fragments **17**–**20**, **24**, **29** and **30** were prepared according to standard acylation and sulphonylation protocols. The *N*H-tetrazol-5-yl-substituted arylbromides (starting material for fragments **26a** and **26b**) were prepared by a [3 + 2] intermolecular cycloaddition of 3- or 4-bromobenzonitrile with trimethyl silyl azide in the presence of dibutyltin oxide in anhydrous 1,4-dioxane. The reaction mixture was subjected to microwave irradiation in a tightly sealed vessel for 50 min at 150 °C to afford 3- or 4-bromobenzotetrazole in 86% and 82% yield, respectively.

In general, couplings under standard aqueous conditions using $PdCl_2(PPh_3)_2$ as catalyst (5–10 mol%), K_3PO_4 as base (5 equiv.) in dioxane/water gave good yields. The couplings leading to fragments **9**, **17**–**20** and **22**–**24** were not successful under these standard conditions. More efficient catalysts (XPhos-Pd G2 or $PdCl_2$(dppf)) and water-free conditions (anhydrous THF instead of dioxane/water) were successfully employed to solve reactivity and solubility problems and to prevent hydrolysis for base sensitive products (**9** and **24**). However, for some products (**19a, 19b** and **20**) the yields were still low (<20%). Generally, the reactions were easily purified by automated C18 flash chromatography to provide compounds of high purity (>95% as determined by UHPLC). For some compounds (**15**, **16**, **19**, **23**, **24**, **32** and **34**), additional silica flash chromatography was necessary to provide sufficiently pure products.

2.1.2. Synthesis of 3,5-disubstituted benzoic acid derivatives

To study inhibitor properties like activity and enzyme interactions of merged fragments, a small series of symmetrical and unsymmetrical 3,5-disubstituted benzoic acids was designed (*vide infra*) and prepared. The synthesis of symmetrical 3,5-disubstituted compounds **36** and **38** was achieved under the conditions established for the coupling of mono-substituted fragments using $Pd_2(dba)_3$/XPhos or XPhos-Pd G2 as catalysts (Scheme 1) [19]. The di-substituted coupling products **36** and **38** were obtained from 3,5-dibromobenzoic acid as starting material and an increased amount of the boronic acid derivative (2 equiv.) in 54% and 65% yield, respectively. Compound **37** was isolated in 11% yield as by-product in an attempt to selectively mono-substituted 3,5-dibromobenzoic acid (*vide infra*).

For the synthesis of unsymmetrical 3,5-disubstituted benzoic acids **39**, the sequential addition of two different aryl boronic acids under the previously established conditions gave only 15% isolated yield (Scheme 2). In addition, the procedure involved tedious HPLC purifications as the reaction mixture was difficult to purify due to occurrence of symmetrical by-products with similar properties. To improve the selectivity of the reaction, we changed the starting material from 3,5-dibromobenzoic acid to 3-iodo-5-bromobenzoic



Fig. 1. The two alternate conformations of fragment **1** (light grey) in complex with OXA-48 (dark grey surface) (A and B), the merged compound **2** (pink) in complex with OXA-48 (dark grey surface) (C), and a schematic view of the merging approach described in previous work (D) [19]. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

acid in order to take advantage of the faster coupling reaction of aryl iodides when compared with aryl bromides and thereby to prevent formation of symmetrical disubstituted by-products (Scheme 2). Investigation of the chemoselective coupling of 3-iodo-5-bromobenzoic acid with quinolin-6ylboronic acid pinacol ester to form mono-substituted **int-40** showed that a second, unwanted coupling was not easily prevented and a careful fine tuning of catalyst (RuPhos-Pd G3, XantPhos-Pd G3, Sphos/Pd_2 $(dba)_3$, Xphos/Pd_2 $(dba)_3$, SPhos-Pd G3, XPhos-Pd G2, Pd_2 $(dppf)Cl_2$), solvent (toluene/water, anhydrous THF, dioxane/water, *tert*-butanol), reaction temperature (40–80 °C) and time (10–48 h) was initiated (Table SI1, see Supporting information). The composition of the crude reaction mixtures with respect to mono- and disubstituted products as well as unreacted starting material was determined by mass spectrometry (MS). The most chemoselective catalysts were XantPhos-Pd G3, Pd_2 $(dppf)Cl_2$ and SPhos/Pd_2 $(dba)_3$ showing good selectivity for the aryl iodide when the reaction was performed with K_3PO_4 as base in dioxane/water at 60 °C for 24 h (Scheme 2). At this conditions with SPhos/Pd_2 $(dba)_3$ as catalyst, the mono-substituted intermediate **int-40** was obtained as main product together with small amounts of the disubstituted by-product (8–10%). Careful purification to remove any traces of the disubstituted compound provided **int-40** in moderate yield (45%). The mono-substituted **int-40** was further subjected to a second coupling with XPhos-Pd G2 (5 mol%) as catalyst to provide **40** in good yields (90%).

2.2. Evaluation of 3-substituted benzoic acids

2.2.1. Inhibitor activity of 3-substituted benzoic acids

The mono-substituted fragments **3**–**35** were initially investigated for their inhibitory activity against OXA-48 in an enzymatic assay and by SPR. Inhibition and binding data are given in Table 1 along with the associated ligand efficiencies (LE). The original hit fragment **1** had an IC_{50} of 250 μM and an LE of 0.32. Most of the fragments in this study showed inhibition at a similar level with $IC_{50} > 200$ μM and LE ≤ 0.30. Fragments **4a** (IC_{50} (μM)/LE: 50/0.38), **18** (IC_{50} (μM)/LE: 60/0.24), **21a** (IC_{50} (μM)/LE: 35/0.33), **26b** (IC_{50} (μM)/LE: 36/0.30) and **35** (IC_{50} (μM)/LE: 35/0.42) showed an order of magnitude stronger inhibition and were the most potent fragments. Even though there are some discrepancies between the inhibition and binding data, the same trends are maintained when comparing similar compounds, indicating that the compounds indeed bind specifically to one site of the enzyme.

2.2.2. Structural analysis of 3-substituted benzoic acids

To evaluate the binding poses of our fragments, enzyme-fragment complexes for x-ray crystallographic analysis were prepared. Rewardingly, 33 out of 49 fragments were successfully soaked with OXA-48 and yielded crystal structures with resolution high enough to warrant placement of the inhibitor in the electron density (Table 1). In addition, a crystal structure of OXA-48 in complex with the substrate imipenem was obtained to better understand substrate binding and to compare substrate and fragment binding interactions.

The crystal structure of the acyl-enzyme complex of OXA-48 with imipenem (Fig. 2A) revealed a conformation close to previously observed conformations with OXA-13 (PDB-ID: 1h5x). In the complex the ring-opened imipenem was bound to OXA-48 covalently with continuous electron density from the hydroxyl group of Ser70. There was an ionic bond from the carboxylate group of imipenem to the guanidine group of Arg250. The carbonyl-group of the now ring-opened β-lactam ring was positioned in the oxyanion-hole forming hydrogen bonds to the main chain amides of Tyr211 and Ser70. The 6α-hydroxyethyl group (R^1) of imipenem was positioned towards the hydrophobic residues Trp105, Val120 and Leu158 and in the following discussion this region will be called the R^1 site. The amidine group (R^2) was situated in the cleft defined by Ile102, Tyr211, Leu247 and Thr213 and this region will be called the R^2 site. The R^1 and R^2 side chains of imipenem (Fig. 2A) had the same overall directions as the pyridinyl substituents in the two overlapping binding conformations observed with our initial hit 3-pyridin-4-ylbenzoic acid **1** [19].

In all our structures of OXA-48 in complex with fragments, an ionic bond between the carboxylate group of the fragments and the guanidine group of Arg250 was observed, which resembled the interaction of the carboxylate group of imipenem or the sulfamate group of avibactam with Arg250 [17,22]. In some cases, the carboxylate group was oriented in such a way that also Thr209 (fragments **9b**, **28, 35**), Lys208 (fragment **34**) or both (fragment **26a**) participated in binding.

Another common feature found in almost all crystal structures, except for fragments **21a** and **26b**, was a π-π stacking interaction of the 3-aryl substituents attached to the benzoic acid scaffold with Tyr211. This is consistent with the binding of imipenem, where the R_2 side chain was oriented towards Tyr211 (Fig. 2C). The importance of Tyr211 as a non-polar patch that contributes in binding substrate side-chains has been recognised before [23]. We also observed this interaction with our unsubstituted pyridyl benzoic acids previously [19].

The weaker binding fragments (**3a, 3b**, **4a**–**c**, **5**, **6a**–**c**, **8a**–**c**, **9b**, **11b**, **12a**, **13**, **14**, **17**, **24**) all bound in nearly the same conformation with the ionic bond of the benzoic acid and Arg250 and the π-π stacking interaction with Tyr211 as major interactions. In these structures, the 3-aryl substituent on the benzoic acid was directed towards the R_2 pocket (Fig. 2C). Only minor conformational differences were observed as described in the following. To help the reader in the following discussion, we will describe the fragments by the identity of the Ar groups (Table 1), as the structural differences of the fragments relate to this group *i.e.* 3-(2-methyl)

Table 1
Preparation strategy and inhibitor activities of a library of 3-substituted benzoic acids analogues against OXA-48 (IC_{50}, K_d and LE).



Comp. ID	Ar =	Strateg. Yield	IC_{50} (μM)	K_D (μM)	LE[d]	Comp. ID	Ar =	Strateg. Yield	IC_{50} (μM)	K_D (μM)	LE[d]
3a*		B 78%	90	170	0.35	**11b***		A 97%	180	350	0.29
3b*		B 67%	170	300	0.33	**12a***		A 82%	120	150	0.29
4a*		A 94%	50	175	0.38	**12b**		A 90%	380	361	0.25
4b*		A 98%	110	110	0.35	**13***		B 35%	330	330	0.29
4c*		A 39%	470	170	0.29	**14***		A 95%	390	220	0.27
5*		A 84%	900	230	0.25	**15a**		B 36%	600	800	0.27
6a*		A 98%	250	123	0.30	**15b**		B 86%	1400	550	0.23
6b*		A 98%	360	226	0.28	**16a**		B 15%	110	300	0.31
6c*		A 86%	150	250	0.31	**16b**		B 67%	1000	970	0.23
7		A 91%	400	1000	0.28	**17***		B[a, c] 41%	370	100	0.24
8a*		A 68%	130	170	0.34	**18**		B[a, c] 65%	60	210	0.24
8b*		A 98%	130	240	0.34	**19a**		B[a, c] 26%	110	110	0.26
8c*		A 78%	360	312	0.30	**19b**		B[a, c] 10%	450	240	0.22
9a		A[a, c] 57%	210	200	0.27	**20**		B[a, c] 11%	370	200	0.22
9b*		A 54%	260	144	0.26	**21a***		A 98%	35	100	0.33
10		A 98%	380	280	0.27	**21b***		A 98%	450	290	0.25
11a		A 98%	260	220	0.28	**22**		B[a, b] 87%	130	130	0.27
23a		B[a, c] 46%	230	170	0.24	**29**		B 36%	170	130	0.33
23b		B[a, c] 34%	520	190	0.22	**30**		B 45%	800	900	0.29

(*continued on next page*)

Table 1 (*continued*)

Comp. ID	Ar =	Strateg. Yield	IC_{50} (μM)	K_D (μM)	LE[d]	Comp. ID	Ar =	Strateg. Yield	IC_{50} (μM)	K_D (μM)	LE[d]
24*		A[a, b] 34%	250	140	0.25	**31**		B 67%	350	113	0.28
25		B 15%	1300	>1000	0.20	**32**		A 6%	500	590	0.31
26a*		B 98%	60	70	0.30	**33**		B 24%	800	900	0.31
26b		B 98%	36	70	0.30	**34**		B 20%	310	400	0.27
27*		B 67%	110	400	0.30	**35***		A 98%	35	159	0.42
28*		B 87%	240	160	0.27						

*X-ray structure of fragment-enzyme complex available. [a] Reaction in anhydrous THF instead of dioxane:water as solvent; [b] XPhos-Pd G2 as catalyst instead of $PdCl_2(PPh_3)_2$; [c] $PdCl_2$(dppf) as catalyst instead of $PdCl_2(PPh_3)_2$. [d] LE = $(-1.4 * \log_{10}IC_{50})$/HeavyAtomCount, with units kcal/(mol per heavy atom).



Scheme 1. Preparation of symmetrical 3,5-disubstituted benzoic acids. Reagents and conditions: **36**: 3-acetamidophenylboronic acid (1.5 equiv.), $Pd_2(dba)_3$•$CHCl_3$ (5 mol%), XPhos (5 mol%), dioxane:water (1:1), 60 °C, 54%; **37**: 4-acetamidophenylboronic acid (0.75 equiv.), $PdCl_2(PPh_3)_2$ (10 mol%), dioxane:water (1:1), 95 °C, 11%; **38**: quinolin-6-ylboronic acid pinacol ester (2.0 equiv.), XPhos-Pd G2 (5 mol%), *tert*-butanol, 60 °C, 65%.

phenylbenzoic acid **3a** will be described as 2-methylphenyl substituted fragment.

The methylphenyl substituted fragments **3a** (IC_{50} (μM)/LE: 90/0.35) and **3b** (IC_{50} (μM)/LE: 170/0.33) had similar conformations, however, the 2-methyl group in **3a** was facing towards the hydrophobic C^{β} of Ser244 explaining the more favourable binding. Fragments **4a**–**c** (IC_{50} (μM)/LE: 50/0.38, 110/0.35 and 470/0.29, respectively) also had very similar conformations, but again we saw that more favourable van der Waals interactions gave higher affinity for the 2-hydroxyphenyl substituted **4a**. The 4-hydroxy isomer **4c** had an unfavourable solvent exposure of the hydroxyl group. Adding a methylene bridge yielding 3-hydroxymethylphenyl **5** (IC_{50} (μM)/LE: 900/0.25) did not lead to any favourable interactions. The methoxyphenyl fragments **6a**–**c** (IC_{50} (μM)/LE: 250/0.30, 360/0.28 and 150/0.31) shared the canonical R^2 binding pose. The methoxy group of the *2*-substituted **6a** appeared more shielded from solvent exposure than in **6b** and **6c**, yet the methoxy group did not seem to make any strong contacts. The weak inhibition seen with methyl thioether **7** (IC_{50} (μM)/LE: 400/0.28) corresponded to the results observed with the methoxy ethers **6**. The fluorophenyl substituted **8a**–**c** (IC_{50} (μM)/LE: 130/0.34, 130/0.34 and 360/0.30) had nearly identical binding poses. The 4-substituted **8c** gave the highest IC_{50} value, most likely due to the solvent exposed fluorine. The 2-substituted **8a** seemed more favourable based on the decreased solvent exposure of the fluorine atom, however, the difference to **8b** was negligible only observed by SPR.

The methoxyacetylphenyl esters **9a** and **9b** (IC_{50} (μM)/LE: 210/0.27 and 260/0.26) showed no clear additional interactions in the complex structures with OXA-48, and the methyl group appeared to be unfavourably exposed to the solvent. The corresponding 4-



Scheme 2. Preparation of unsymmetrical 3,5-disubstituted benzoic acids. Reagents and conditions: **39**: i. X = Br, 3-acetamidophenylboronic acid (0.75 equiv.), $PdCl_2(PPh_3)_2$ (10 mol %), dioxane:water (1:1), 60 °C; ii. pyridin-4-ylboronic acid (1.2 equiv.), $PdCl_2(PPh_3)_2$ (10 mol%), dioxane:water (1:1), 60 °C; **int-40**: X = I, quinolin-6-ylboronic acid pinacol ester (2.0 equiv.), $Pd_2(dba)_3$•$CHCl_3$ (5 mol%), SPhos (5 mol%), dioxane:water (1:1), 60 °C; **40**: 3-acetamidophenylboronic acid (1.5 equiv.), XPhos-Pd G2 (5 mol%), *tert*-BuOH, 60 °C.



Fig. 2. The crystal structure of imipenem in complex with OXA-48 (A) shows that the two side chains of imipenem extends in separate directions. The carbapenem substrates of OXA-48 have small R^1 side chains. We were however able to fit larger groups in the R^1 site like the N-acetamide substituted phenyl ring in compound **21a** (B). Yet, most of the tested 3-substituted benzoic acids bind towards the larger R^2 site, like the quinolin-7-yl substituted compound **28** (C).

acetylphenyl substituted **10** (IC_{50} (μM)/LE: 380/0.27) and carbamoylphenyl substituted **11a** and **11b** (IC_{50} (μM)/LE: 260/0.28 and 180/0.29) gave generally weak inhibition indicating that a carbonyl group attached to the aromatic ring was not contributing to binding. No complex structures are available for **10** and **11a**, but the complex structure of 4-carbamoylphenyl **11b** was similar in conformation to the esters **9a** and **9b**. Slightly tighter binding was observed with the *meta*-substituted sulfone **12a** (IC_{50} (μM)/LE: 120/0.29), which also shares the same overall conformation.

The 4-aminophenyl substituent of **13** (IC_{50} (μM)/LE: 330/0.30) did not appear to make any interaction with the enzyme, and the inhibition was weak. The complex structure of the corresponding *N*,*N*-dimethyl-4-aminophenyl substituted **14** (IC_{50} (μM)/LE: 390/0.27) showed that the two methyl groups are solvent exposed, and this is reflected in the poor inhibition by this compound. Similar to the complex structure of **14**, the methyl 4-sulfonamidophenyl group of **17** (IC_{50} (μM)/LE: 370/0.24) was seemingly pushed out of the active site and appears completely exposed to the solvent. The larger phenyl 4-sulfonamidophenyl substituted fragment **18** (IC_{50} (μM)/LE: 60/0.24) showed lower IC_{50} values probably driven by the increase in hydrophobicity, and no complex structure was obtained.

The corresponding *4*-acetamidophenyl **21b** (IC_{50} (μM)/LE: 450/0.25) showed weak inhibition, likely due to the solvent exposure of the hydrophobic methyl group. The 3-acetamidophenyl containing fragment **21a** (Fig, 3), however, showed a 10-fold increased inhibition (IC_{50} (μM)/LE: 35/0.33). The complex structure of OXA-48 with fragment **21a** revealed that the carbonyl of the acetyl formed a hydrogen bond to the guanidine group of Arg214, which directs the 3-acetamidophenyl substituent to the R^1 site (Fig. 2B) and lead to a T-shaped π-π-stacking interaction of the 3-acetamidophenyl substituent with Trp105. The π-π stacking of the 3-acetamidophenyl substituent to Tyr211 normally observed with these fragments was not observed; instead Tyr211 interacted with the benzoic acid by T-shaped π-π-stacking. The interaction of an acetamide with Arg214 has been described previously for the avibactam analogue FPI-1523 in complex with OXA-48 (PDB-ID: 5fas) [22].

Encouraged by the results for fragment **21a**, we designed a series of fragments incorporating a hydrocarbon linker between the phenyl ring and the amino, sulfonamido or acetamido groups of **13**, **18** and **21.** The amines **15** and **16**, the sulfonamides **19** and **20**, the amides **22**, **23a, 23b** and the acetate **24** are more flexible, thus, increasing the potential of hydrogen bonding. However, none of these fragments showed substantially improved binding (IC_{50}: 110–1000; LE: 0.19–0.30). Moreover, the crystal structures of the amides **22**, **23a**, **23b** and the acetate **24** (IC_{50} (μM)/LE: 230/0.24, 520/0.22 and 250/0.25) did not show any specific interactions for the functional groups.

In fragments **26a** and **26b** *N*H-tetrazole substituted phenyl rings were investigated as Ar substituents. Introducing the weakly acidic tetrazol-5-ylphenyl substituent in either 3-position **26a** (IC_{50} (μM)/LE: 60/0.30) or 4-position **26b** (IC_{50} (μM)/LE: 36/0.30) yielded good binding for both fragments. However, the binding poses for the two compounds were very different. The 3-tetrazol-5-ylphenyl substituted **26a** bound in two alternate positions. The π-π-stacking with Tyr211 was maintained for both conformations, but the tetrazoles appeared completely solvent exposed with no interactions with the enzyme. The 4-tetrazol-5-ylphenyl substituted **26b** formed a hydrogen bond with the guanidine group of Arg214 (Fig. 4), interrupting the π-π-stacking with Tyr211. Fragment **26b** occupied the R^1 site rather than the more common R^2 site.

A number of heterocyclic aryl substituents were also evaluated (fragments **25**, **28**–**35**). With some exceptions of the pyridinyls **29** and **35** (IC_{50} (μM)/LE: 170/0.33 and 35/0.42) most of these fragments showed only weak inhibition. The quinolin-7-yl substituted fragment **28** (IC_{50} (μM)/LE: 240/0.30) did maintain the overall conformation of the previous R^2 binding fragments (Fig. 5), and so did the corresponding naphtalen-2-yl substituted fragment **27** (IC_{50} (μM)/LE: 110/0.29). In the same manner the indol-5-yl substituted fragment **34** (IC_{50} (μM)/LE: 310/0.27) did show acceptable binding, yet no specific interaction except for the π-stacking with Tyr211. In our previous paper, we investigated pyridin-4-yl and pyridin-3-yl substituted fragments [19], and both inhibited OXA-48 with the same potency (IC_{50} (μM)/LE: 250/0.32). The pyridin-2-yl substituted fragments **35** (IC_{50} (μM)/LE: 35/0.41) showed a 10-fold improvement in binding (Fig. 6A and B). In the crystal structure, two alternative conformations were observed (Fig. 6C). One conformation was the canonical with π-stacking of the pyridinyl ring with Tyr211 occupying the R^2 site (Fig. 6E), but in the other conformation the pyridinyl ring was orientated to the R^1 site. The second conformation showed a hydrogen bond from the protonated N atom in the pyridine ring to the backbone carbonyl of Tyr117,



Fig. 3. Compound **21a** was one of the most potent 3-substituted benzoic acid derivatives we found. The IC_{50}-value (A) was determined to be 35 μM, while the K_d was found to be 100 μM (B). The crystal structure of the complex OXA-48:**21a** with an omit-type polder-map (2.5σ) (C) and its 2D-representation (D) shows that the carbonyl of the acetamido-group forms a hydrogen bond with the guanidine of Arg214. The interaction with Arg214 causes the B-ring to move away from Tyr211, introducing a new interaction with Trp105.

which represents a unique interaction for the fragments in the library (Fig. 6D). Only the protonated pyridinyl-nitrogen would be able to form hydrogen bonds to the Tyr117 mainchain, which may explain the slower on/off-rates observed for fragment **35** in the SPR-experiments (Fig. 6B).

In the discussion above most fragments were identified as R^2 binders with fragment **4a** (IC_{50} (μM)/LE: 50/0.38) being the strongest binder among them. For R^2 binders, the edge-to-face π-π-stacking with Tyr211 appears to be an important interaction in accordance with previous analyses [23]. Fragment **35** showed the best ligand efficiency (IC_{50} (μM)/LE: 35/0.42), but could not be classified as a R^1 or R^2 binder as both binding pockets showed useful interactions (Fig. 6C–E). Only two R^1 binders – fragments **21a** and **26b** - were identified, both showing hydrogen bonds with Arg214 as cause for the fragments orientation towards the R^1 site.

2.2.3. NMR studies

In order to evaluate the fragment-enzyme binding in solution, a ^{13}C NMR experiment for OXA-48 was developed based on previous studies [24,25]. OXA enzymes can be selectively carbamylated with bicarbonate at an active site lysine to provide the corresponding carbamic acid [24,26,27]. For OXA-48 the carbamylated residue is Lys73, which is situated in the R^1 site (Fig. 2B). By using ^{13}C-labeled sodium bicarbonate ($NaH^{13}CO_3$), a ^{13}C atom was introduced in the R^1 site of OXA-48, which can be used as a reporter probe for fragment binding in ^{13}C NMR studies.

Fragments binding in the R^1 site were expected to change the local environment of the ^{13}C labeled Lys73, which results in a change of the ^{13}C chemical shift of Lys–NH–^{13}**C**O_2H, while ligands binding in the R^2 site are further than ~9 Å away from the Lys73 carbamic acid, and are therefore not expected to directly affect the ^{13}C chemical shift.

NMR experiments were performed by equilibrating OXA-48 with ^{13}C-labeled sodium bicarbonate followed by the addition of inhibitor **2** and selected fragments **21a**, **28** and **35** with known binding modes from X-ray analysis. The results are shown in Fig. 7. The ^{13}C NMR spectrum of OXA-48 after equilibration with $NaH^{13}CO_3$ showed the carbamate resonance at 163.95 ppm as a broad signal (Fig. 7E), which is in good agreement with the reported chemical shift for carbamylated OXA-48 [28]. In addition, two unassigned signals were observed at 164.04 ppm similar to the results reported for carbamylation of OXA-58 [27]. Here the authors speculated that the unassigned signal may be related to a second carbamylation site [27].

On addition of R^1 binding fragment **21a** and inhibitor **2**, the ^{13}C chemical shifts of the carbamate signal were consistently deshielded in both experiments ($\delta = 164.25$, $\Delta\delta = 0.28$ ppm, Fig. 7E and F). These findings support that the compounds bind competitively in the active site. Moreover, the observed chemical shift perturbation indicates that the compounds occupy the R^1 site as found in the crystal structures. The R^2 binding fragment **28** showed a similar deshielding of the carbamate signal though at a smaller amplitude ($\delta = 164.13$, $\Delta\delta = 0.16$ ppm, Fig. 7D) supporting that the fragment binds in the active site, while fragment **35**, which was identified as R^1 or R^2 binder, only slightly affected the chemical shift ($\delta = 164.00$, $\Delta\delta = 0.04$ ppm, Fig. 7C). The observed chemical shift perturbations for fragments **28** and **35** may indicate that fragment **28** has an effect on carbamylated Lys73, while fragment **35** do not interact with the R^1 site, which is not consistent with the X-ray structures. However, a more detailed study of the NMR conformations would be needed to be conclusive about the binding poses in solution.

The small amplitudes of the observed chemical shift



Fig. 4. The IC_{50}-value of compound **26b** (A) was determined to be 36 μM, while the K_D was found to be 70 μM (B). The crystal structure of the complex OXA-48:**26b** with an omit-type polder-map (2.5σ) (C) and a 2D-representation of the protein:compound complex interactions. (D).



Fig. 5. The IC_{50}-value of compound **28** (A) was determined to be 240 μM, while the K_D was found to be 160 μM (B). The crystal structure of the complex OXA-48:**28** with an omit-type polder-map (2.5σ) (C) and a 2D-representation of the protein:compound complex interactions. (D).



Fig. 6. Compound **35** bound in the two alternate conformations. The IC_{50}-value (A) was determined to be 35 μM, while the K_D was found to be 159 μM (B). The crystal structure of the complex OXA-48:**35** with an omit-type polder-map (2.5σ) (C) and a 2D-representation of the protein:compound complex interactions. (D for green colored conformation, E for magenta colored conformation). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

perturbations indicated that the effect is not caused by direct hydrogen bonding of the carbamic carbonyl, for which a Δδ of several ppm would be expected, even for a μM binder [29]. This was supported by the crystal structures of OXA-48 indicating that the Lys73 carbamic acid was preoccupied in hydrogen bonding to Trp157 and was not affected by ligand binding. The observed consistent, but rather subtle, deshielding of the Lys73 carbamic acid ($\delta = 164.25$, $\Delta\delta = 0.28$ ppm, Fig. 7E and F) for our R^1 binding fragments can possibly be explained by an anisotropic magnetic deshielding by the edge of the aromatic rings of these fragments, which were positioned roughly 5 Å away from the reporter carbon for R^1 binding fragments. Moreover, amplitude of the chemical shift perturbation observed with R^1 binding fragments **21a** and inhibitor **2** (Fig. 7E and F) were in line with the reported changes observed for OXA enzymes on coordination with inhibitors like β-hydroxyisopropylpenicillanates [24], cyclic boronates [25] and avibactam [28].

2.3. Inhibitor activity and structural analysis of 3,5-disubstituted benzoic acids

In an attempted to design more potent inhibitors from our fragments, the mono-substituted benzoic acids were evaluated for a merging approach (Fig. 8). By overlaying X-ray structures, promising combinations showing orthogonal binding poses were identified and some of the combined structures were prepared and evaluated with good results.

An overlay of fragment **21a** as well as **26b** with several R^2 binders identified the combinations of fragments **21a**/**28**, **21a**/**1** and **26b**/**35** as interesting partners (Fig. 9). The combination **21a**/**1** and **21a**/**28** were synthetically feasible and gave compounds **39** and **40** (Scheme 2), respectively. In addition, the symmetrical 3,5-disubstituted benzoic acids **36**–**38** representing the symmetrical combinations of fragments **21a**, **21b** and **28** were included in this



Fig. 7. ^{13}C NMR of the buffer alone including ^{13}C labeled bicarbonate (A); OXA-48 without ^{13}C labeled bicarbonate (B), OXA-48 with ^{13}C labeled bicarbonate and fragment **35** (C); OXA-48 with ^{13}C labeled bicarbonate and fragment **28** (D); OXA-48 with ^{13}C labeled bicarbonate and fragment **21a** (E); OXA-48 with ^{13}C labeled bicarbonate and 3,5-di (4-pyridinyl)benzoic acid **2** (F) and OXA-48 with ^{13}C labeled bicarbonate and no fragment (G). Two unassigned signals were observed at 164.1 ppm, and are believed to originate in a second carboxylated site of OXA-48.

study (Scheme 1).

The 3,5-disubstituted compounds **36**–**40** were evaluated for their inhibitory activity against OXA-48 as measured by their IC_{50}, K_d and LE and complex structures with OXA-48 and compounds **36**, **38** and **40** were obtained (Table 2). The merged compounds **37**, **38** and **39** (IC_{50} (μM)/LE: 110/0.19, 48/0.21, 100/0.22) failed to adequately maintain the binding interactions as the IC_{50} values were at a similar level as the corresponding mono-substituted fragments **28, 1** and **21a** (IC_{50} (μM)/LE: 240/0.33, 250/0.32 and 35/0.33). When comparing the IC_{50} values of compounds **36, 37** and **40** (IC_{50} (μM)/LE: 2.9/0.27, 48/0.21 and 2.9/0.27) with the corresponding fragments **21a**, **21b** and **28** (IC_{50} (μM)/LE: 35/0.33, 450/0.26, 240/0.3), a 10-fold decrease of the IC_{50} value was observed. Nevertheless, the improved binding was associated with a decrease in LE showing that the fragment-enzyme interactions are less efficient with the merged compounds. The reduction in LE probably relates to the rigid structure of the merged compounds allowing for little conformational freedom. Overall, the strongest inhibitors in this study are compounds **36** and **40** with IC_{50} values of 2.9 μM and LE of 0.27.

The structural analysis of the OXA-48 complexes with **36**, **38** and **40** showed that the interaction of the carboxylic acid with Arg214 is maintained. For compound **36**, a near perfect overlay was obtained with the complex structure of fragment **21a** showing that all interactions seen with the fragments were preserved in the larger compound (Fig. 10). The second 3-*N*-acetamidophenyl group forms a not previously observed hydrogen bond with Ser244. In the SPR sensorgrams some concentration dependent aggregation was observed [30].

Interestingly, the conformation of compound **38** in complex with OXA-48 was changed compared with the mono-substituted fragment **28**. In the OXA-48:**38** complex, one quinolinyl group bound in the R^1 site similar to fragment **21a**. The other quinolinyl group positions itself in a conformation similar to the alternative conformation observed with fragment **35** (Fig. 6). No specific interactions were observed, but this conformation shielded the hydrophobic quinoline ring from solvent exposure by burying the compound deep in the hydrophobic cleft.

The complex structure of the unsymmetrical compound **40** (Fig. 11) that was composed of the quinoline ring of fragment **28** and the 3-*N*-acetamidophenyl substituent of fragment **13a** shared the key interactions of both mono-substituted fragments validating our approach, with an IC_{50} of 2.9 μM.

3. Conclusion

A targeted fragment library consisting of 49 diversely 3-substituted benzoic acid derivatives was prepared and biochemically analyzed for their inhibitory activity against OXA-48. Enzyme-fragment complexes for crystallographic studies were obtained for 33 fragments. By systematically changing the substituent-groups of the benzoic acid derivatives we were able to identify inhibitory fragments with $IC_{50} < 40$ μM (**21a**, **26b**, **35**). Based on the structural information, fragments could be classified according to their preferred binding pocket. Most fragments were orientated towards the R^2 site induced by a π-π-stacking with Tyr221. Unfortunately, no further interactions in the R^2 site could be identified from our library. The strongest binding fragments **21a** and **26b** were binding in the R^1 site due to a hydrogen bond to Arg214 and for fragment **35** a hydrogen bond to the carbonyl backbone of Tyr117 was observed. By overlaying the complex crystal structures of fragments **1, 21a, 26b, 28** and **35,** the design of five new 3,5-disubstituted inhibitors evolved. The strongest 3,5-disubstituted inhibitors **36** and **40** showed IC_{50} values as low as 2.9 μM, thus have improved inhibitory potential. The complex crystal structures of **36** and **40** revealed that the interactions of the individual fragments were mainly retained in the merged structures. In addition, for inhibitor **36** a previously not observed hydrogen bond from the 3-*N*-acetamidophenyl group in the R^2 site to Ser244 was found, which is interesting as we otherwise found few interactions in this region. Future work will focus on the evaluation of fragments with increased flexibility e.g. by introducing a CH_2 or heteroatom linker bridging the aromatic ring systems to further explore the active site.



Fig. 8. Strategy for substitution of the Ar^1 and Ar^2 groups in the focused fragment library of 3-substituted benzoic acids analogues.



Fig. 9. Superimpositions of the binding poses observed for **21a**/**28** (A), **21a**/**1** (B, **1:** PDB-ID:5dva) and **26b**/**35** (C) showing some of the possible combinations for 3,5-disubstituted benzoic acids.

Table 2
Inhibitor activities of 3,5-disubstituted benzoic acids analogues against OXA-48 (IC_{50}, K_D and LE).



Ar^1	Ar^2	ID	IC_{50} (μM)	K_D (μM)	LE[a]
		**36***	2.9	20	0.27
		**37**	48	70	0.21
		**38***	110	70	0.19
		**39**	100	70	0.22
		**40***	2.9	49	0.27

*X-ray structure of fragment-enzyme complex available.
[a] $LE = (-1.4 * \log_{10} IC_{50})$/HeavyAtomCount, with units kcal/(mol heavy atom).



Fig. 10. Compound **36** maintained the interaction with Arg214 as we observed for the 3-substituted benzoic acid derivate. The IC_{50}-value (A) was determined to be 2.9 μM, while the K_D was found to be 30 μM (B). For the higher concentrations of compound **36** some unspecific binding was observed. The crystal structure of the complex OXA-48:**36** with an omit-type polder-map (2.5σ) (C) and its 2D-representation (D) shows one of the acetamide-groups interacted with the guanidine group of Arg214, while the other group was solvent exposed.



Fig. 11. Compound **40** maintained the interaction with Arg214 as we observed for the 3-substituted benzoic acid derivate. The IC_{50}-value (A) was determined to be 2.9 μM, while the K_D was found to be 49 μM (B). The crystal structure of the complex OXA-48:**40** with an omit-type polder-map (2.5σ) (C) and its 2D-representation (D) shows that the acetamide-group interacted with the guanidine group of Arg214, while the quinoline-ring was partially solvent exposed.

4. Experimental

4.1. Synthesis

4.1.1. Synthesis of 3-substituted benzoic acids (complete data for all procedures and compounds is found in the Supporting information)

4.1.1.1. General procedure A – aqueous conditions. The halo aryl (1.0 equiv) was dissolved in a mixture of water:dioxane (1:1). The boronic acid or ester (1.5 equiv) and potassium phosphate (5.0 equiv) were added. The solution was degassed by vacuum/Argon cycles (10 times) before addition of $PdCl_2(PPh_3)_2$ (10 mol%) and further degassed (5 times). The resulting mixture was stirred at 95 °C under argon atmosphere for 16–20 h. The reaction mixture was filtered through Celite and diluted with water (approx. 30 mL) before washing with chloroform (3 × 30 mL). If not stated otherwise, the aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification on a 10 g or 60 g C18 column with a gradient of acetonitrile in water (10–100%) to yield the desired product.

4.1.1.2. General procedure B – anhydrous conditions. The halo aryl (1.0 equiv) was dissolved in anhydrous THF. The aryl boronic acid or aryl boronic ester (1.5 equiv) and inorganic base (5.0 equiv) were added. The solution was degassed by vacuum/Argon cycles (10 times), before addition of a palladium catalyst (10 mol%) and further degassed (5 times). The resulting mixture was stirred at 75–90 °C under an inert atmosphere for 16–20 h. The reaction mixture was filtered through Celite and diluted with water (approx. 30 mL) before washing with ethyl acetate (3 × 30 mL). If not stated otherwise, the aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification on a 10 g or 60 g C18 column with a gradient of acetonitrile in water (10–80%) to yield the desired molecule.

4.1.2. Screening of catalysts (for results see Table SI1)

4.1.2.1. General procedure. 3-Bromo-5-iodobenzoic acid (0.03–0.06 mmol, 1.0 equiv.) was dissolved in the indicated solvent (0.5–1 mL/0.01 mmol substrate). The boronic acid or ester (1.5 equiv.) and base (5.0 equiv.) were added. The solution was degassed by vacuum/Ar cycles (10 times) before addition of the palladium catalyst and further degassed (5 times). The resulting mixture was stirred at the indicated temperature under an inert atmosphere for the indicated reaction time. The crude reaction mixture was analyzed by HRMS to determine the ratio of **int-39**: disubstituted **38**: starting material. The reaction mixture was filtered through Celite bed and diluted with water (approx. 30 mL) before washing with chloroform (3 × 30 mL). The aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification on a 60 g C18 column with a gradient of acetonitrile in water (0–5% over 15 min) to yield the product.

4.1.3. Synthesis of symmetrical 3,5-disubstituted benzoic acid derivatives

*4.1.3.1. 3,5-Di(3-acetamidophenyl)benzoic acid **36**.* 3-Bromo-5-iodobenzoic acid (0.30 mmol, 100 mg, 1.0 equiv), 3-acetamidophenylboronic acid (0.45 mmol, 816 mg, 1.5 equiv), potassium phosphate (1.5 mmol, 324 mg, 5.0 equiv) were dissolved in a mixture of water/dioxane (1:1). The solution was degassed by vacuum/Ar cycles (10 times) before addition of $Pd_2(dba)_3$•$CHCl_3$ (15 mg, 5 mol%), and XPhos (7.2 mg, 5 mol%) and further degassed (5 times). The resulting mixture was stirred at 60 °C for 20–24 h. The reaction mixture was filtered through Celite bed and diluted with water (approx. 30 mL) before washing with chloroform (3 × 30 mL). The aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification on a 60 g C18 column with a gradient of acetonitrile in water (0–5% over 15 min) to provide **36** (60 mg, 54%) as white powder. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.21 (s, 2H), 7.90 (t, J = 1.7 Hz, 1H), 7.81 (t, J = 1.7 Hz, 2H), 7.68 (d, J = 8 Hz, 2H), 7.43 (s, 1H), 7.49–7.46 (m, 2H), 7.43–7.39 (m, 2H), 2.16 (s, 6H). ^{13}C NMR (101 MHz, methanol-d_4) δ 175.0, 171.8, 142.9, 142.3, 140.5, 132.2, 130.4, 128.2, 128.1, 123.9, 120.3, 119.7, 24.0. HRMS (ESI): Calcd. for $C_{23}H_{19}N_2O_4$ $[M-H]^-$ 387.1350; found 387.1342. UPLC: purity = 97.5%

*4.1.3.2. 3,5-di(4-acetamidophenyl)benzoic acid **37**.* 3,5-Dibromobenzoic acid (1.01 mmol, 300 mg, 1.0 equiv), 3-acetamidophenylboronic acid (0.81 mmol, 178 mg, 0.75 equiv), potassium phosphate (3.76 mmol, 0.80 g, 3.5 equiv) and $PdCl_2(PPh_3)_2$ (0.11 mmol, 77 mg, 10 mol%) were stirred in a mixture of water/dioxane (1:1) for 24 h at 95 °C under argon atmosphere. The crude reaction mixture was filtered through Celite and diluted with water (approx. 30 mL) before washing with chloroform (3 × 30 mL). The aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification on a 60 g C18 column with a gradient of acetonitrile in water (0–100% over 12 min). The fractions were analyzed by MS and fractions containing **37** were combined. The product was purified by reverse-phase automated flash chromatography before being subjected to purification by HPLC, to yield **37** (0.09 mmol, 34 mg, 11%) as a white solid. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.24 (s, 2H), 7.98 (d, J = 7.8 Hz, 2H), 7.85 (d, J = 7.9 Hz, 2H), 7.68–7.66 (m, 2H), 7.63–7.60 (m, 2H), 7.57–7.53 (m, 1H), 2.16 (s, 6H). ^{13}C NMR (101 MHz, methanol-d_4) δ 175.2, 171.7, 142.0, 140.2, 139.4, 137.9, 131.7, 128.4, 128.2, 127.6, 127.4, 123.3, 121.4, 116.2, 23.9. HRMS (ESI): Calcd. for $C_{23}H_{19}N_2O_4$ $[M-H]^-$ 387.1350; found 387.1340. UPLC: purity >99.5%

*4.1.3.3. 3,5-Diquinolin-6-ylbenzoic acid **38**.* 3,5-Dibromobenzoic acid (0.11 mmol, 33 mg, 1.0 equiv), 6-quinolinylboronic acid pinacol ester (0.23 mmol, 60 mg, 2.0 equiv), potassium phosphate (0.58 mmol, 125 mg, 5.0 equiv) were dissolved in tert-butanol. The solution was degassed by vacuum/Ar cycles (10 times) before addition of XPhos-Pd G2 (5 mol%, 5 mg) and further degassed (5 times). The resulting mixture was stirred at 60 °C for 20–24 h. The reaction mixture was filtered through Celite bed and diluted with water (approx. 30 mL) before washing with chloroform (3 × 30 mL). The aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification by C18 RP flash chromatography with a gradient of acetonitrile in water (0–5% over 15 min) to yield **38** (0.08 mmol, 29 mg, 65%) as white powder. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.87–8.86 (m, 2H), 8.52 (s, 1H), 8.50 (s, 1H), 8.46 (m, 2H), 8.38 (m, 2H), 8.29–8.26 (m, 3H), 8.18 (s, 1H), 8.16 (s, 1H), 7.61–7.58 (dd, J = 8.3, 4.2 Hz, 2H). ^{13}C NMR (101 MHz, methanol-d_4) δ 174.4, 151.1, 148.0, 141.5, 140.5, 138.6, 130.6, 130.1, 129.5, 128.7, 126.9, 122.8. HRMS (ESI): Calcd. for $C_{25}H_{15}N_2O_2$ $[M-H]^-$ 375.1139; found 375.1133. UPLC: purity = 99.1%

4.1.4. Synthesis of unsymmetrical 3,5-disubstituted benzoic acid derivatives

*4.1.4.1. 3-(3′-Acetamidophenyl)-5-pyridin-4-ylbenzoic acid **39**: attempted synthesis from 3,5-dibromobenzoic acid.* 3,5-Dibromobenzoic acid (1.01 mmol, 300 mg, 1.0 equiv), 3-acetamidophenylboronic acid (0.81 mmol, 178 mg, 0.75 equiv), potassium phosphate (3.76 mmol, 0.80 g, 3.5 equiv) and $PdCl_2(PPh_3)_2$ (0.11 mmol, 77 mg, 10 mol%) were stirred in a mixture of water/dioxane (1:1) for 24 h at 95 °C under argon atmosphere. The crude reaction mixture was filtered through Celite and diluted with water (approx. 30 mL) before washing with chloroform (3 × 30 mL). The aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification by C18

RP flash chromatography with a gradient of acetonitrile in water (10–100% over 12 min). The fractions were analyzed by MS and fractions containing **int-39** were combined and reacted with pyridin-4-ylboronic acid (0.97 mmol, 119 mg, 1.2 equiv), potassium phosphate (4.05 mmol, 0.86 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.08 mmol, 56 mg, 10 mol%). The product was purified by reverse-phase automated flash chromatography before being subjected to purification by HPLC, to yield **39** (0.12 mmol, 39 mg, 15%) as a white solid. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.22 (s, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.76 (s, 2H), 7.68–7.60 (m, 3H), 7.46–7.33 (m, 4H), 2.14 (s, 3H). ^{13}C NMR (101 MHz, methanol-d_4) δ 175.3, 171.7, 143.0, 141.5, 140.4, 139.8, 130.3, 129.7, 129.3, 129.3, 128.9, 123.7, 120.1, 119.6, 23.9. UPLC: purity = 97.9%

*4.1.4.2. 3-Bromo-5-(quinolin-6-yl) benzoic acid **int-40**.* 3-Bromo-5-iodobenzoic acid (0.15 mmol, 50 mg, 1.0 equiv), 6-quinolinylboronic acid pinacol ester (0.22 mmol, 58 mg, 1.5 equiv) and potassium phosphate (0.76 mmol, 162 mg, 5.0 equiv) were dissolved in a mixture of water/dioxane (1:1). The solution was degassed by vacuum/Ar cycles (10 times) before addition of $Pd_2(dba)_3.CHCl_3$ (5 mol%, 7.5 mg), and SPhos (5 mol%, 3.1 mg) and further degassed (5 times). The resulting mixture was stirred at 60 °C for 20–24 h. The reaction mixture was filtered through a Celite bed and diluted with water (approx. 30 mL) before washing with chloroform (3 × 30 mL). The aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification on a 60 g C18 column with a gradient of acetonitrile in water (0–5% over 20 min). Product **int-40** (0.07 mmol, 23 mg, 45%) was obtained as a white powder. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.92–8.91 (m,1H), 8.49–8.46 (m, 1H), 8.35 (s, 1H), 8.28 (s, 2H), 8.10 (s, 2H), 8.02–8.01 (m, 1H), 7.97–7.96 (m,1H), 7.59–7.56 (dd, J = 8.3, 4.2 Hz, 1H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 166.6, 150.8, 147.2, 143.6, 140.6, 136.8, 136.5, 131.7, 131.1, 129.6, 128.5, 128.2, 127.4, 126.5, 125.8, 121.9, 121.7; HRMS (ESI): Calcd. for $C_{16}H_9^{79}BrNO_2$ $[M-H]^-$ 325.9822; found 325.9822.

*4.1.4.3. 3-(3′-Acetamidophenyl)-5-quinolin-6-ylbenzoic acid **40**.* 3-Bromo-5-(quinolin-6-yl) benzoic acid **int-40** (0.039 mmol, 13 mg, 1.0 equiv), 3-acetamidophenylboronic acid (0.55 mmol, 10 mg, 1.5 equiv) and potassium phosphate (0.20 mmol, 0.42 g, 5.0 equiv) were dissolved in *tert*-butanol. The solution was degassed by vacuum/Ar cycles (10 times) before addition of Xphos-Pd G2 (5 mol%, 1.5 mg) and further degassed (5 times). The resulting mixture was stirred at 60 °C for 20–24 h. The reaction mixture was filtered through Celite bed and diluted with water (approx. 30 mL) before washing with chloroform (3 × 30 mL). The aqueous phase was concentrated under reduced pressure and applied to a C18 pre-column before purification on a 60 g C18 column with a gradient of acetonitrile in water (0–5% over 20 min). Product **40** (0.023 mmol, 9 mg, 90%) was obtained as white powder. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.87–8.83 (m, 1H), 8.56–8.45 (m, 1H), 8.41–8.39 (m, 1H), 8.35–8.20 (m, 3H), 8.18–8.11 (m, 1H), 8.08 (t, J = 1.8 Hz, 1H), 7.87–7.86 (m, 1H), 7.72–7.68 (m, 1H), 7.62–7.56 (m, 1H), 7.56–7.49 (m, 1H), 7.46–7.42 (m, 1H), 2.17 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 174.7, 171.8, 151.2, 148.2, 142.8, 142.5, 141.4, 140.8, 140.7, 140.5, 138.8, 130.8, 130.4, 130.3, 129.7, 128.6, 128.5, 128.5, 127.0, 123.9, 123.0, 120.3, 119.7, 23.9. HRMS (ESI): Calcd. for $C_{24}H_{18}N_2O_3$ $[M-H]^-$ 381.1245; found 381.1243.UPLC: purity = 96.4%

4.2. Protein production

For the biochemical assay OXA-48 was expressed with the native signal-peptide and purified from the periplasm as described earlier [31]. For surface plasmon resonance assays, nuclear magnetic resonance and crystallization a His-tagged construct was used [19].

4.3. Biochemical assay

All experiments were performed using a Spectramax M2e at 25 °C in 100 mM sodium phosphate (pH 7.0) supplemented with 50 mM $NaHCO_3$ and 0.2 mg/mL bovine serum albumin (BSA). Velocities from the linear range were determined in the SoftMax Pro software (Molecular Devices). All experiments were done with a sample volume of 100 μL. IC_{50} values were determined for all compounds in competition with 25 μM of the chromogenic substrate nitrocefin. The $\log_{10}$ of the inhibitor concentrations to the response with bottom and top constant based on controls were fitted nonlinearly in GraphPad Prism 6 (GraphPad Software) to determine the IC_{50} value.

4.4. Surface plasmon resonance

All SPR experiments were performed on a Biacore T200 at 25 °C. The data were analyzed using Biacore T200 Evaluation Software 2.0 (GE Healthcare). The sensorgrams were double reference subtracted using a reference surface and blank injections. The final running buffer included 50 mM HEPES pH 7.0, 50 mM K_2SO_4, 0.5% Tween-20, 50 mM $NaHCO_3$, and 2.5% DMSO. The enzyme, OXA-48, was diluted to 25 μg/mL in 10 mM MES pH 5.5. The enzyme was immobilized to a level of around 5000 RU on a CM5 chip using standard amine coupling.

Compounds were tested with 10 dilutions from 400 μM to 10.5 μM, with 30 s injection and 60 s dissociation time. Compounds exhibiting kinetic behavior had the dissociation time extended to 300 s. Seven startup cycles with buffer were performed. Solvent correction was performed every 48th cycle and a positive control was included every 24th cycle with 3.5-Di (4-pyridinyl)benzoic acid as the control [19]. Affinities were calculated from the steady-state affinity model with a constant R_{max} adjusted by the control and the molecular weight of the compound.

4.5. ^{13}C nuclear magnetic resonance

A solution of $NaH^{13}CO3$ in D_2O (50 mM) was prepared. The $NaH^{13}CO_3/D_2O$-mixture was added to 1 mM OXA-48 in 50 mM sodium phosphate and 50 mM sodium bicarbonate pH 6.5 in a 1: 9 ratio of bicarbonate to enzyme. Compounds were diluted from a 150 mM stock solution in 100% DMSO to a final concentration of 3.75 mM (2.5% DMSO). Sample volumes of 500 μL were used. We performed the experiment at 37 °C with a Bruker Avance III HD with an inverse detected TCI probe with cryogenic enhancement for ^{1}H, ^{13}C and ^{2}H, operating at 599.90 MHz for protons and 150.86 MHz for carbon. 10 000 scans at 30° pulse angle with 2 s relaxation delay were collected using 1D ^{13}C NMR with power-gated decoupling of protons (zgpg30 using waltz16).

4.6. Crystallization and data processing

Crystals of OXA-48 was grown from hanging drops containing 0.1 M HEPES pH 7.5, 8–11% PEG 8000 and 4–8% 1-butanol as previously described [17]. Compounds were diluted to 3.75 mM in the cryo solution with 0.1 M HEPES pH 7.5, 10% PEG 8000, 5% 1-butanol, and 25% ethanediol, usually overnight. The exception was the crystal soaked in imipenem. Imipenem was added to saturation in the cryosolution, and the crystal was just given a quick soak.

Crystals were flash cooled in liquid nitrogen. X-ray diffraction data were collected at BL 14.1 and BL14.2 at BESSY (Berlin, Germany) [32], and at ID23-1, ID23-2 and ID30B at ESRF (Grenoble, France). In most cases the structures were solved by refining

against the protein-atoms of previous structures ($P2_12_12_1$ PDB ID: 5DVA and $P2_1$ PDB ID: 5DTK), but in cases where the unit cells were to different PHASER was used with chain A from PDB ID: 5dtk as the search model for molecular replacement. In most cases images were autoprocessed using the tools at the beamlines [33–37], but in some cases we found it useful to reprocess using DIALS or XDS together with AIMLESS [38–40].

The compounds were built into difference density maps after initial refinement in phenix.refine [41], with waters deleted from the active site. Restraints for the compounds were prepared using the GRADE Web Server [42]. Omit maps were calculated using the phenix.polder-tool which excludes bulk-solvent from the volume surrounding the ligand [43]. Figures were made using PyMOL [44]. Ligand-interaction diagrams were prepared using the Maestro-suite from Schrödinger Release 2016-3 (Schrödinger, LLC, New York).

Author contributions

Designed the experiments: AB, BAL, HKSL, SA, TC. Performed the organic synthesis: SA, AI, ML. Determined IC_{50} values and K_d-values: BAL. Prepared and solved crystal structures: BAL. Analyzed 3D structures: AB, BAL, SA. NMR studies: BAL, JI. Analyzed data and wrote the paper: AB, BAL, HKSL, JI, SA, TC. All authors have given approval to the final version of the manuscript.

PDB accession codes

Coordinates and structure factors for all OXA-48 complexes are deposited in the Protein Data Bank. Accession numbers are listed with reference to the complexed compound. PDB IDs: imipenem: 5QB4; **3a**: 5QA4; **3b**: 5QA5; **4a**: 5QA6; **4b**: 5QA7; **4c**: 5QA8; **5**: 5QA9; **6a**: 5QAA; **6b**: 5QAB; **6c**: 5QAC; **8a**: 5QAD; **8b**: 5QAE; **8c**: 5QAF; **9a**: 5QAG; **9b**: 5QAH; **12a**: 5QAI: **13**: 5QAJ; **14**: 5QAK; **11b**: 5QAL; **17**: 5QAM; **19a**: 5QAN; **19b**: 5QAO; **21a**: 5QAP; **21b**: 5QAQ; **23a**: 5QAR; **23b**: 5QAS; **24**: 5QAT; **26a**: 5QAU; **26b**: 5QAV; **27**: 5QAW; **28**: 5QAX; **32**: 5QAY; **34**: 5QAZ; **35**: 5QB0; **36**: 5QB1; **38**: 5QB2; **40**: 5QB3.

Acknowledgement

This study was supported by The National Graduate School in Structural Biology (BioStruct) and The Norwegian Research Council (FRIMEDBIO project number 213808 and SYNKNOYT project number 218539). Provision of beam time at BL14.1 and BL14.2, Bessy II, Berlin, Germany, and the MX beamlines ID23-1, ID23-2 and ID30B at the European Synchrotron Radiation Facility (ESRF), Grenoble, France are highly valued.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.ejmech.2017.12.085.

References

[1] T. Guillard, S. Pons, D. Roux, G.B. Pier, D. Skurnik, Antibiotic resistance and virulence: understanding the link and its consequences for prophylaxis and therapy, Bioessays 38 (2016) 682–693.
[2] L. Chen, R. Todd, J. Kiehlbauch, M. Walters, A. Kallen, Notes from the Field: Pan-Resistant New Delhi Metallo-β-lactamase-producing Klebsiella pneumoniae - Washoe County, Nevada, 2016, MMWR Morb. Mortal. Wkly. Rep. 66, 2017, p. 33.
[3] J. O'Neill, Tackling Drug-resistant Infections Globally (final report and recommendations. Review on Antimicrobial Resistance, London, UK), 2016.
[4] K. Bush, P.A. Bradford, β-lactams and β-lactamase inhibitors: an overview, CSH Perspect. Med. 6 (2016).
[5] B.G. Hall, M. Barlow, Evolution of the serine β-lactamases: past, present and future, Drug Resist. Update. 7 (2004) 111–123.
[6] L. Poirel, T. Naas, P. Nordmann, Diversity, epidemiology, and genetics of class D β-lactamases, Antimicrob. Agents Chemother. 54 (2010) 24–38.
[7] K. Bush, G.A. Jacoby, Updated functional classification of β-lactamases, Antimicrob. Agents Chemother. 54 (2010) 969–976.
[8] T. Naas, S. Oueslati, R.A. Bonnin, M.L. Dabos, A. Zavala, L. Dortet, P. Retailleau, B.I. Iorga, Beta-lactamase database (BLDB) – structure and function, J. Enzym. Inhib. Med. Chem. 32 (2017) 917–919.
[9] R.P. Ambler, The structure of β-lactamases, Philos. Trans. R. Soc., B 289 (1980) 321–331.
[10] D. Golemi, L. Maveyraud, S. Vakulenko, J.-P. Samama, S. Mobashery, Critical involvement of a carbamylated lysine in catalytic function of class D β-lactamases, Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14280–14285.
[11] L. Poirel, A. Potron, P. Nordmann, OXA-48-like carbapenemases: the phantom menace, J. Antimicrob. Chemoth. 67 (2012) 1597–1606.
[12] S.M. Drawz, R. a Bonomo, Three decades of β-lactamase inhibitors, Clin. Microbiol. Rev. 23 (2010) 160–201.
[13] J.D. Buynak, Understanding the longevity of the β-lactam antibiotics and of antibiotic/β-lactamase inhibitor combinations, Biochem. Pharmacol. 71 (2006) 930–940.
[14] N. Antunes, J. Fisher, Acquired class D β-lactamases, Antibiotics 3 (2014) 398.
[15] J.L. Liscio, M.V. Mahoney, E.B. Hirsch, Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections, Int. J. Antimicrob. Agents 46 (2015) 266–271.
[16] D.E. Ehmann, H. Jahić, P.L. Ross, R.-F. Gu, J. Hu, T.F. Durand-Réville, S. Lahiri, J. Thresher, S. Livchak, N. Gao, T. Palmer, G.K. Walkup, S.L. Fisher, Kinetics of avibactam inhibition against class a, C, and D β-Lactamases, J. Bio. Chem. 288 (2013) 27960–27971.
[17] S.D. Lahiri, S. Mangani, H. Jahic, M. Benvenuti, T.F. Durand-Reville, F. De Luca, D.E. Ehmann, G.M. Rossolini, R.A. Alm, J.D. Docquier, Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48, ACS Chem. Biol. 10 (2015) 591–600.
[18] R.K. Shields, L. Chen, S.J. Cheng, K.D. Chavda, E.G. Press, A. Snyder, R. Pandey, Y. Doi, B.N. Kreiswirth, M.H. Nguyen, C.J. Clancy, Emergence of ceftazidime-avibactam resistance due to plasmid-borne bla(KPC-3) mutations during treatment of carbapenem-resistant *Klebsiella pneumoniae* infections, Antimicrob. Agents Chemother. 61 (2017).
[19] B.A. Lund, T. Christopeit, Y. Guttormsen, A. Bayer, H.K.S. Leiros, Screening and design of inhibitor scaffolds for the antibiotic resistance Oxacillinase-48 (OXA-48) through surface plasmon resonance screening, J. Med. Chem. 59 (2016) 5542–5554.
[20] M. Congreve, R. Carr, C. Murray, H. Jhoti, A 'Rule of Three' for fragment-based lead discovery? Drug Discov. Today 8 (2003) 876–877.
[21] S.M. Lukyanov, I.V. Bliznets, S.V. Shorshnev, G.G. Aleksandrov, A.E. Stepanov, A.A. Vasil'ev, Microwave-assisted synthesis and transformations of sterically hindered 3-(5-tetrazolyl)pyridines, Tetrahedron 62 (2006) 1849–1863.
[22] A.M. King, D.T. King, S. French, E. Brouillette, A. Asli, J.A.N. Alexander, M. Vuckovic, S.N. Maiti, T.R. Parr, E.D. Brown, F. Malouin, N.C.J. Strynadka, G.D. Wright, Structural and kinetic characterization of diazabicyclooctanes as dual inhibitors of both serine-β-lactamases and penicillin-binding proteins, ACS Chem. Biol. 11 (2016) 864–868.
[23] D.A. Leonard, R.A. Bonomo, R.A. Powers, Class D β-lactamases: a reappraisal after five decades, Acc. Chem. Res. 46 (2013) 2407–2415.
[24] L. Maveyraud, D. Golemi-Kotra, A. Ishiwata, O. Meroueh, S. Mobashery, J.-P. Samama, High-resolution x-ray structure of an acyl-enzyme species for the class D OXA-10 β-lactamase, J. Am. Chem. Soc. 124 (2002) 2461–2465.
[25] S.T. Cahill, R. Cain, D.Y. Wang, C.T. Lohans, D.W. Wareham, H.P. Oswin, J. Mohammed, J. Spencer, C.W.G. Fishwick, M.A. McDonough, C.J. Schofield, J. Brem, Cyclic boronates inhibit all classes of β-lactamases, Antimicrob. Agents Chemother. 61 (2017).
[26] J. Li, J.B. Cross, T. Vreven, S.O. Meroueh, S. Mobashery, H.B. Schlegel, Lysine carboxylation in proteins: OXA-10 β-lactamase, Proteins 61 (2005) 246–257.
[27] V. Verma, S.A. Testero, K. Amini, W. Wei, J. Liu, N. Balachandran, T. Monoharan, S. Stynes, L.P. Kotra, D. Golemi-Kotra, Hydrolytic mechanism of OXA-58 enzyme, a carbapenem-hydrolyzing class D β-lactamase from acinetobacter baumannii, J. Bio. Chem. 286 (2011) 37292–37303.
[28] C.T. Lohans, D.Y. Wang, C. Jorgensen, S.T. Cahill, I.J. Clifton, M.A. McDonough, H.P. Oswin, J. Spencer, C. Domene, T.D.W. Claridge, J. Brem, C.J. Schofield, ^{13}C-Carbamylation as a mechanistic probe for the inhibition of class D β-lactamases by avibactam and halide ions, Org. Biomol. Chem. 15 (2017) 6024.
[29] N. Asakawa, S. Kuroki, H. Kurosu, I. Ando, A. Shoji, T. Ozaki, Hydrogen-bonding effect on carbon-13 NMR chemical shifts of L-alanine residue carbonyl carbons of peptides in the solid state, J. Am. Chem. Soc. 114 (1992) 3261–3265.
[30] A.M. Giannetti, B.D. Koch, M.F. Browner, Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors, J. Med. Chem. 51 (2008) 574–580.
[31] B.A. Lund, H.K.S. Leiros, G.E. Bjerga, A high-throughput, restriction-free cloning and screening strategy based on *ccd*B-gene replacement, Microb. Cell Fact. 13 (2014) 38.
[32] U. Mueller, R. Förster, M. Hellmig, F.U. Huschmann, A. Kastner, P. Malecki, S. Pühringer, M. Röwer, K. Sparta, M. Steffien, M. Ühlein, P. Wilk, M.S. Weiss, The macromolecular crystallography beamlines at BESSY II of the Helmholtz-

Zentrum Berlin: current status and perspectives, Eur. Phys. J. Plus 130 (2015) 141.
[33] J. Gabadinho, A. Beteva, M. Guijarro, V. Rey-Bakaikoa, D. Spruce, M.W. Bowler, S. Brockhauser, D. Flot, E.J. Gordon, D.R. Hall, B. Lavault, A.A. McCarthy, J. McCarthy, E. Mitchell, S. Monaco, C. Mueller-Dieckmann, D. Nurizzo, R.B.G. Ravelli, X. Thibault, M.A. Walsh, G.A. Leonard, S.M. McSweeney, MxCuBE: a synchrotron beamline control environment customized for rna-cromolecular crystallography experiments, J. Synchrotron Radiat. 17 (2010) 700–707.
[34] M.F. Incardona, G.P. Bourenkov, K. Levik, R.A. Pieritz, A.N. Popov, O. Svensson, EDNA: a framework for plugin-based applications applied to X-ray experiment online data analysis, J. Synchrotron Radiat. 16 (2009) 872–879.
[35] S. Delageniere, P. Brenchereau, L. Launer, A.W. Ashton, R. Leal, S. Veyrier, J. Gabadinho, E.J. Gordon, S.D. Jones, K.E. Levik, S.M. McSweeney, S. Monaco, M. Nanao, D. Spruce, O. Svensson, M.A. Walsh, G.A. Leonard, ISPyB: an information management system for synchrotron macromolecular crystallography, Bioinformatics 27 (2011) 3186–3192.
[36] G.P. Bourenkov, A.N. Popov, Optimization of data collection taking radiation damage into account, Acta Cryst. Section D 66 (2010) 409–419.
[37] K.M. Sparta, M. Krug, U. Heinemann, U. Mueller, M.S. Weiss, XDSAPP2. 0, J. Appl. Cryst. 49 (2016) 1085–1092.
[38] D.G. Waterman, G. Winter, R.J. Gildea, J.M. Parkhurst, A.S. Brewster, N.K. Sauter, G. Evans, Diffraction-geometry refinement in the DIALS framework, Acta Cryst. Section D 72 (2016) 558–575.
[39] P.R. Evans, G.N. Murshudov, How good are my data and what is the resolution? Acta Cryst. Section D 69 (2013) 1204–1214.
[40] W. Kabsch, XDS, Acta Cryst. Section D 66 (2010) 125–132.
[41] P.V. Afonine, R.W. Grosse-Kunstleve, N. Echols, J.J. Headd, N.W. Moriarty, M. Mustyakimov, T.C. Terwilliger, A. Urzhumtsev, P.H. Zwart, P.D. Adams, Towards automated crystallographic structure refinement with phenix.refine, Acta Cryst. Section D 68 (2012) 352–367.
[42] O.S. Smart, T.O. Womack, A. Sharff, C. Flensburg, P. Keller, W. Paciorek, C. Vonrhein, G. Bricogne, Grade, version 1.102. Global Phasing, 2014.
[43] D. Liebschner, *phenix.polder* - a Tool for Calculating Difference Maps Around Atom Selections by Excluding the Bulk Solvent Mask (The Phenix Project, Berkeley, California), 2016.
[44] L.L.C. Schrodinger, The PyMOL Molecular Graphics System, Version 1.8, 2015.

Supporting information for

A focused fragment library targeting the antibiotic resistance enzyme - oxacillinase-48: synthesis, structural evaluation and inhibitor design

Sundus Akhter[1,#],Bjarte Aarmo Lund[2,#], Aya Ismael[1], Manuel Langer[1], Johan Isaksson[1], Tony Christopeit[2], Hanna-Kirsti Schrøder Leiros[2,*], Annette Bayer[1,*]

[1] Department of Chemistry, Faculty of Science and Technology, UiT The Arctic University of Norway, N-9037 Tromsø, Norway. [2] The Norwegian Structural Biology Centre (NorStruct), Department of Chemistry, Faculty of Science and Technology, UiT The Arctic University of Norway, N-9037 Tromsø, Norway.

* Corresponding authors: Annette Bayer, E-mail: annette.bayer@uit.no , Phone +47 77 64 40 69; Hanna-Kirsti S. Leiros, E-mail: hanna-kirsti.leiros@uit.no , Phone +47 77 64 57 06;

# These authors have contributed equally to this work.

Table of content:

1 Synthesis

1.1 Material and methods

All reagents and solvents were purchased from commercial sources and used as supplied, unless otherwise stated. Solvent mixtures are given in (v|v). The water used for reactions, was purified on a Millipore RiOs™ device. The aqueous phase was concentrated under reduced pressure and Purification of compounds was carried out by automated RP flash chromatography with preloading to a C18 Samplet® cartridge (Biotage) before purification on a C18 RP column (Biotage) or by flash chromatography using silica gel from Merck (Silica gel 60, 0.040–0.063 mm). For thin layer chromatography TLC-PET sheets precoated with silica gel (60 F254) were used. Visualization was accomplished with either UV light or by immersion in potassium permanganate, phosphomolybdic acid (PMA) or ninhydrin followed by light heating with a heating gun. Purity analysis was carried out on Waters Acquity UHPLC® BEH C18 (1.7 µm, 2.1 × 100 mm) column on a Waters Acquity I-class UHPLC with a photodiode array setector. NMR spectra were recorded on a 400 MHz Bruker Avance III HD equipped with a 5 mm SmartProbe BB/1H (BB = ^{19}F, ^{31}P, ^{15}N). Data are represented as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dt = double triplet, m = multiplet), coupling constant (*J*, Hz) and integration. Chemical shifts (δ) are reported in ppm relative to the residual solvent peak ($CDCl_3$: δ_H 7.26 and δ_C 77.16; methanol-d_4 : δ_H 3.31 and δ_C 49.00, deuterium oxide: δ_H 4.79 and δ_C 49.00; DMSO-d_6 δ_H 2.51 and δ_C 39.52). The raw data was analysed with MestReNova (Version 10.0.2-15465). Electrospray ionization mass spectrometry was conducted on a Thermo electron LTQ Orbitrap XL spectrometer. The data was analyzed with Thermo Scientific Xcalibur software. Melting points were determined on a Büchi 535 device or a ThermoFischer Scientific IA9100 Digital Melting Point apparatus.

1.2 Synthesis of 3-substituted benzoic acids

General procedure A – Aqueous conditions:

The halo aryl (1.0 equiv) was dissolved in a mixture of water:dioxane (1:1). The boronic acid or ester (1.5 equiv) and potassium phosphate (5.0 equiv) were added. The solution was degassed by vacuum/argon cycles (10 times) before addition of $PdCl_2(PPh_3)_2$ (10 mol%) and further degassed (5 times). The resulting mixture was stirred at 95 °C under argon atmosphere for 16-20 hours. The reaction mixture was filtered through Celite and diluted with water (approx. 30 mL) before washing with chloroform (3 x 30 mL). If not stated otherwise, the aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification on a 10g or 60 g C18 column with a gradient of acetonitrile in water (10-100%) to yield the desired product.

General procedure B – Anhydrous conditions:

The halo aryl (1.0 equiv) was dissolved in anhydrous THF. The aryl boronic acid or aryl boronic ester (1.5 equiv) and inorganic base (5.0 equiv) were added. The solution was degassed by vacuum/Argon cycles (10 times), before addition of a palladium catalyst (10 mol%) and further degassed (5 times). The resulting mixture was stirred at 75–90 °C under an inert atmosphere for 16-20 hours. The reaction mixture was filtered through Celite and diluted with water (approx. 30 mL) before washing with ethyl acetate (3 x 30 mL). If not stated otherwise, the aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification on a 10 g or 60 g C18 column with a gradient of acetonitrile in water (10–80%) to yield the desired molecule.

2'-methylbiphenyl-3-carboxylic acid, **3a**:

According to procedure A, 3-carboxyphenylboronic acid pinacol ester (1.32 mmol, 326 mg, 1.5 equiv), 2-bromotoluene (0.88mmol, 150 mg, 1 equiv), potassium phosphate (4.39 mmol, 929 mg, 5 equiv) and $PdCl_2(PPh_3)_2$ (0.088 mmol, 62 mg, 10 mol%) gave **3a** (0.64 mmol, 136 mg, 78 %) as white solid. T_m

= 288-289°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 7.90-7.79 (m, 2H), 7.33-7.29 (m, 1H), 7.24 (dt, *J* = 7.6, 1.6 Hz, 1H), 7.18-7.07 (m, 4H), 2.14 (s, 3H). ^{13}C NMR (101 MHz, methanol-d_4) δ 175.4, 143.2, 142.9, 139.1, 136.4, 131.9, 131.3, 131.1, 130.7, 128.7, 128.5, 128.3, 126.8, 20.6. HRMS (ESI): Calcd. for $C_{14}H_{10}O_2$ $[M-H]^-$ 211.0765; found 211.0766. UHPLC: purity = 97.5 %

3'-methylbiphenyl-3-carboxylic acid, **3b**:

According to procedure A, 3-carboxyphenylboronic acid pinacol ester (1.32 mmol, 326 mg, 1.5 equiv), 3-bromotoluene (0.88 mmol, 150 mg, 1.0 equiv), potassium phosphate (4.39 mmol, 929 mg, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.088 mmol, 62 mg, 10 mol%) gave **3b** (0.59 mmol, 124 mg, 67 %) as white solid. T_m = 257-258°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.12 (s, 1H), 7.81 (d, *J* = 7.7 Hz, 1H), 7.55 (d, *J* = 7.8 Hz, 1H), 7.40-7.28 (m, 3H), 7.21 (t, *J* = 7.6 Hz, 1H), 7.05 (d, *J* = 7.5 Hz, 1H), 2.31 (s, 3H).^{13}C NMR (101 MHz, methanol-d_4) δ 175.4, 142.3, 142.1, 139.6, 139.5, 129.7, 129.7, 129.2, 129.1, 128.9, 128.9, 128.7, 125.1, 21.6. HRMS (ESI): Calcd. for $C_{14}H_{10}O_2$ $[M-H]^-$ 211.0765; found 211.0768. UHPLC: purity = 95.5 %

2'-hydroxybiphenyl-3-carboxylic acid, **4a**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 3-hydroxyphenylboronic acid (1.86 mmol, 256 mg, 1.5 equiv), potassium phosphate (6.20 mmol, 1.32 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **4a** (1.17 mmol, 250 mg, 94 %) as white solid. T_m = 290-291°C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.09 (s, 1H), 7.79 (d, *J* = 7.7 Hz, 1H), 7.47 (d, *J* = 7.7 Hz, 1H), 7.27 (t, *J* = 7.6 Hz, 1H), 7.21 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.14-6.99 (m, 2H), 6.82 (td, *J* = 7.2, 1.6 Hz, 1H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 169.9, 155.6, 141.0, 138.2, 130.6, 130.4, 129.7, 128.7, 128.5, 127.7, 127.0, 119.2, 116.7. HRMS (ESI): Calcd. for $C_{13}H_9O_3$ $[M-H]^-$ 213.0557 found 213.0561. UHPLC: purity > 99.5%

3'-hydroxybiphenyl-3-carboxylic acid, **4b**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 3-hydroxyphenyl boronic acid (1.86 mmol, 256 mg, 1.5 equiv), potassium phosphate (6.20 mmol, 1.32 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave, **4b**(1.21 mmol, 260 mg, 98 %) as white solid. T_m = 279-280°C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.19 (s, 1H), 7.82 (d, *J* = 7.5 Hz, 1H), 7.53 (d, *J* = 7.7 Hz, 1H), 7.32 (t, *J* = 7.6 Hz, 1H), 7.23-7.17 (m, 2H), 7.01 (s, 1H), 6.73 (d, *J* = 7.9 Hz, 1H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 169.5, 159.4, 142.2, 141.8, 139.7, 130.1, 128.4, 128.0, 127.6, 127.1, 116.8, 114.9, 114.1. HRMS (ESI): Calcd. for $C_{13}H_9O_3$ $[M-H]^-$ 213.0557; found 213.0565. UHPLC: purity = 96.0 %

4'-hydroxybiphenyl-3-carboxylic acid, **4c**:

According to general procedure A, 3-bromobenzoic acid (0.75 mmol, 150 mg, 1.0 equiv), (4-hydroxyphenyl)boronic acid (1.12 mmol, 154 mg, 1.5 equiv), potassium phosphate (3.73 mmol, 792 mg, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.07 mmol, 52 mg, 10 mol%) were stirred at 95°C. The aqueous phase was washed with a mixture of hexane/ethyl acetate (1:1, v/v, 3 x 30 mL) instead of chloroform. After purification the title compound, **4c** (0.29 mmol, 63 mg, 39%) was obtained as a dark brown solid. T_m = 257-259°C.^{1}H NMR (400 MHz, methanol-d_4) δ 8.13 (t, *J* = 1.8 Hz, 1H), 7.83 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.62 (dt, *J* = 7.8, 1.4 Hz, 1H), 7.55-7.49 (m, 2H), 7.43 (t, *J* = 7.7 Hz, 1H), 6.95-6.88 (m, 2H). ^{13}C NMR (101 MHz, methanol-d_4) δ 175.7, 157.5, 141.5, 138.8, 133.5, 129.4, 129.3, 129.0, 128.3, 128.0, 116.8. HRMS (ESI): Calcd. for $C_{13}H_9O_3$ $[M-H]^-$ 213.0557; found 213.0577. UHPLC: purity = 97.8 %

3'-(hydroxymethyl)biphenyl-3-carboxylic acid, **5**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 3-(Hydroxymethyl)phenylboronic acid (1.86 mmol, 282 mg, 1.5 equiv), potassium phosphate (6.20

mmol, 1.32 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **5,** (1.04 mmol, 239 mg, 84 %) as white solid. T_m = 241-242°C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.14 (s, 1H), 7.87 (d, *J* = 7.9 Hz, 1H), 7.81 (d, *J* = 8.0 Hz, 1H), 7.68 (d, *J* = 13.8 Hz, 2H), 7.58-7.52 (m, 2H), 7.42 (d, *J* = 8.0 Hz, 1H), 4.72 (s, 2H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 169.1, 143.7, 142.6, 141.1, 139.4, 129.1, 128.5, 128.1, 127.8, 126.9, 125.7, 125.3, 125.1, 63.4. HRMS (ESI): Calcd. for $C_{14}H_{11}O_3$ $[M-H]^-$ 227.0714; found 227.0716. UHPLC: purity = 95.1 %

2'-methoxybiphenyl-3-carboxylic acid, **6a**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 3-methoxyphenylboronic acid (1.86 mmol, 282 mg, 1.5 equiv), potassium phosphate (6.20 mmol, 1.32 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **6a** (0.89 mmol, 205 mg, 73 %) as white solid. T_m = 88-89°C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.93 (s, 1H), 7.79 (d, *J* = 7.6 Hz, 1H), 7.38-7.22 (m, 4H), 7.10 (d, *J* = 8.2 Hz, 1H), 7.02 (t, *J* = 7.4 Hz, 1H), 3.75 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 169.2, 156.7, 141.9, 137.3, 131.1, 130.9, 130.4, 129.5, 128.9, 127.9, 126.9, 121.1, 112.1, 55.9. HRMS (ESI): Calcd. for $C_{14}H_{11}O_3$ $[M-H]^-$ 227.0714; found 227.0712. UHPLC: purity = 98.0 %

3'-methoxybiphenyl-3-carboxylic acid, **6b**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 3-methoxyphenylboronic acid (1.86 mmol, 282 mg, 1.5 equiv), potassium phosphate (6.20 mmol, 1.32 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **6b** (1.04 mmol, 237 mg, 84 %) as white solid. T_m = 149-150°C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.12 (s, 1H), 7.84 (d, *J* = 7.0 Hz, 1H), 7.55 (d, *J* = 7.7 Hz, 1H), 7.35 (dt, *J* = 18.7, 7.7 Hz, 2H), 7.21 (d, *J* = 7.6 Hz, 1H), 7.15 (s, 1H), 6.92 (dd, *J* = 8.2, 2.5 Hz, 1H), 3.83 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 168.3, 159.7, 142.5, 138.7, 129.9, 128.3, 127.5, 127.3, 126.5, 118.9, 112.7, 111.9, 99.5, 55.1. HRMS (ESI): Calcd. for $C_{14}H_{11}O_3$ $[M-H]^-$ 227.0714; found 227.0711. UHPLC: purity > 99.5 %

4'-methoxybiphenyl-3-carboxylic acid, **6c**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 4-methoxyphenyl boronic acid (1.86 mmol, 282 mg, 1.5 equiv), potassium phosphate (7.44 mmol, 1.58 g, 6.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **6c** (1.07 mmol, 244 mg, 86 %) as white solid. ^{1}H NMR (400 MHz, Methanol-d_4) δ 8.19 (s, 1H), 7.87 (d, *J* = 7.5 Hz, 1H), 7.75-7.51 (m, 3H), 7.40 (t, *J* = 7.7 Hz, 1H), 7.00 (d, *J* = 8.0 Hz, 2H), 3.83 (s, 3H).^{13}C NMR (101 MHz, Methanol-d_4) δ 175.3, 160.6,141.5, 139.4, 134.7, 129.2, 129.1, 128.9, 128.4, 128.3, 115.2, 55.6. HRMS (ESI): Calcd. for $C_{14}H_{11}O_3$ $[M-H]^-$ 227.0708; found 227.0724. UHPLC: purity = 98.8 %

4'-methylthiobiphenyl-3-carboxylic acid, **7**:

According to general procedure B, 3-bromobenzoic acid (0.75 mmol, 150 mg, 1.0 equiv), 4-(methylthio)phenyl boronic acid (1.12 mmol, 188 mg, 1.5 equiv), Na_2CO_3 (3.73 mmol, 395 mg, 5.0 equiv), $PdCl_2$(dppf) (0.07 mmol, 55 mg, 10 mol%) in anhydrous THF (8 mL) was stirred at 75°C for 18h. After purification the title compound, **7** (0.68 mmol, 167 mg, 91%) was obtained as a brownish solid. T_m = 228°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 7.93-7.85 (m, 1H), 7.69-7.62 (m, 1H), 7.63-7.58 (m, 2H), 7.45 (t, *J* = 7.9 Hz, 1H), 7.37-7.30 (m, 2H). ^{13}C NMR (101 MHz, methanol-d_4) δ 175.4, 141.0, 139.2, 138.9, 138.7, 129.5, 129.5, 129.0, 128.3, 127.8, 15.7. HRMS (ESI): Calcd. for $C_{14}H_{11}O_2S$ $[M-H]^-$ 243.0485; found 243.0483. UHPLC: purity = 98.4 %

2'-fluorobiphenyl-3-carboxylic acid, **8a**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 2-flourophenylboronic acid (1.86 mmol, 256 mg, 1.5 equiv), potassium phosphate (6.20 mmol, 1.32 g,

5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **8a** (0.84 mmol, 181 mg, 68 %) as white solid. T_m = 260-261°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.04 (s, 1H), 7.86 (d, *J* = 7.6 Hz, 1H), 7.49 (d, *J* = 7.7 Hz, 1H), 7.42 (t, *J* = 7.8 Hz, 1H), 7.37-7.20 (m, 1H), 7.15 (t, *J* = 7.5 Hz, 1H), 7.12-7.02 (m, 1H). ^{13}C NMR (101 MHz, methanol-d_4) δ 175.1, 161.1 (d, *J* = 246.5 Hz), 139.5, 136.6, 131.9 (d, *J* = 3.4 Hz), 131.8 (d, *J* = 3.5 Hz), 130.9 (d, *J* = 2.4 Hz), 130.3 (d, *J* = 8.4 Hz), 129.6, 128.8, 125.6 (d, *J* = 3.8 Hz), 116.9 (d, *J* = 22.9 Hz). HRMS (ESI): Calcd. for $C_{13}H_8FO_2$ $[M-H]^-$ 215.0514; found 215.0511. UHPLC: purity > 99.5%

3'-fluorobiphenyl-3-carboxylic acid, **8b**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 3-flourophenylboronic acid (1.86 mmol, 256 mg, 1.5 equiv), potassium phosphate (6.20 mmol, 1.32 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **8b** (1.03 mmol, 222 mg, 83 %) as white solid. T_m = 239-241°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.13 (s, 1H), 7.85 (d, *J* = 7.6 Hz, 1H), 7.58 (d, *J* = 7.7 Hz, 1H), 7.49-7.20 (m, 4H), 6.97 (t, *J* = 8.6 Hz, 1H). ^{13}C NMR (101 MHz, Methanol-d_4) δ 175.05, 164.71 (d, *J* = 244.0 Hz), 144.83, 140.56, 139.90, 131.53, 129.78, 129.68, 129.44, 128.89, 123.87, 123.84, 114.74 (dd, *J* = 25.9, 21.8 Hz). HRMS (ESI): Calcd. for $C_{13}H_8FO_2$ $[M-H]^-$ 215.0514; found 215.0511. UHPLC: purity = 98.7%

4'-fluorobiphenyl-3-carboxylic acid, **8c**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 4-flourophenylboronic acid (1.86 mmol, 256 mg, 1.5 equiv), potassium phosphate (6.20 mmol, 1.32 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **8c** (0.97 mmol, 169 mg, 78 %) as white solid. T_m = 298-299°C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.10 (s, 1H), 7.83 (d, *J* = 7.5 Hz, 1H), 7.75-7.58 (m, 2H), 7.52 (d, *J* = 7.8 Hz, 1H), 7.42-7.19 (m, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 168.9, 162.1 (d, *J* = 243.6 Hz), 142.8, 138.27, 137.8, 137.81, 128.9, 128.9, 128.6, 128.1, 127.7, 126.8, 116.1 (d, *J* = 21.2 Hz). HRMS (ESI): Calcd. for $C_{13}H_8FO_2$ $[M-H]^-$ 215.0514; found 215.0511. UHPLC: purity > 99.5%

2'-(methoxycarbonyl)biphenyl-3-carboxylic acid, **9a**:

According to general procedure B, 3-bromobenzoic acid (0.75 mmol, 150 mg, 1.0 equiv), (2-(methoxycarbonyl)phenyl)boronic acid (1.12 mmol, 201 mg, 1.5 equiv), Na_2CO_3 (3.73 mmol, 395 mg, 5.0 equiv) and $PdCl_2$(dppf) (0.07 mmol, 55 mg, 10 mol%) in anhydrous THF (8 mL) was stirred at 90 °C for 20h. After purification the title compound, **9a** (0.43 mmol, 109 mg, 57%) was obtained as a brown solid. T_m = 206-208°C.^{1}H NMR (400 MHz, Methanol-d_4) δ 7.97-7.92 (m, 2H), 7.77 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.61-7.53 (m, 1H), 7.47-7.36 (m, 3H), 7.31 (dt, *J* = 7.7, 1.5 Hz, 1H), 3.60 (s, 3H). ^{13}C NMR (101 MHz, Methanol-d_4) δ 175.1, 171.0, 143.6, 142.1, 139.2, 132.5, 132.4, 131.8, 131.2, 130.6, 130.3, 129.2, 128.5, 128.3, 52.4. HRMS (ESI): Calcd. for $C_{15}H_{11}O_4$ $[M-H]^-$ 255.0663; found 255.0660. UHPLC: purity > 99.5%

3'-(methoxycarbonyl)biphenyl-3-carboxylic acid, **9b**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 3-Methoxycarbonylphenylboronic acid (1.86 mmol, 335 mg, 1.5 equiv), potassium phosphate (6.20 mmol, 1.32 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **9b** (0.68 mmol, 174 mg, 54 %) as white solid. T_m = 163-164°C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.21 (s, 1H), 8.18 (s, 1H), 7.97-7.94 (m, 2H), 7.88 (d, *J* = 7.6 Hz, 1H), 7.63 (t, *J* = 8.0 Hz, 2H), 7.38 (t, *J* = 7.6 Hz, 1H), 3.91 (s, 3H).^{13}C NMR (101 MHz, DMSO-d_6) δ 168.6, 166.7, 142.9, 141.7, 138.1, 131.8, 130.7, 129.9, 129.1, 128.3, 128.2, 127.7, 127.4, 126.9, 52.7. HRMS (ESI): Calcd. for $C_{15}H_{11}O_4$ $[M-H]^-$ 255.0663; found 255.0669. UHPLC: purity = 97.8 %

4'-acetylbiphenyl-3-carboxylic acid, **10**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 4-acetylphenylboronic acid (1.86 mmol, 305 mg, 1.5 equiv), potassium phosphate (6.20 mmol, 1.32 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **10** (0.68 mmol, 174 mg, 54 %) as white solid. T_m = 287-289°C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.23 (s, 1H), 8.06 (d, *J* = 8.2 Hz, 2H), 7.91 (d, *J* = 7.6 Hz, 1H), 7.82 (d, *J* = 8.1 Hz, 2H), 7.66 (d, *J* = 7.9 Hz, 1H), 7.40 (t, *J* = 7.6 Hz, 1H), 2.63 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 197.9, 168.7, 145.7, 142.9, 138.0, 135.8, 129.5, 129.4, 128.3, 127.9, 127.2, 127.2, 27.2. HRMS (ESI): Calcd. for $C_{15}H_{11}O_3$ $[M-H]^-$ 239.0714; found 239.0709. UHPLC: purity = 95.4 %

3'-carbamoylbiphenyl-3-carboxylic acid, **11a**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 3-aminocarbonylphenylboronic acid (1.86 mmol, 307 mg, 1.5 equiv), potassium phosphate (6.20 mmol, 1.32 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **11a** (1.59 mmol, 383 mg, 85 %) as white solid. T_m = 235-237°C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.25 (s, 1H), 8.23 (s, 2H), 7.93-7.90 (m, 2H), 7.85 (d, *J* = 7.8 Hz, 1H), 7.67 (d, *J* = 7.5 Hz, 1H), 7.59 (t, *J* = 7.7 Hz, 1H), 7.46-7.40 (m, 2H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 168.8, 168.4, 142.9, 141.3, 138.7, 135.4, 129.8, 129.3, 128.9, 128.1, 127.9, 126.9, 126.7, 126.1. HRMS (ESI): Calcd. for $C_{14}H_{10}NO_3$ $[M-H]^-$ 240.0666; found 240.0662. UHPLC: purity = 96.7 %

4'-carbamoylbiphenyl-3-carboxylic acid, **11b**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 4-aminocarbonylphenylboronic acid (1.86 mmol, 307 mg, 1.5 equiv), potassium phosphate (6.20 mmol, 1.32 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **11b** (1.20 mmol, 290 mg, 97 %) as white solid. T_m = 262-263°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.19 (s, 1H), 7.92-7.83 (m, 3H), 7.71-7.59 (m, 3H), 7.37 (t, *J* = 7.7 Hz, 1H). ^{13}C NMR (101 MHz, Methanol-d_4) δ 175.0, 172.1, 145.8, 140.7, 139.9, 133.6, 130.7, 129.9, 129.8, 129.5, 129.3, 129.0, 128.0, 116.5. HRMS (ESI): Calcd. for $C_{14}H_{10}NO_3$ $[M-H]^-$ 240.0666; found 240.0671. UHPLC: purity = 97.5 %

3'-(methylsulfonyl)biphenyl-3-carboxylic acid, **12a**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 3-methanesufonylphenyl boronic acid (1.24 mmol, 248 mg, 1 equiv), potassium phosphate (3.72 mmol, 789 mg, 3 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **21a** (1.02 mmol, 283 mg, 82 %) as white solid. T_m = 96-98°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.20 (s, 1H), 8.15 (s, 1H), 7.95-7.88 (m, 2H), 7.84 (d, *J* = 7.8 Hz, 1H), 7.67-7.61 (m, 2H), 7.40 (t, *J* = 7.7 Hz, 1H), 3.09 (s, 3H).^{13}C NMR (101 MHz, Methanol-d_4) δ 174.8,143.9, 142.8, 140.2, 139.9, 133.3, 131.1, 130.2, 129.8, 129.7, 129.0, 126.9, 126.6, 44.4. HRMS (ESI): Calcd. for $C_{14}H_{11}O_4S$ $[M-H]^-$ 275.0384; found 275.0389. UHPLC: purity = 95.4 %

4'-(methylsulfonyl)biphenyl-3-carboxylic acid, **12b**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 4-methanesufonylphenyl boronic acid (1.24 mmol, 248 mg, 1.0 equiv), potassium phosphate (3.72 mmol, 789 mg, 3.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **21b** (1.12 mmol, 309 mg, 90 %) as white solid. T_m = 127-129°C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.23 (s, 1H), 8.05-7.86 (m, 5H), 7.66 (d, *J* = 7.6 Hz, 1H), 7.41 (t, *J* = 7.6 Hz, 1H), 3.26 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 168.7, 146.2, 142.9, 139.7, 137.6, 129.8, 128.4, 128.10, 127.9, 127.4, 44.1. HRMS (ESI): Calcd. for $C_{14}H_{11}O_4S$ $[M-H]^-$ 275.0384; found 275.0380. UHPLC: purity = 96.2 %

4'-aminobiphenyl-3-carboxylic acid, **13**:

According to general procedure A, 4-bromoaniline (1.45 mmol, 250 mg, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (2.18 mmol, 541 mg, 1.5 equiv) potassium phosphate (7.27 mmol, 1.54 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.15 mmol, 102 mg, 10 mol%), gave **13** (0.51 mmol, 109 mg, 35%) as a white solid. T_m = 195°C.^{1}H NMR (400 MHz, methanol-d_4) δ 8.13 (t, *J* = 1.8 Hz, 1H), 7.85-7.77 (m, 1H), 7.65-7.57 (m, 2H), 7.41 (t, *J* = 7.7 Hz, 1H), 6.90-6.84 (m, 2H). ^{13}C NMR (101 MHz, Methanol-d_4) δ 169.0, 148.0, 141.9, 139.3, 128.2, 127.3, 127.0, 126.5, 126.1, 125.2, 114.2. HRMS (ESI): Calcd. for $C_{13}H_{10}O_2N$ $[M-H]^-$ 212.0717; found 212.0712. HPLC, purity = 98.3 %

4'-dimethylaminobiphenyl-3-carboxylic acid, **14**:

According to general procedure A, 3-bromobenzoic acid (0.75 mmol, 150 mg, 1.0 equiv), 3-dimethylaminophenyl) boronic acid (1.12 mmol, 185 mg, 1.5 equiv), potassium phosphate (3.73 mmol, 792 mg, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.07 mmol, 52 mg, 10 mol%) gave **14** (0.71 mmol, 172 mg, 95%) as red solid. T_m = 192-194°C. ^{1}H NMR (400 MHz, deuterium oxide) δ 8.09 (t, *J* = 1.7 Hz, 1H), 7.89-7.80 (m, 1H), 7.68-7.60 (m, 1H), 7.47 (t, *J* = 7.7 Hz, 1H), 7.32 (t, *J* = 7.9 Hz, 1H), 7.12 (t, *J* = 2.0 Hz, 1H), 7.11-7.04 (m, 1H), 6.96-6.88 (m, 1H), 2.80 (s, 6H). ^{13}C NMR (101 MHz, Deuterium Oxide) δ 175.3, 151.8, 141.2, 140.7, 136.8, 129.9, 129.6, 128.8, 127.9, 127.4, 118.1, 114.9, 113.8, 41.1. HRMS (ESI): Calcd. for $C_{15}H_{14}NO_2$ $[M-H]^-$ 240.1030; found 240.1029. HPLC purity = 95.1 %

3'-(aminomethyl)biphenyl]-3-carboxylic acid, **15a**:

According to general procedure A, 3-bromobenzylamin hydrochloride (250 mg, 1.12 mmol, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzoic acid (1.69 mmol, 418 mg, 1.5 equiv), potassium phosphate (5.62 mmol, 1.19 g, 5.0 equiv), $PdCl_2(PPh_3)_2$ (0.11 mmol, 79 mg, 10 mol%), after purification by flash chromatography on silica gel using a mixture of an acidic stock solution (acetic acid/H_2O/MeOH/ethyl acetate, 3:2:3:3) and ethyl acetate (1:9), then acidic stock solution/ethyl acetate (1:2) as eluent, gave **15a** (0.40 mmol, 91 mg, 36%) as a slightly yellow solid. T_m = 346°C (decomposes).^{1}H NMR (400 MHz, Deuterium Oxide) δ 8.06 (d, *J* = 1.8 Hz, 1H), 7.80-7.77 (m, 1H), 7.66-7.63 (m, 1H), 7.52-7.42 (m, 3H), 7.38 (t, *J* = 7.6 Hz, 1H), 7.25 (d, *J* = 7.5 Hz, 1H), 3.71 (s, 2H). ^{13}C NMR (101 MHz, Deuterium Oxide) δ 176.1, 144.2, 141.5, 141.4, 138.1, 130.4, 130.3, 129.8, 128.9, 128.3, 127.6, 126.7, 126.4, 45.8. HRMS (ESI): Calcd. for $C_{14}H_{12}NO_2$ $[M-H]^-$ 226.0874; found 226.0872. UHPLC: purity = 95.2 %

4'-(aminomethyl)biphenyl-3-carboxylic acid, **15b**:

According to general procedure A, 4-bromobenzylamin hydrochloride (250 mg, 1.12 mmol, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzoic acid (1.69 mmol, 418 mg, 1.5 equiv), potassium phosphate (5.62 mmol, 1.19 g, 5.0 equiv), $PdCl_2(PPh_3)_2$ (0.11 mmol, 79 mg, 10 mol%), after purification by flash chromatography on silica gel using a mixture of an acidic stock solution (acetic acid/H_2O/MeOH/ethyl acetate, 3:2:3:3) and ethyl acetate (1:9), then acidic stock solution/ethyl acetate (1:2) as eluent, gave **15b** (0.96 mmol, 220 mg, 86%) as a slightly yellow solid. T_m = 213-215°C. ^{1}H NMR (400 MHz, Deuterium Oxide) δ 8.00 (s, 1H), 7.74 (d, *J* = 7.7 Hz, 1H), 7.64 (d, *J* = 8.2 Hz, 1H), 7.54 (d, *J* = 8.0 Hz, 2H), 7.42 (t, *J* = 7.7 Hz, 1H), 7.31 (d, *J* = 8.0 Hz, 1H), 3.67 (s, 2H). ^{13}C NMR (101 MHz, Deuterium Oxide) δ 175.3, 141.9, 140.1, 138.5, 136.9, 129.4, 128.9, 127.9, 127.8, 127.1, 127.0, 44.3. HRMS (ESI): Calcd. for $C_{14}H_{12}NO_2$ $[M-H]^-$ 226.0874; found 226.0872. UHPLC: purity = 83.2 %

3'-(2-aminoethyl)biphenyl-3-carboxylic acid, **16a**:

According to general procedure A, 3-bromobenzylamin hydrochloride (250 mg, 1.25 mmol, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzoic acid (1.87 mmol, 465 mg, 1.5 equiv), potassium phosphate (1.33 mmol, 1.33 g, 5.0 equiv), $PdCl_2(PPh_3)_2$ (0.12 mmol, 88 mg, 10 mol%), after

purification by flash chromatography on silica gel using a mixture of an acidic stock solution (acetic acid/H_2O/MeOH/ethyl acetate, 3:2:3:3) and ethyl acetate (1:9), then acidic stock solution/ethyl acetate (1:2) as eluent, gave **16a** (0.19 mmol, 45 mg, 15%) as a slightly yellow solid. T_m = 232-235°C. ^{1}H NMR (400 MHz, Methanol-*d*$_4$) δ 8.23 (s, 1H), 7.93-7.91 (m, 1H), 7.65-7.63 (m, 1H), 7.52-7.48 (m, 2H), 7.43-7.31 (m, 2H), 7.20-7.18 (m, 1H), 2.97 (t, J = 7.1 Hz, 2H), 2.85 (t, J = 7.1 Hz, 2H). ^{13}C NMR (101 MHz, Methanol-*d*$_4$) δ 173.8, 141.1, 140.2, 139.4, 138.0, 128.5, 128.1, 127.7, 127.6, 127.4, 127.2, 127.0, 124.6, 42.3, 38.1. HRMS (ESI): Calcd. for $C_{14}H_{12}O_2N$ $[M-H]^-$ 240.1030; found 240.1028. UHPLC: purity = 95.5 %

4'-(2-aminoethyl)biphenyl-3-carboxylic acid, **16b**:

The compound was prepared according to general procedure A. 4-Bromophenethylamine (1.25 mmol, 250 mg, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (1.87 mmol, 465 mg, 1.5 equiv), potassium phosphate (6.25 mmol, 1.33 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.12 mmol, 88 mg, 10 mol%), after purification by flash chromatography on silica gel with a mixture of an acidic stock solution (acetic acid/H_2O/MeOH/ethyl acetate, 3:2:3:3) and ethyl acetate (1:9), then acidic stock solution/ethyl acetate (1:2) as eluent, gave **16b** (0.84 mmol, 201 mg, 67%) as a slightly brownish solid. T_m = 312°C (decomposes). ^{1}H NMR (400 MHz, Deuterium Oxide) δ 8.06 (s, 1H), 7.79 (d, *J* = 7.7 Hz, 1H), 7.67 (d, *J* = 8.2 Hz, 1H), 7.55 (d, *J* = 7.9 Hz, 4H), 7.46 (t, *J* = 7.7 Hz, 2H), 7.27 (d, *J* = 7.9 Hz, 5H), 2.79 (t, *J* = 7.0 Hz, 4H), 2.69 (t, *J* = 6.9 Hz, 4H).^{13}C NMR (101 MHz, Methanol-*d*$_4$) δ 176.2, 141.2, 140.7, 139.0, 138.0, 130.5, 130.3, 129.9, 128.7, 128.0, 127.9, 43.1, 38.8. HRMS (ESI): Calcd. for $C_{15}H_{14}NO_2$ $[M-H]^-$ 240.1030; found 240.1029. UHPLC: purity = 95.8 %

4'-(methylsulfonamido)biphenyl-3-carboxylic acid, **17**:



Synthesis of *N*-(4-bromobenzyl)methanesulfonamide: To a solution of methanesulfonyl chloride (1.60 mmol, 0.12 mL, 1.0 equiv) in ethanol (5 mL) 4-bromoaniline (3.20 mmol, 550 mg, 2.0 equiv) was added and the mixture was stirred at room temperature. The reaction was monitored by TLC until completion. After 2 h, the solvent was removed under reduced pressure and the remaining solid dissolved in a small amount of water. The remaining solid was dissolved in a small amount of water and applied to a C18 precolumn before purification on a 60 g C18 column with a gradient of acetonitrile in water (10-80%) to yield the sulfonamide (0.93 mmol, 232 mg, 93%) as a white solid. ^{1}H NMR (400 MHz, CH_3OD): δ 7.27 (2H, dd, J = 8.8 Hz, J = 2.0 Hz), 7.02 (2H, dd, J = 9.0 Hz, J= 2.1 Hz), 2.84 (3H, s). ^{13}C NMR (101 MHz, CH_3OD): δ 146.5, 132.6, 123.8, 113.5, 39.0. HRMS (ESI): Calcd. for $C_7H_7O_2NBrS$ $[M+H]^+$ 247.9386; found 247.9389.

Synthesis of 4'-(methylsulfonamido)biphenyl-3-carboxylic acid, **17**: The compound was prepared according to general procedure B. *N*-(4-bromobenzyl)methanesulfonamide, (0.72 mmol, 180 mg, 1.5 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (0.48 mmol, 119 mg, 1.0 equiv), Na_2CO_3 (2.40 mmol, 254 mg, 5.0 equiv) and $PdCl_2$(dppf) (0.05 mmol, 35 mg, 10 mol%) in anhydrous THF (6 mL) was stirred at 80 °C for 20h. After purification the title compound, **17** (0.20 mmol, 58 mg, 41%) was obtained as a yellowish solid. T_m = 280°C. ^{1}H NMR (400 MHz, Methanol-*d*$_4$) δ 8.20 (t, *J* = 1.8 Hz, 1H), 7.84 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.66-7.58 (m, 1H), 7.55-7.49 (m, 2H), 7.38 (t, *J* = 7.7 Hz, 1H), 7.23-7.16 (m, 2H), 2.88 (s, 3H). ^{13}C NMR (101 MHz, Methanol-*d*$_4$) δ 175.7, 147.0, 142.0, 139.5, 134.1, 129.1, 129.0, 128.3, 128.2, 122.5, 39.0, 25.0. HRMS (ESI): Calcd. for $C_{14}H_{12}NO_4S$ $[M-H]^-$ 290.0493 found 290.0485. UHPLC: purity > 99.5%

4'-(phenylsulfonamido)biphenyl-3-carboxylic acid, **18:**



Synthesis of *N*-(4-bromophenyl)benzenesulfonamide: To a solution of benzenesulfonyl chloride (1.28 mmol, 0.16 mL, 1.0 equiv) in ethanol (5 mL) 4-bromoaniline (2.56 mmol, 441 mg, 2.0 equiv) was added and the mixture stirred at rt. The reaction was monitored by TLC until completion. After 2 h the solvent was removed and the remaining solid dissolved in ethyl acetate. The solution was submitted to a silica precolumn and purified on a silica column with a gradient of ethyl acetate in heptane (10-35%) and then a constant value of 35% ethyl acetate in heptane. The title compound (300 mg, 75%) was obtained as a yellowish solid. ^{1}H NMR (400 MHz, Chloroform- *d*): δ 7.78-7.74 (m, 2H), 7.82-7.76 (m, 2H), 7.55 (m, 1H), 7.49-7.43 (m, 2H), 7.37-7.32 (m, 2H), 7.00-6.95 (m, 2H). ^{13}C NMR (101 MHz, Chloroform- *d*): δ 138.7, 135.6, 133.4, 132.5, 129.3, 127.3, 123.4, 118.9. HRMS (ESI): Calcd. for $C_{12}H_9O_2BrNS$ $[M+H]^+$ 309.9543; found 309.9537.

Synthesis of 4'-(phenylsulfonamido)biphenyl-3-carboxylic acid, **18**: The compound was prepared according to general procedure B. *N*-(4-bromophenyl)benzenesulfonamide (0.48 mmol, 150 mg, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (0.72 mmol, 180 mg, 1.5 equiv), potassium phosphate (1.92 mmol, 408 mg, 4.0 equiv) and XPhos-Pd G2 ($4.8x10^{-3}$ mmol, 3.8 mg, 1 mol%) in anhydrous THF (4 mL) was stirred at 84 °C for 16 h. The aqueous phase was washed with hexane (3 x 30 mL). After purification **18** (0.31 mmol, 110 mg, 65%) was obtained as beige solid. T_m = 303°C. ^{1}H NMR (400 MHz, Methanol-d_4) δ 8.09 (s, 1H), 7.94-7.83 (m, 2H), 7.75 (d, *J* = 9.2 Hz, 1H), 7.51 (d, *J* = 9.5 Hz, 1H), 7.41-7.24 (m, 6H), 6.98 (d, *J* = 8.5 Hz, 2H). ^{13}C NMR (101 MHz, Methanol-d_4) δ 175.8, 148.9, 146.6, 142.2, 139.3, 132.8, 131.3, 129.3, 129.0, 128.9, 128.0, 127.9, 127.9, 127.8, 123.0. HRMS (ESI): Calcd. for $C_{19}H_{14}NO_4S$ $[M-H]^-$ 352.0649; found, 352.0642. UHPLC: purity = 95.6 %

3'-(methylsulfonamidomethyl)biphenyl-3-carboxylic acid, **19a**:



Synthesis of *N*-(3-bromobenzyl)methanesulfonamide: A solution of 3-bromobenzylamine hydrochloride (1.51 mmol, 337 mg, 1.0 equiv) and triethylamine (3.18 mmol, 0.44 mL, 2.1 equiv) in CH_2Cl_2 (5.5 mL) was cooled to 0 °C. Methanesulfonyl chloride (1.52 mmol, 0.12 mL, 1.01 equiv) was added dropwise and the reaction mixture was allowed to warm to room temperature with stirring. The reaction was monitored by TLC until completion. After 1h 45 minutes the reaction was stopped and the mixture was washed with water (3 x 10 mL). The organic layer was dried over $MgSO_4$, filtrated and the solvent removed under reduced pressure. The title compound (1.34 mmol, 349 mg, 88%) was obtained as a offwhite solid and used in the next step without further purification. ^{1}H NMR (400 MHz, methanol-d_4): δ 7.51 (t, J = 1.9 Hz, 1H), 7.45 (dt, J_1 = 7.6 Hz, J_2 = 1.6 Hz, 1H), 7.29 (m, 1H), 7.24 (t, J = 7.6 Hz, 1H), 4.81 (s, 1H), 4.30 (s, 2H), 2.90 (s, 3H). ^{13}C NMR (101 MHz, methanol-d_4): δ 139.2, 131.3, 131.0, 130.6, 126.6, 123.0, 46.6, 41.3. HRMS (ESI): Calcd. for $C_8H_{10}O_2NBrNaS$ $[M+Na]^+$ 285.9508; found 285.9503.

Synthesis of 3'-(methylsulfonamidomethyl)biphenyl-3-carboxylic acid, **19a**: The compound was synthesized according to general procedure B. *N*-(3-bromobenzyl) methanesulfonamide, (0.57 mmol, 150 mg, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzoic acid (0.85 mmol, 211 mg, 1.5 equiv), Na_2CO_3 (2.84 mmol, 301 mg, 5.0 equiv) and $PdCl_2$(dppf) (0.06 mmol, 42 mg, 10 mol%) in anhydrous THF (8 mL), was stirred at 84 °C for 20 h. Additional purification was carried out by flash chromatography on silica gel with hexane/ethyl acetate/acetic acid (1:1:1%). To the resulting solid was added heptane (10 mL x 3) and removed under reduced pressure to remove residual acetic acid. The title compound, **19a** (0.15 mmol, 45 mg, 26%) was obtained as a slightly yellow solid. T_m = 175-177°C. ^{1}H NMR (400 MHz, Methanol-d_4) δ) δ 8.28 (s, 1H), 8.01 (d, *J* = 7.7 Hz, 1H), 7.86 (d, *J* = 7.9 Hz, 1H), 7.68 (s, 1H), 7.60-7.54 (m, 4H), 7.47 (t, *J* = 7.6 Hz, 2H), 7.41 (d, *J* = 7.7 Hz, 2H). ^{13}C NMR (101 MHz, Methanol-d_4) δ 169.9, 142.4, 141.9, 140.2, 132.9, 132.4, 130.4, 130.1, 129.7, 129.1, 128.4, 127.6, 127.3, 47.7, 40.6. HRMS (ESI): Calcd. for $C_{15}H_{14}NO_4S$ $[M-H]^-$ 304.0649; found 304.0647. UHPLC: purity = 95.0 %

4'-(methylsulfonamidomethyl)biphenyl-3-carboxylic acid, **19b**:



Synthesis of *N*-(4-bromobenzyl)methanesulfonamide: The compound was prepared according to the procedure described for *N*-(3-bromobenzyl)methanesulfonamide. The title compound (1.45 mmol, 380 mg, 95%) was obtained as a beige solid. ^{1}H NMR (400 MHz, chloroform-*d*): δ 7.49 (m, 2H), 7.23 (m, 2H), 4.80 (s, 1H), 4.27 (d, *J* = 4.5 Hz, 2H), 2.88 (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$): δ 135.9, 132.2 (2C), 129.7 (2C), 122.2, 46.7, 41.4. HRMS (ESI): Calcd. for $C_8H_{10}O_2NBrClS$ $[M+Cl]^+$ 285.9508; found, 299.2368.

Synthesis of 4'-(methylsulfonamidomethyl)biphenyl-3-carboxylic acid, **19b**. The compound was prepared according to general procedure B. *N*-(4-bromobenzyl)methanesulfonamide (0.57 mmol, 150 mg, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (0.85 mmol, 211 mg, 1.5 equiv), Na_2CO_3 (2.84 mmol, 301 mg, 5.0 equiv) and $PdCl_2$(dppf) (0.06 mmol, 42 mg, 10 mol%) in anhydrous THF (8 mL) was stirred at 84 °C for 20 h. Additional purification was carried out by flash chromatography on silica gel with hexane/ethyl acetate/acetic acid (10:10:0.1) as eluent. To the resulting solid was added heptane (10 mL) and removed under reduced pressure (3 times) to remove residual acetic acid. The title compound, **19b** (0.06 mmol, 17 mg, 10%) was obtained as a white solid. T_m = 216-220°C. ^{1}H NMR (400 MHz, Methanol-d_4) δ 8.16 (s, 1H), 7.90 (d, *J* = 7.7 Hz, 1H), 7.75 (d, *J* = 7.8 Hz, 1H), 7.56 (d, *J* = 8.1 Hz, 2H), 7.49-7.36 (m, 3H), 4.21 (s, 2H), 2.78 (s, 3H). ^{13}C NMR (101 MHz, Methanol-d_4) δ 170.1, 142.2, 140.8, 139.0, 133.1, 132.2, 130.1, 129.6, 129.6, 129.0, 128.2, 47.4, 40.6. HRMS (ESI): Calcd. for $C_{15}H_{14}O_4NS[M-H]^-$ 304.0649; found 304.0646. UHPLC: purity = 96.4 %

3'-(2-methylsulfonamidoethyl)biphenyl-3-carboxylic acid, **20**:



Synthesis of *N*-(3-bromophenethyl)methanesulfonamide: To a solution of methanesulfonyl chloride (1.60 mmol, 0.12 mL, 1.0 equiv) in ethanol (3 mL), 2-(3-bromophenyl)ethan-1-amine (3.20 mmol, 639 mg, 2.0 equiv) was added and the mixture was stirred at room temperature. The reaction was monitored by TLC. After completion the solvent was removed under reduced pressure and the remaining solid dissolved in a small amount of water. The solution was applied to a C18 precolumn before purification on a 60 g C18 column with a gradient of acetonitrile in water (10–80%). The title compound (1.07 mmol, 295 mg, 66%) was obtained as a white solid. ^{1}H NMR (400 MHz, chloroform-*d*): δ 7.41-7.36 (m, 2H), 7.19 (t, *J* = 7.6 Hz 1H), 7.15 (m, 1H), 3.38 (t, *J* = 6.9 Hz, 2H), 2.86 (s, 3H), 2.85 (t, *J* = 7.6 Hz, 2H). ^{13}C NMR (101 MHz, chloroform-*d*): δ 140.3, 132.0, 130.5, 130.2, 127.7, 123.0, 44.2, 40.6, 36.3. HRMS (ESI): Calcd. for $C_9H_{13}O_2NBrS$ $[M+H]^+$ 277.9850; found 277.9674.

Synthesis of 3'-(2-methylsulfonamidoethyl)biphenyl-3-carboxylic acid, **20**: The compound was prepared according to general procedure B. *N*-(3-bromophenethyl)methanesulfonamide (0.72 mmol, 200 mg, 1.5 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (0.48 mmol, 119 mg, 1.0 equiv), Na_2CO_3 (2.40 mmol, 254 mg, 5.0 equiv) and $PdCl_2$(dppf) (0.05 mmol, 35 mg, 10 mol%) in anhydrous THF (8 mL) was stirred at 85 °C for 20h. The aqueous mixture was washed with hexane (3 x 30 mL) instead of ethyl acetate. After purification the title compound, **20** (0.11 mmol, 35 mg, 11%) was obtained as a white solid). T_m = 130°C. ^{1}H NMR (400 MHz, Methanol-d_4) δ 8.24 (t, *J* = 1.8 Hz, 1H), 7.93 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.67 (s, 1H), 7.57 (s, 1H), 7.53 (d, *J* = 7.8 Hz, 1H), 7.41 (m, 2H), 7.24 (d, *J* = 7.7 Hz, 1H), 3.40-3.34 (m, 2H), 2.92 (t, *J* = 7.4 Hz, 2H), 2.82 (s, 3H). ^{13}C NMR (101 MHz, Methanol-d_4) δ 175.3, 142.6, 141.8, 140.8, 139.7, 130.1, 129.7, 129.3, 129.2, 129.0, 128.9, 128.7, 126.2, 45.7, 39.9, 37.8. HRMS (ESI): Calcd. $C_{16}H_{16}O_4NS$ $[M-H]^-$ 318.0806; found 318.0797. UHPLC: purity = 99.0 %

3'-acetamidobiphenyl-3-carboxylic acid, **21a**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1 equiv), 3-acetamidophenylboronic acid (1.86 mmol, 333 mg, 1.5 equiv), potassium phosphate (6.20 mmol, 1.32 g, 5 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **21a** (1.21 mmol, 310 mg, 98 %) as white solid. T_m = 294°C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 10.30 (s, 1H), 8.15 (t, *J* = 1.7 Hz, 1H), 7.91 (t, *J* = 1.9 Hz, 1H), 7.84 (dt, *J* = 7.6, 1.3 Hz, 1H), 7.64 (d, *J* = 9.0 Hz, 1H), 7.52-4.49 (m, 1H), 7.40-7.27 (m, 3H), 2.08 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 169.0168.9, 142.6, 141.7, 140.4, 139.2, 129.6, 128.7, 128.1, 127.7, 126.8, 121.6, 118.1, 117.7, 24.5. HRMS (ESI): Calcd. for $C_{15}H_{12}NO_3$ $[M-H]^-$ 254.0823; found 254.0828. UHPLC: purity = 97.4 %

4'-acetamidobiphenyl-3-carboxylic acid, **21b**:

According to procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 4-acetamidophenylboronic acid (1.86 mmol, 307 mg, 1.5 equiv), potassium phosphate (6.20 mmol, 1.32 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 87 mg, 10 mol%) gave **21b** (1.20 mmol, 290 mg, 97 %) as white solid. T_m = 295-296°C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 10.29 (s, 1H), 8.13 (s, 1H), 7.80 (d, *J* = 7.4 Hz, 1H), 7.71 (d, *J* = 8.3 Hz, 2H), 7.58 (d, *J* = 8.3 Hz, 2H), 7.53 (d, *J* = 7.6 Hz, 1H), 7.31 (t, *J* = 7.5 Hz, 1H), 2.08 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 168.9, 168.9, 142.7, 139.1, 138.9, 135.8, 128.1, 128.0, 127.3, 127.1, 126.4, 119.8, 24.50. HRMS (ESI): Calcd. for $C_{15}H_{12}NO_3$ $[M-H]^-$ 254.0823; found 254.0818. UHPLC: purity = 99.1 %

3'-(acetamidomethyl)biphenyl-3-carboxylic acid, **22**:



Synthesis of *N*-(3-bromobenzyl)acetamide: A solution of 3-bromobenzylamine hydrochloride (1.75 mmol, 389 mg, 1.0 equiv) and Et_3N (17.5 mmol, 2.44 mL, 10.0 equiv) in CH_2Cl_2 (3.5 mL) was cooled to 0 °C. Acetyl chloride (2.28 mmol, 0.16 mL, 1.3 equiv) was added and the mixture was stirred for 3 h at 30 °C. The solvent was removed under reduced pressure and the resulting solid dissolved in CH_2Cl_2 (40 mL). The organic phase was washed with 1N HCl (1 x) and water (3 x 30 mL). It was dried over Na_2SO_4, filtered and the solvent removed under reduced pressure. The title compound (373 mg, 93%) was obtained as a yellowish solid and used without further purification for the next step. ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.43-7.38 (m, 2H), 7.22-7.18 (m, 2H), 4.41 (m,2H), 2.03 (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$): δ 170.1, 140.8, 130.8, 130.7, 130.4, 126.5, 122.8, 43.2, 23.4. HRMS (ESI): Calcd. for $C_9H_{11}ONBr$ $[M+H]^+$ 228.0019; found, 228.0018; $[M + Na]^+$, calcd for $C_9H_{10}ONBrNa$, 249.9838; found, 249.9837.

Synthesis of 3'-(acetamidomethyl)biphenyl-3-carboxylic acid, **22:** According to general procedure B, *N*-(3-bromobenzyl)acetamide (0.66 mmol, 150 mg, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (0.99 mmol, 245 mg, 1.5 equiv), potassium phosphate (2.63 mmol, 558 mg, 4.0 equiv) and XPhos-Pd G2 ($6.6x10^{-3}$ mmol, 5.2 mg, 1 mol%) in anhydrous THF (4 mL) was stirred at 85 °C for 16.5 h. The aqueous mixture was washed with hexane (3 x 30 mL). After purification the title compound, **22** (0.57 mmol, 155 mg, 87%) was obtained as a white solid. T_m = 129°C. ^{1}H NMR (400 MHz, Methanol-d_4) δ 8.23 (s, 1H), 7.93 (d, *J* = 9.0 Hz, 1H), 7.66 (d, *J* = 6.2 Hz, 1H), 7.62-7.51 (m, 2H), 7.38-7.45 (m, 2H), 7.27 (d, *J* = 7.5 Hz, 1H), 4.43 (s, 2H), 2.01 (s, 3H). ^{13}C NMR (101 MHz, Methanol-d_4) δ 175.3, 173.1, 142.7, 141.7, 140.5, 139.8, 130.1, 129.7, 129.3, 129.3, 128.9, 127.6, 127.3, 126.9, 44.3, 25.0. HRMS (ESI): Calcd. for $C_{16}H_{14}NO_3$ $[M-H]^-$ 268.0979; found 268.0977. UHPLC: purity = 82.6 %

3'-(2-acetamidoethyl)biphenyl-3-carboxylic acid, **23a**:



Synthesis of *N*-(3-bromophenethyl)acetamide: To a solution of 2-(3-bromophenyl)ethan-1-amine (1.65 mmol, 0.24 mL, 1.0 equiv) in CH_2Cl_2 (3.5 mL), Et_3N (1.82 mmol, 0.25 mL, 1.1 equiv) and acetic anhydride (1.98 mmol, 0.19 mL, 1.2 equiv) were added. The reaction mixture was stirred at rt and monitored by TLC. After 1.5 h the solvent was removed under reduced pressure and the resulting yellow oil diluted with CH_2Cl_2. The organic phase was washed with water (3 x 20 mL), dried over Na_2SO_4, filtered and the solvent removed under reduced pressure. The title compound (400 mg, 100%) was obtained as a yellowish oil. ^{1}H NMR (400 MHz, Chloroform- *d*): δ 7.38-7.32 (m, 2H), 7.17 (m, 1H), 7.11 (m, 1H), 5.64 (1H, s), 3.48 (m, 2H), 2.78 (t, *J* = 7.0 Hz, 2H), 1.94 (3H, s). ^{13}C NMR (101

MHz, Chloroform- *d*): δ 170.3, 141.4, 131.9, 130.3, 129.8, 127.5, 122.8, 40.6, 35.4, 23.4. HRMS (ESI): Calcd. for $C_{10}H_{13}ONBr$ $[M+H]^+$ 242.0175; found 242.0174.

Synthesis of 3'-(2-acetamidoethyl)biphenyl-3-carboxylic acid, **23a**: The compound was prepared according to general procedure B. *N*-(3-bromophenethyl)acetamide (0.62 mmol, 150 mg, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (0.93 mmol, 231 mg, 1.5 equiv), Na_2CO_3 (3.10, 328 mg, 5.0 equiv) and $PdCl_2$(dppf) (0.06 mmol, 45 mg, 10 mol%) in anhydrous THF (8 mL) was stirred at 85 °C for 19 h. After RP chromatography, the compound was further purified by flash chromatography on silica gel using a mixture of an acidic stock solution (acetic acid/H_2O/MeOH/ethyl acetate, 3:2:3:3) and ethyl acetate (1:25) as eluent. To the resulting solid heptane (10 mL x 3) was added and removed under reduced pressure to remove residual acetic acid. Compound **23a** (0.29 mmol, 80 mg, 46%) was obtained as a slightly yellow solid. T_m = 54-56°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.25 (s, 1H), 7.99 (d, *J* = 7.7 Hz, 1H), 7.81 (d, *J* = 8.7 Hz, 1H), 7.57 – 7.45 (m, 3H), 7.38 (t, *J* = 7.6 Hz, 1H), 7.23 (d, *J* = 7.5 Hz, 1H), 3.44 (t, *J* = 7.3 Hz, 2H), 2.87 (t, *J* = 7.3 Hz, 2H), 1.92 (s, 3H). ^{13}C NMR (101 MHz, methanol-d_4) δ 174.7, 171.9, 144.0, 143.1, 142.7, 133.5, 131.5, 131.3, 130.8, 130.6, 130.5, 129.9, 127.5, 43.4, 37.9, 23.9. HRMS (ESI): Calcd. for $C_{17}H_{16}NO_3$ $[M-H]^-$ 282.1136; found 282.1129. UHPLC: purity = 97.9 %

4'-(2-acetamidoethyl)biphenyl-3-carboxylic acid, **23b**:



Synthesis of N-(3'-bromobiphenyl-3-yl)methylacetamide: The compound was prepared according to the procedure described for starting material of **23a**. The title compound (399 mg, 100%) was obtained as a white solid. ^{1}H NMR (400 MHz, Chloroform- *d*): δ 7.42 (m, 2H), 7.06 (m, 2H), 5.54 (s, 1H), 3.47 (m, 2H), 2.77 (t, *J* = 7.0 Hz, 2H), 1.93 (s, 3H). ^{13}C NMR (101 MHz, Chloroform- *d*): δ 170.2, 138.0, 131.8, 130.6, 120.5, 40.6, 35.2, 23.4. HRMS (ESI): Calcd. for $C_{10}H_{13}ONBr$ $[M+H]^+$ 242.0175; found 242.0177.

Synthesis of 4'-(2-acetamidoethyl)biphenyl-3-carboxylic acid, **23b**. The compound was prepared according to general procedure B. N-(3'-bromobiphenyl-3-yl)methylacetamide (0.62 mmol, 150 mg, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (0.93 mmol, 231 mg, 1.5 equiv), Na_2CO_3 (3.10 mmol, 328 mg, 5.0 equiv) and $PdCl_2$(dppf) (0.06 mmol, 45 mg, 10 mol%) in anhydrous THF (8 mL) was stirred at 85 °C for 18.5 h. After RP chromatography, the compound was further purified by flash chromatography on silica gel using a mixture of an acidic stock solution (acetic acid/H_2O/MeOH/ethyl acetate, 3:2:3:3) and ethyl acetate (1:59) and then acidic stock solution/ethyl acetate (1:9) as eluent. To the resulting solid heptane (10 mL x 3) was added and removed under reduced pressure to remove residual acetic acid. Compound **23b** (0.21 mmol, 60 mg, 34%) was obtained as a white solid. T_m = 204-205°C. ^{1}H NMR (400 MHz, Methanol-d_4) δ 8.24 (s, 1H), 7.98 (d, *J* = 7.7 Hz, 1H), 7.82 (d, *J* = 7.7 Hz, 1H), 7.62-7.47 (m, 3H), 7.32 (d, *J* = 8.2 Hz, 2H), 3.43 (t, *J* = 7.3 Hz, 2H), 2.84 (t, *J* = 7.3 Hz, 2H), 1.92 (s, 3H). ^{13}C NMR (101 MHz, Methanol-d_4) δ 211.4, 174.7, 171.3, 143.9, 141.7, 140.9, 134.0, 133.7, 131.9, 131.4, 130.8, 130.3, 129.5, 129.4, 43.4, 37.5, 23.9. HRMS (ESI): Calcd. for $C_{17}H_{16}NO_3$ $[M-H]^-$ 282.1136; found 282.1129. UHPLC: purity = 99.2%

3'-acetoxymethylbiphenyl-3-carboxylic acid, **24**:



Synthesis of 3-(acetoxymethylphenyl)boronic acid: To a stirred mixture of (3-(hydroxymethylphenyl) boronic acid (1.03 mmol, 157 mg, 1.0 equiv), DMAP (0.11 mmol, 14 mg, 11 mol%) and Et_3N (3.09 mmol, 0.43 mL, 3.0 equiv) in CH_2Cl_2/anhydrous THF (7.2 mL, 5:1) and acetic anhydride (3.09 mmol, 0.29 mL, 3.0 equiv) was added. The solution was stirred at rt and monitored by TLC. After 5h the reaction mixture was washed with 1N HCl (3 x 20 mL) and $NaHCO_3$ solution (3 x 20 mL). The organic phase was dried over Na_2SO_4, filtered and the solvent removed under reduced pressure. The crude product was purified with flash chromatography on silica gel with 5% MeOH in CH_2Cl_2 as eluent. The title compound (0.86 mmol, 166 mg, 86%) was obtained as a white solid. ^{1}H NMR (400 MHz, Methanol-d_4): δ 7.73-7.44 (m, 2H), 7.37-7.20 (m, 2H), 5.03 (2H, s), 2.00 (s, 3H). ^{13}C NMR (101 MHz, Methanol-d_4): δ 172.7, 134.7, 134.4, 131.1, 130.6, 128.7, 67.5, 20.8. HRMS (ESI): Calcd. for $C_9H_{10}O_4B$ $[M-H]^-$ 193.0678; found 193.0680.

Synthesis of 3'-acetoxymethyl-biphenyl-3-carboxylic acid **24**: According general procedure B, 3-(acetoxymethyl)phenyl)boronic acid, **7** (0.39 mmol, 75 mg, 1.5 equiv), potassium phosphate (1.03 mmol, 219 mg, 4.0 equiv), XPhos Pd G2 ($2.58x10^{-3}$ mmol, 2.0 mg, 1 mol%), in anhydrous THF (6 mL) was stirred at 88 °C for 20 h. The crude product was purified by flash chromatography on silica gel with hexane/ethyl acetate/acetic acid (9:1:1%) as eluent gave **24** (0.13 mmol, 35 mg, 34%) as a brownish solid. T_m = 80°C. ^{1}H NMR (400 MHz, Methanol-d_4) δ 8.26 (s, 1H), 8.01 (d, *J* = 7.7 Hz, 1H), 7.85 (d, *J* = 7.7 Hz, 1H), 7.68-7.51 (m, 3H), 7.47 (t, *J* = 7.6 Hz, 1H), 7.38 (d, *J* = 7.7 Hz, 1H), 5.18 (s, 2H), 2.10 (s, 3H). ^{13}C NMR (101 MHz, Methanol-d_4) δ 172.7, 169.8, 142.4, 141.8, 138.5, 132.7, 132.5, 130.3, 130.1, 129.7, 129.1, 128.6, 127.9, 67.2, 20.8. HRMS (ESI): Calcd. for $C_{16}H_{13}O_4$ $[M-H]^-$ 269.0819; found 269.0817. UHPLC: purity = 95.7%

4'-(1H-imidazol-1-yl)biphenyl-3-carboxylic acid, **25**:

According to general procedure A, 5-bromo-2-(1H-imidazol-1-yl)pyrimidine (0.39 mmol, 100 mg, 1.0 equiv), 3-carboxyphenylboronic acid pinacol ester (0.39 mmol, 97 mg, 1.0 equiv), potassium phosphate (1.95 mmol, 413 mg, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.04 mmol, 27 mg, 10 mol%) after purification gave **25** (0.28 mmol, 75 mg, 72%) was obtained as a white solid. T_m = 297°C. ^{1}H NMR (400 MHz, Deuterium Oxide) δ 8.78 (s, 2H), 8.37 (s, 1H), 7.95 (s, 1H), 7.82-7.72 (m, 1H), 7.68 (s, 1H), 7.56 (d, *J* = 7.6 Hz, 1H), 7.46-7.35 (m, 1H), 7.11 (s, 1H), 7.04 (s, 1H). ^{13}C NMR (101 MHz, Deuterium Oxide) δ 174.2, 156.4, 152.3, 137.2, 136.2, 131.9, 131.3, 129.4, 129.3, 129.2, 128.6, 126.6, 121.7, 117.0. HRMS (ESI): Calcd. for $C_{14}H_9N_4O_2$ $[M-H]^-$ 265.0731; found 265.0731. UHPLC: purity = 95.2%

3'-(1H-tetrazol-5-yl)-biphenyl-3-carboxylic acid, **26a**:



Synthesis of 5-(3-bromophenyl)-1H-tetrazole: Dibutyltin oxide (0.33 mmol, 82 mg, 0.2 equiv), and trimethylsilyl azide (3.33 mmol, 383 mg, 2 equiv) were added to a solution of 3-bromobenzonitrile (300 mg, 1.67 mmol, 1 equiv) in anhydrous 1,4-dioxane (2 mL/mmol). The reaction mixture was subjected to microwave irradiation in a tightly sealed microwave vessel for 50 min at 150 ^{0}C, then cooled to room temperature. The solvent was removed under reduced pressure. The residue was dissolved in diethyl ether (10 mL and extracted with 2 M aq. NaOH (3 x 10 mL). The aqueous layer was acidified with 4 M aq. HCl to pH 1 and extracted with ethyl acetate (4 x 10 mL). The organic extract was washed with brine (10 mL), dried over MgSO4, and evaporated under reduced pressure to give the intermediate tetrazole(1.45 mmol, 326 mg, 86%) as a white solid. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.22-8.21 (m, 1H), 8.01 (d, J = 7.9 Hz, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.50 (t, J = 7.9 Hz, 1H). ^{13}C NMR (101 MHz, methanol-d_4) δ 157.3, 135.3, 132.3, 131.0, 128.0, 126.9, 124.2.

According to general procedure A, 5-(3-bromophenyl)-1H-tetrazole (0.73 mmol, 163 mg, 1.2 equiv), 3-carboxyphenylboronic acid pinacol ester (0.60 mmol, 150 mg, 1.0 equiv), potassium phosphate (3.00 mmol, 636 mg, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.06 mmol, 42 mg, 10 mol%) after purification gave **26a** (0.58 mmol, 159 mg, 99%) as a white solid. T_m = 295-297°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.41 (s, 1H), 8.35 (s, 1H), 8.04 (d, *J* = 8.1 Hz, 1H), 7.98 (d, *J* = 8.1 Hz, 1H), 7.82 (d, *J* = 8.0 Hz, 1H), 7.74 (d, *J* = 7.9 Hz, 1H), 7.56 (t, *J* = 7.8 Hz, 1H), 7.50 (t, *J* = 7.6 Hz, 1H). ^{13}C NMR (101 MHz, methanol-d_4) δ 175.3, 162.9, 142.8, 141.6, 139.8, 131.9, 130.2, 129.8, 129.3, 128.9, 126.6, 126.3, 128.3. HRMS (ESI): Calcd. $C_{14}H_9N_4O_2$ $[M-H]^-$ 265.0731; found 265.0728. UHPLC: purity = 96.7%

4'-(1H-Tetrazol-5-yl)biphenyl-3-carboxylic acid, **26b**:



Synthesis of 5-(4-bromophenyl)-1H-tetrazole: Dibutyltin oxide (0.33 mmol, 82 mg, 0.2 equiv), and trimethylsilyl azide (3.33 mmol, 383 mg, 2 equiv) were added to a solution of 4-bromobenzonitrile (300 mg, 1.67 mmol, 1 equiv) in anhydrous 1,4-dioxane (2 mL/mmol). The reaction mixture was subjected to microwave irradiation in a tightly sealed vessel for 50 min at 150 0C, then cooled to room temperature. The solvent was removed under reduced pressure. The residue was dissolved in diethyl ether (10 mL and extracted with 2 M aq. NaOH (3 x 10 mL). The aqueous layer was acidified with 4 M aq. HCl to pH 1 and extracted with ethyl acetate (4 x 10 mL). The organic extract was washed with brine (10 mL), dried over MgSO4, and evaporated under reduced pressure to give the intermediate tetrazole (1.36 mmol, 307 mg, 82%) as a white solid. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.07-7.92 (m, 2H), 7.91-7.76 (m, 2H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 155.6, 132.9, 129.3, 125.0, 124.3.

According to general procedure A, 5-(4-bromophenyl)-1H-tetrazole (0.58 mmol, 130 mg, 1.2 equiv), 3-carboxyphenylboronic acid pinacol ester (0.48 mmol, 120 mg, 1.0 equiv), potassium phosphate (2.93 mmol, 614 mg, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.05 mmol, 34 mg, 10 mol%) after purification gave the title compound, **26b** (0.44 mmol, 119 mg, 93%) as a white solid. T_m = 301°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.32 (s, 1H), 8.15 (d, *J* = 8.3 Hz, 2H), 7.97 (d, *J* = 7.6 Hz, 1H), 7.83-7.72 (m, 3H), 7.48 (t, *J* = 7.7 Hz, 1H). ^{13}C NMR (101 MHz, methanol-d_4) δ 175.2, 162.7, 142.6, 141.4, 139.8, 130.4, 129.7, 129.4, 128.8, 128.3, 128.2. HRMS (ESI): Calcd. for $C_{14}H_9N_4O_2$ $[M-H]^-$ 265.0731; found 265.0722. UHPLC: purity = 98.3%

3-(Naphthalen-2-yl)benzoic acid, **27**:

According to general procedure A, 2-bromonaphthalene (1.20 mmol, 250 mg, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (1.81 mmol, 448 mg, 1.5 equiv), potassium phosphate (6.02 mmol, 1.28 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.124 mmol, 85 mg, 10 mol%) after purification gave **27** (0.81 mmol, 200 mg, 67%) was obtained as a white solid. T_m = 263-266 °C. ^{1}H NMR (400 MHz, deuterium oxide) δ 8.04 (t, *J* = 1.8 Hz, 1H), 7.74 (m, 1H), 7.35 (s, 0H), 7.23-7.08 (m, 4H), 7.03 (t, *J* = 7.7 Hz, 1H), 6.99-6.87 (m, 2H).^{13}C NMR (101 MHz, deuterium oxide) δ 175.0, 139.8, 136.9, 136.7, 132.9, 132.0, 129.3, 128.6, 128.2, 127.8, 127.8, 127.4, 127.2, 126.0, 125.7, 125.0, 124.7. HRMS (ESI): Calcd. for $C_{17}H_{11}O_2$ $[M-H]^-$ 247.0765; found 247.0759. UHPLC: purity = 98.6%

3-(Quinolin-7-yl)benzoic acid, **28**:

The compound was prepared according to general procedure A. 6-Bromoquinoline (1.20 mmol, 250 mg, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzoic acid (1.80 mmol, 447 mg, 1.5 equiv), potassium phosphate (6.00 mmol, 1.28 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.12 mmol, 84 mg, 10 mol%) gave **28** (1.04 mmol, 260 mg, 87%) as a white solid. T_m = 295-298 °C. ^{1}H NMR (400 MHz, methanol-d_4) δ ^{1}H NMR (400 MHz,) δ 8.86 (dd, *J* = 4.4, 1.7 Hz, 1H), 8.47 (dd, *J* = 8.3, 1.7 Hz, 1H), 8.43 (t, *J* = 1.8 Hz, 1H), 8.25 (d, *J* = 1.9 Hz, 1H), 8.20-8.10 (m, 2H), 8.03 (d, *J* = 7.7 Hz, 1H), 7.87 (dt, *J* = 7.8, 1.5 Hz, 1H), 7.63-7.42 (m, 2H). ^{13}C NMR (101 MHz, ethanol-d_4) δ 175.0, 151.1, 148.1, 140.9, 140.6, 140.0, 138.7, 130.7, 130.2, 130.1, 129.8, 129.6, 129.6, 129.3, 126.7, 122.9. HRMS (ESI): Calcd. for $C_{16}H_{10}NO_2$ $[M-H]^-$ 248.0717; found 248.0714. UHPLC: purity = 96.2 %

3-(6-Aminopyridin-3-yl)benzoic acid, **29**:

According to general procedure A, 5-bromopyridin-2-amine (0.87 mmol, 150 mg, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (1.30 mmol, 323 mg, 1.5 equiv), potassium phosphate (4.34 mmol, 920 mg, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.09 mmol, 61 mg, 10 mol%) gave **29** (0.26 mmol, 56 mg, 36%) as an orange solid. T_m = 277°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.21 (s, 1H), 8.14 (t, *J* = 1.8 Hz, 1H), 7.88 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.80 (dd, *J* = 8.7, 2.5 Hz, 1H), 7.60-7.50 (m, 1H), 7.41 (t, *J* = 7.7 Hz, 1H), 6.82-6.55 (m, 1H). ^{13}C NMR (101 MHz, methanol-d_4) δ 175.3, 160.1, 145.9, 139.8, 138.9, 138.0, 129.4, 128.7, 128.6, 127.8, 127.4, 110.3. HRMS (ESI): Calcd. for $C_{12}H_9N_2O_2$ $[M-H]^-$ 213.0670; found 213.0669. UHPLC: purity = 96.3 %

3-(Pyrimidin-5-yl)benzoic acid, **30**:

According to general procedure A, 5-bromopyrimidine (1.57 mmol, 250 mg, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (2.36 mmol, 585 mg, 1.5 equiv), potassium phosphate (7.86 mmol, 1.67 g, 5.0 equiv), $PdCl_2(PPh_3)_2$ (0.16 mmol, 110 mg, 10 mol%), gave **30** (0.70 mmol, 140 mg, 45%) as a light brown solid. T_m = T_m = 289°C decomposes. ^{1}H NMR (400 MHz, deuterium oxide) δ 9.00 (s, 1H), 8.88 (s, 2H), 7.99 (t, *J* = 1.8 Hz, 1H), 7.86 (m, 1H), 7.67-7.61 (m, 1H), 7.50 (t, *J* = 7.7 Hz, 1H). ^{13}C NMR (101 MHz, deuterium oxide) δ 174.5, 155.7, 154.6, 137.3, 133.7, 132.8, 129.5, 129.3, 129.2, 127.0. HRMS (ESI): Calcd. for $C_{11}H_7N_2O_2$ $[M-H]^-$ 199.0513 found 199.0511. UHPLC: purity = 99.4 %

3-(2-Aminopyrimidin-4-yl)benzoic acid, **31**:

According to general procedure A, 5-bromo-4-methylpyrimidin-2-amine (0.80 mmol, 150 mg, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzoic acid (1.20 mmol, 298 mg, 1.5 equiv), potassium phosphate (4.01 mmol, 851 mg, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.08 mmol, 56 mg, 10 mol%) gave **31** (0.53 mmol, 122 mg, 67%) as a yellow solid. T_m = 330°C (decomposes).^{1}H NMR (400 MHz, methanol-d_4) δ 8.12 (s, 1H), 8.03-7.92 (m, 1H), 7.89 (s, 1H), 7.50 (t, *J* = 7.7 Hz, 1H), 7.44-7.33 (m, 1H). ^{13}C NMR (101 MHz, methanol-d_4) δ 175.0, 167.4, 162.8, 158.7, 139.1, 136.9, 132.2, 131.0, 129.4,

129.3, 126.0, 22.6. HRMS (ESI): Calcd. for $C_{12}H_{10}N_3O_2$ $[M-H]^-$ 228.0778; found 228.0776. UHPLC: purity = 99.0 %

3-(1-Methyl-1H-pyrrol-2-yl)benzoic acid, **32**:

The compound was prepared according to general procedure A. 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 1-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole (1.87 mmol, 386 mg, 1.5 equiv), potassium phosphate (6.22 mmol, 1.32 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.12 mmol, 81 mg, 10 mol%) after purification by flash chromatography on silica gel using 2% methanol in CH_2Cl_2 as eluent afforded **32** (0.03 mmol, 15 mg, 6%) as a white solid. T_m = 162-165 °C. ^{1}H NMR (400 MHz, methanol-d_4) δ 7.94 (s, 1H), 7.83 (d, *J* = 7.7 Hz, 1H), 7.52 (d, *J* = 6.2 Hz, 1H), 7.39 (t, *J* = 7.8 Hz, 2H), 6.65 (s, 1H), 6.18-5.82 (m, 5H), 3.56 (s, 3H). ^{13}C NMR (101 MHz, methanol-d_4) δ 169.8, 135.3, 134.5, 133.7, 132.2, 130.3, 129.6, 128.7, 125.5, 110.0, 108.8, 35.3. HRMS (ESI): Calcd. for $C_{12}H_{10}NO_2$ $[M-H]^-$ 200.0717; found 200.0715. UHPLC: purity = 95.5 %

3-(Thiazol-5-yl)benzoic acid, **33**:

The compound was prepared according to general procedure A. 5-bromothiazole (1.52 mmol, 250 mg, 1.0 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (2.29 mmol, 567 mg, 1.5 equiv), potassium phosphate (7.62 mmol, 1.62 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.15 mmol, 107 mg, 10 mol%), gave **33** (0.37 mmol, 76 mg, 24%) as a brownish solid. T_m = 208°C (decomposes).^{1}H NMR (400 MHz, deuterium oxide) δ 8.21 (t, *J* = 1.8 Hz, 1H), 7.93-7.83 (m, 2H), 7.77 (d, *J* = 3.3 Hz, 1H), 7.52 (d, *J* = 3.3 Hz, 1H), 7.47 (t, *J* = 7.7 Hz, 1H). ^{13}C NMR (101 MHz, deuterium oxide) δ 174.5, 168.9, 142.8, 137.2, 132.4, 130.6, 129.2, 128.7, 126.8, 120.6. HRMS (ESI): Calcd. for $C_{10}H_6O_2NS$ $[M-H]^-$ 204.0125; found 204.0120. UHPLC: purity = 96.0 %

3-(1H-Indol-5-yl)benzoic acid, **34**:

According to general procedure A, 5-bromo-1H-indole (1.28 mmol, 250 mg, 1 equiv), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (1.91 mmol, 475 mg, 1.5 equiv), potassium phosphate (6.38 mmol, 1.35 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.13 mmol, 90 mg, 10 mol%) after purification by flash chromatography on silica gel using hexane/ethyl acetate/acetic acid (9:1:0.01) as eluent gave **34** (0.25 mmol, 60 mg, 20 %) as a yellowish solid. T_m = 190-192 °C ^{1}H NMR (400 MHz, methanol-d_4) δ 8.30 (s, 1H), 7.94 (d, *J* = 7.7 Hz, 1H), 7.87 (d, *J* = 7.8 Hz, 1H), 7.82 (s, 1H), 7.57-7.35 (m, 3H), 7.27 (d, *J* = 3.1 Hz, 1H), 6.52 (d, *J* = 3.3 Hz, 1H). ^{13}C NMR (101 MHz, methanol-d_4) δ 170.2, 144.5, 137.5, 132.6, 132.6, 132.3, 130.1, 129.8, 129.2, 128.3, 126.5, 121.7, 119.7, 112.6, 102.9. HRMS (ESI): Calcd. for $C_{15}H_{10}O_2N$ $[M-H]^-$ 236.0717; found 236.0716. UHPLC: purity = 95.8 %

3-(Pyridin-2-yl)benzoic acid, **35**:

According to general procedure A, 3-bromobenzoic acid (1.24 mmol, 250 mg, 1.0 equiv), 2-Pyridineboronic acid N-phenyldiethanolamine ester (1.86 mmol, 499 mg, 1.5 equiv), potassium phosphate (6.20 mmol, 1.31 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.12 mmol, 87 mg, 10 mol%) gave **35** (1.13 mmol, 224 mg, 91%) as white solid. T_m = 101-103°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.64 (d, *J* = 5.0 Hz, 1H), 8.56 (s, 1H), 8.08 (t, *J* = 7.6 Hz, 2H), 8.03-7.89 (m, 2H), 7.57-7.50 (m, 1H), 7.47-7.30 (m, 2H). ^{13}C NMR (101 MHz, methanol-d_4) δ 173.6, 158.7, 150.3, 140.2, 138.9, 138.2, 132.1, 131.1, 130.5, 129.5, 129.1, 128.9, 123.8, 122.6. HRMS (ESI): Calcd. for $C_{12}H_8O_2N$ $[M-H]^-$ 198.0561; found 198.0552. UHPLC: purity = 98.6 %

1.3 Screening of catalysts

General procedure:

3-Bromo-5-iodobenzoic acid (0.03–0.06 mmol, 1.0 equiv.) was dissolved in the indicated solvent (0.5–1 mL/0.01 mmol substrate). The boronic acid or ester (1.5 equiv.) and base (5.0 equiv.) were added. The solution was degassed by vacuum/Ar cycles (10 times) before addition of the palladium catalyst and further degassed (5 times). The resulting mixture was stirred at the indicated temperature under an inert atmosphere for the indicated reaction time. The crude reaction mixture was analysed by HRMS to determine the ratio of **int-39** : disubstituted **38** : starting material. The reaction mixture was filtered through Celite bed and diluted with water (approx. 30 mL) before washing with chloroform (3 x 30 mL). The aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification on a 60 g C18 column with a gradient of acetonitrile in water (0–5% over 15 min) to yield the product.

Table SI1: Screening of reaction conditions for the coupling of *3-bromo-5-iodobenzoic acid*

Entry	Catalyst [mol% in Pd]	Base	Temp [°C] / Time [h]	Solvent	Ratio (**int-39**:**38**:sm)	Isol. yield [%]
1	RuPhos-Pd G3 (10)	K_3PO_4	60 / 24	dioxane/water (1:1)	8 : 10 : 10	nd
2	RuPhos-Pd G3 (5)	K_3PO_4	60 / 24	toluene/water (1:1)	10 : 6 : 0.3	nd
3	XantPhos-Pd G3 (5)	K_3PO_4	40 / 48	dioxane/water (1:1)	10 : 1 : 0	nd
4	XantPhos-Pd G3 (5)	K_3PO_4	40 / 24	toluene/water (1:1)	10 : 1 : 3	70
5	Pd(dppf)Cl_2 (5)	K_3PO_4	60 / 24	dioxane/water (1:1)	10 : 1 : 3	80
6	XPhos-Pd G2 (1)	K_3PO_4	60 / 24	dioxane/water (1:1)	10 : 7 : 1	nd
7	SPhos-Pd G3 (5)	K_3PO_4	60 / 24	dioxane/water (1:1)	10 : 2 : 0	40
8	$Pd_2(dba)_3$•$CHCl_3$/SPhos 1:1 (10)	K_3PO_4	60 / 24	dioxane/water (1:1)	10 : 1 : 0.4	55
9	$Pd_2(dba)_3$•$CHCl_3$/SPhos 1:1 (10)	K_3PO_4	80 / 24	dioxane/water (1:1)	10 : 1 : 0.3	55
8	$Pd_2(dba)_3$•$CHCl_3$/SPhos 1:1 (10)	K_3PO_4	40 / 24	*tert*-BuOH	10 : 4 : 4	nd
9	$Pd_2(dba)_3$•$CHCl_3$/SPhos 1:1 (10)	K_3PO_4	40 / 20	toluene/water (1:1)	10 : 1 : 3	65
10	$Pd_2(dba)_3$•$CHCl_3$/SPhos 1:1 (10)	K_3PO_4	60 / 10	dioxane:water (1:1)	5 : 4 : 10	nd
11	$Pd_2(dba)_3$•$CHCl_3$/SPhos 1:1 (10)	K_3PO_4	60 / 48	dioxane:water (1:1)	10 : 4 : 1	nd
12	$Pd_2(dba)_3$•$CHCl_3$/SPhos 1:2 (5)	K_3PO_4	60 / 24	dioxane/water (1:1)	10 : 0.7 : 0	40

1.4 Synthesis of symmetrical 3,5-disubstituted benzoic acid derivatives

3,5-Di(3-acetamidophenyl)benzoic acid **36**:

3-Bromo-5-iodobenzoic acid (0.30 mmol, 100 mg, 1.0 equiv), 3-acetamidophenylboronic acid (0.45 mmol, 816 mg, 1.5 equiv), potassium phosphate (1.5 mmol, 324 mg, 5.0 equiv) were dissolved in a mixture of water/dioxane (1:1). The solution was degassed by vacuum/Ar cycles (10 times) before addition of $Pd_2(dba)_3$•$CHCl_3$ (15 mg, 5 mol%), and XPhos (7.2 mg, 5 mol%) and further degassed (5 times). The resulting mixture was stirred at 60 °C for 20–24 hours. The reaction mixture was filtered through Celite bed and diluted with water (approx. 30 mL) before washing with chloroform (3 x 30 mL). The aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification on a 60 g C18 column with a gradient of acetonitrile in water (0–5% over 15 min) to provide **36** (60 mg, 54%) as white powder. T_m = 211-212°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.21 (s, 1H), 7.90 (t, *J* = 1.7 Hz, 1H), 7.81 (t, *J* = 1.7 Hz , 2H), 7.68 (d, *J* = 8 Hz, 2H), 7.43 (s, 1H), 7.49-7.46 (m, 2H), 7.43-7.39 (m, 2H), 2.16 (s, 6H). ^{13}C NMR (101 MHz, methanol-d_4) δ 175.0, 171.8, 142.9, 142.3, 140.5, 132.2, 130.4, 128.2, 128.1, 123.9, 120.3, 119.7, 24.0. HRMS (ESI): Calcd. for $C_{23}H_{19}N_2O_4$ $[M-H]^-$ 387.1350; found 387.1342. UHPLC: purity = 97.5 %

3,5-di(4-acetamidophenyl)benzoic acid **37**:

3,5-Dibromobenzoic acid (1.01 mmol, 300 mg, 1.0 equiv), 3-acetamidophenylboronic acid (0.81 mmol, 178 mg, 0.75 equiv), potassium phosphate (3.76 mmol, 0.80 g, 3.5 equiv) and $PdCl_2(PPh_3)_2$ (0.11 mmol, 77 mg, 10 mol%) were stirred in a mixture of water/dioxane (1:1) for 24 hours at 95 °C under argon atmosphere. The crude reaction mixture was filtered through Celite and diluted with water (approx. 30 mL) before washing with chloroform (3 x 30 mL). The aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification on a 60 g C18 column with a gradient of acetonitrile in water (0–100 % over 12 minutes). The fractions were analysed by MS and fractions containing **37** were combined. The product was purified by reverse-phase automated flash chromatography before being subjected to purification by HPLC, to yield **37** (0.09 mmol, 34 mg, 11%) as a white solid. T_m = 245-247°C. ^{1}H NMR (400 MHz, methanol-*d*$_4$) δ 8.24 (s, 2H), 7.98 (d, *J* = 7.8 Hz, 2H), 7.85 (d, *J* = 7.9 Hz, 2H), 7.68-7.66 (m, 2H), 7.63-7.60 (m, 2H), 7.57-7.53 (m, 1H), 2.16 (s, 6H). ^{13}C NMR (101 MHz, methanol-*d*$_4$) δ 175.2, 171.7, 142.0, 140.2, 139.4, 137.9, 131.7, 128.4, 128.2, 127.6, 127.4, 123.3, 121.4, 116.2, 23.9. HRMS (ESI): Calcd. for $C_{23}H_{19}N_2O_4$ $[M-H]^-$ 387.1350; found 387.1340. UHPLC: purity = 100 %

3,5-diquinolin-6-ylbenzoic acid **38**:

3,5-Dibromobenzoic acid (0.11 mmol, 33 mg, 1.0 equiv), 6-quinolinylboronic acid pinacol ester (0.23 mmol, 60 mg, 2.0 equiv), potassium phosphate (0.58 mmol, 125 mg, 5.0 equiv) were dissolved in tert-butanol. The solution was degassed by vacuum/Ar cycles (10 times) before addition of XPhos-Pd G2 (5 mol%, 5 mg) and further degassed (5 times). The resulting mixture was stirred at 60 °C for 20–24 hours. The reaction mixture was filtered through Celite bed and diluted with water (approx. 30 mL) before washing with chloroform (3 x 30 mL). The aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification by C18 RP flash chromatography with a gradient of acetonitrile in water (0–5% over 15 min) to yield **38** (0.08 mmol, 29 mg, 65%) as white powder. T_m = 291-292°C. ^{1}H NMR (400 MHz, methanol-*d*$_4$) δ 8.87-8.86 (m, 2H), 8.52-8.50 (m, 2H), 8.46 (m, 2H), 8.38 (m, 2H), 8.29-8.26 (m, 3H), 8.18 (s, 1H), 8.16 (s, 1H), 7.61-7.58 (dd, *J* = 8.3, 4.2 Hz, 2H). ^{13}C NMR (101 MHz, methanol-*d*$_4$) δ 174.4, 151.1, 148.0, 141.5, 140.5, 138.6, 130.6, 130.1, 129.5, 128.7, 126.9, 122.8. HRMS (ESI): Calcd. for $C_{25}H_{15}N_2O_2$ $[M-H]^-$ 375.1139; found 375.1133. UHPLC: purity = 99.1 %

1.5 Synthesis of unsymmetrical 3,5-disubstituted benzoic acid derivatives

3-(3'-Acetamidophenyl)-5-pyridin-4-ylbenzoic acid **39**: attempted synthesis from 3,5-dibromobenzoic acid

3,5-Dibromobenzoic acid (1.01 mmol, 300 mg, 1.0 equiv), 3-acetamidophenylboronic acid (0.81 mmol, 178 mg, 0.75 equiv), potassium phosphate (3.76 mmol, 0.80 g, 3.5 equiv) and $PdCl_2(PPh_3)_2$ (0.11 mmol, 77 mg, 10 mol%) were stirred in a mixture of water/dioxane (1:1) for 24 hours at 95 °C under argon atmosphere. The crude reaction mixture was filtered through Celite and diluted with water (approx. 30 mL) before washing with chloroform (3 x 30 mL). The aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification by C18 RP flash chromatography with a gradient of acetonitrile in water (10–100 % over 12 minutes). The fractions were analysed by MS and fractions containing **int-39** were combined and reacted with pyridin-4-ylboronic acid (0.97 mmol, 119 mg, 1.2 equiv), potassium phosphate (4.05 mmol, 0.86 g, 5.0 equiv) and $PdCl_2(PPh_3)_2$ (0.08 mmol, 56 mg, 10 mol%). The product was purified by reverse-phase automated flash chromatography before being subjected to purification by HPLC, to yield **39** (0.12 mmol, 39 mg, 15%) as a white solid. T_m = 244°C. ^{1}H NMR (400 MHz, methanol-*d*$_4$) δ 8.22 (s, 1H), 7.92 (d, *J* = 7.6 Hz, 1H), 7.76 (s, 2H), 7.68-7.60 (m, 3H), 7.46-7.33 (m, 4H), 2.14 (s, 3H). ^{13}C NMR (101 MHz,

methanol-d_4) δ 175.3, 171.7, 143.0, 141.5, 140.4, 139.8, 130.3, 129.7, 129.3, 129.3, 128.9, 123.7, 120.1, 119.6, 23.9. UHPLC: purity = 97.9%

3-Bromo-5-(quinolin-6-yl) benzoic acid int-40:

3-Bromo-5-iodobenzoic acid (0.15 mmol, 50 mg, 1.0 equiv), 6-quinolinylboronic acid pinacol ester (0.22 mmol, 58 mg, 1.5 equiv) and potassium phosphate (0.76 mmol, 162 mg, 5.0 equiv) were dissolved in a mixture of water/dioxane (1:1). The solution was degassed by vacuum/Ar cycles (10 times) before addition of $Pd_2(dba)_3$•$CHCl_3$ (5 mol%, 7.5 mg), and SPhos (5 mol%, 3.1 mg) and further degassed (5 times). The resulting mixture was stirred at 60 °C for 20–24 hours. The reaction mixture was filtered through a Celite bed and diluted with water (approx. 30 mL) before washing with chloroform (3 x 30 mL). The aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification on a 60 g C18 column with a gradient of acetonitrile in water (0–5% over 20 min). Product **int-40** (0.07 mmol, 23 mg, 45%) was obtained as a white powder. T_m = 288°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.92-8.91 (m, 1H), 8.49-8.46 (m, 1H), 8.35 (s, 1H), 8.28 (s, 2H), 8.10 (s, 2H), 8.02-8.01 (m, 1H), 7.97-7.96 (m,1H), 7.59-7.56 (dd, *J* = 8.3, 4.2 Hz, 1H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 166.6, 150.8, 147.2, 143.6, 140.6, 136.8, 136.5, 131.7, 131.1, 129.6, 128.5, 128.2, 127.4, 126.5, 125.8, 121.9, 121.7; HRMS (ESI): Calcd. for $C_{16}H_9{}^{79}BrNO_2$ $[M-H]^-$ 325.9822; found 325.9822.

3-(3'-Acetamidophenyl)-5-quinolin-6-ylbenzoic acid 40:

3-Bromo-5-(quinolin-6-yl) benzoic acid **int-40** (0.039 mmol, 13 mg, 1.0 equiv), 3-acetamidophenylboronic acid (0.55 mmol, 10 mg, 1.5 equiv) and potassium phosphate (0.20 mmol, 0.42 g, 5.0 equiv) were dissolved in tert-butanol. The solution was degassed by vacuum/Ar cycles (10 times) before addition of Xphos-Pd G2 (5 mol%, 1.5 mg) and further degassed (5 times). The resulting mixture was stirred at 60 °C for 20–24 hours. The reaction mixture was filtered through Celite bed and diluted with water (approx. 30 mL) before washing with chloroform (3 x 30 mL). The aqueous phase was concentrated under reduced pressure and applied to a C18 precolumn before purification on a 60 g C18 column with a gradient of acetonitrile in water (0–5% over 20 min). Product **40** (0.023 mmol, 9 mg, 90%) was obtained as white powder. T_m = 261-264°C. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.87-8.83 (m, 1H), 8.56-8.45 (m, 1H), 8.41-8.39 (m, 1H), 8.35-8.20 (m, 3H), 8.18-8.11 (m, 1H), 8.08 (t, *J* = 1.8 Hz, 1H), 7.87-7.86 (m, 1H), 7.72-7.68 (m, 1H), 7.62-7.56 (m, 1H), 7.56-7.49 (m, 1H), 7.46-7.42 (m, 1H), 2.17 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 174.7, 171.8, 151.2, 148.2, 142.8, 142.5, 141.4, 140.8, 140.7, 140.5, 138.8, 130.8, 130.4, 130.3, 129.7, 128.6, 128.5, 128.5, 127.0, 123.9, 123.0, 120.3, 119.7, 23.9. HRMS (ESI): Calcd. for $C_{24}H_{18}N_2O_3$ $[M-H]^-$ 381.1245; found 381.1243. UHPLC: purity = 96.4 %.

2 NMR spectra of compounds 3–40:

2.1 2'-methylbiphenyl-3-carboxylic acid, **3a**:

2.1.1 ^{1}H NMR of **3a**



2.1.2 ^{13}C NMR of **3a**



2.2 3'-methylbiphenyl-3-carboxylic acid, **3b**:

2.2.1 ^{1}H NMR of **3b**



2.2.2 ^{13}C NMR of **3b**



2.3 2'-hydroxybiphenyl-3-carboxylic acid **4a**:

2.3.1 ^{1}H NMR of 4a



2.3.2 ^{13}C NMR of **4a**



2.4 3'-hydroxybiphenyl-3-carboxylic acid, **4b**:

2.4.1 ^{1}H NMR of **4b**



2.4.2 ^{13}C NMR of **4b**



2.5 4'-hydroxybiphenyl-3-carboxylic acid, **4c**:

2.5.1 ^{1}H NMR of **4c**



2.5.2 ^{13}C NMR of **4c**



2.6 3'-(hydroxymethyl)biphenyl-3-carboxylic acid **5**:

2.6.1 ^{1}H NMR of **5**



2.6.2 ^{13}C NMR of **5**



2.7 2'-methoxybiphenyl-3-carboxylic acid, **6a**:

2.7.1 ^{1}H NMR of **6a**



2.7.2 ^{13}C NMR of **6a**



2.8 3'-methoxybiphenyl-3-carboxylic acid, **6b**:

2.8.1 ^{1}H NMR of **6b**



2.8.2 ^{13}C NMR of **6b**:



2.9 4'-methoxybiphenyl-3-carboxylic acid **6c**:

2.9.1 ^{1}H NMR of **6c**



2.9.2 13C NMR of **6c**



2.10 4'-methylthiobiphenyl]-3-carboxylic acid, **7**:

2.10.1 ^{1}H NMR of **7**



2.10.2 ^{13}C NMR of **7**



2.11 2'-fluorobiphenyl-3-carboxylic acid, **8a**:

2.11.1 ^{1}H NMR of **8a**



2.11.2 ^{13}C NMR of **8a**



2.12 3'-fluorobiphenyl-3-carboxylic acid **8b**:

2.12.1 ^{1}H NMR of **8b**



2.12.2 ^{13}C NMR of **8b**



2.13 4'-fluorobiphenyl-3-carboxylic acid, **8c**:

2.13.1 ^{1}H NMR of **8c**



2.13.2 ^{13}C NMR of **8c**



2.14 2'-(methoxycarbonyl)biphenyl-3-carboxylic acid, **9a**:

2.14.1 ^{1}H NMR of **9a**



2.14.2 ^{13}C NMR of **9a**



2.15 3'-(methoxycarbonyl)biphenyl-3-carboxylic acid, **9b**:

2.15.1 ^{1}H NMR of **9b**



2.15.2 ^{13}C NMR of **9b**



2.16 4'-acetylbiphenyl-3-carboxylic acid **10**:

2.16.1 1H NMR of 10



2.16.2 ^{13}C NMR of **10**



2.17 3'-carbamoylbiphenyl-3-carboxylic acid, **11a**:

2.17.1 ^{1}H NMR of **11a**



2.17.2 ^{13}C NMR of **11a**



2.18 4'-carbamoylbiphenyl-3-carboxylic acid, **11b**:

2.18.1 ^{1}H NMR of **11b**



2.18.2 ^{13}C NMR of **11b**



2.19 3'-(methylsulfonyl)biphenyl-3-carboxylic acid, **12a**:

2.19.1 ^{1}H NMR of **12a**



2.19.2 ^{13}C NMR of **12a**



2.20 4'-(methylsulfonyl)biphenyl-3-carboxylic acid, 12b:

2.20.1 ^{1}H NMR of **12b**



2.20.2 ^{13}C NMR of **12b**



2.21 4'-aminobiphenyl-3-carboxylic acid, **13**:

2.21.1 ^{1}H NMR of **13**



2.21.2 ^{13}C NMR of **13**



2.22 4'-dimethylaminobiphenyl-3-carboxylic acid, **14**:

2.22.1 ^{1}H NMR of **14**



2.22.2 13C NMR of 14



2.23 3'-aminomethylbiphenyl-3-carboxylic acid, **15a**:

2.23.1 ^{1}H NMR of **15a**



2.23.2 ^{13}C NMR of **15a**



2.24 4'-(aminomethyl)biphenyl-3-carboxylic acid, **15b**:

2.24.1 ^{1}HNMR of 15b



2.24.2 ^{13}CNMR of 15b



2.25 3'-(2-aminoethyl)biphenyl-3-carboxylic acid, **16a**:

2.25.1 1H NMR of **16a**



2.25.2 13C NMR of **16a**



2.26 4'-(2-aminoethyl)biphenyl-3-carboxylic acid, **16b**:

2.26.1 1H NMR of **16b**



2.26.2 ^{13}C NMR of **16b**



2.27 4'-(methylsulfonamido)biphenyl-3-carboxylic acid, **17**:

2.27.1 ^{1}H NMR of **17**



2.27.2 ^{13}C NMR of **17**



2.28 4'-(phenylsulfonamido)biphenyl-3-carboxylic acid, **18**:

2.28.1 ^{1}H NMR of **18**



2.28.2 ^{13}C NMR of **18**



2.29 3'-(methylsulfonamidomethyl)biphenyl-3-carboxylic acid, **19a**:

2.29.1 ^{1}H NMR of **19a**



2.29.2 ^{13}C NMR of **19a**



2.30 4'-(methylsulfonamidomethyl)biphenyl-3-carboxylic acid, **19b**:

2.30.1 ^{1}H NMR of **19b**



2.30.2 ^{13}C NMR of **19b**



2.31 3'-(2-methylsulfonamidoethyl)biphenyl-3-carboxylic acid, **20**:

2.31.1 ^{1}H NMR of **20**



2.31.2 ^{13}C NMR of **20**



2.32 3'-acetamidobiphenyl-3-carboxylic acid, **21a**:

2.32.1 ^{1}H NMR of **21a**



2.32.2 ^{13}C NMR of **21a**



2.33 4'acetamidobiphenyl-3-carboxylic acid, **21b**:

2.33.1 ^{1}H NMR of **21b**



2.33.2 ^{13}C NMR of **21b**



2.34 3'-(acetamidomethyl)biphenyl]-3-carboxylic acid, **22**:

2.34.1 ^{1}H NMR of **22**



2.34.2 ^{13}C NMR of **22**



2.35 3'-(2-acetamidoethyl)biphenyl]-3-carboxylic acid, **23a**:

2.35.1 ^{1}H NMR of **23a**



2.35.2 ^{13}C NMR of **23a**



2.36 4'-(2-acetamidoethyl)biphenyl]-3-carboxylic acid, 23b:

2.36.1 ^{1}H NMR of **23b**



2.36.2 ^{13}C NMR of **23b**



2.37 3'-acetoxymethylbiphenyl-3-carboxylic acid, **24**:

2.37.1 ^{1}H NMR of **24**



2.37.2 ^{13}C NMR of **24**



2.38 4'-(1H-imidazol-1-yl)biphenyl-3-carboxylic acid, **25**:

2.38.1 ^{1}H NMR of **25**



2.38.2 ^{13}C NMR of **25**



2.39 3'-(1H-tetrazol-5-yl)biphenyl-3-carboxylic acid, **26a**:

2.39.1 ^{1}H NMR of **26a**



2.39.2 ^{13}C NMR of **26a**



2.40 4'-(1H-tetrazol-5-yl)biphenyl-3-carboxylic acid, **26b**:

2.40.1 ^{1}H NMR of **26b**



2.40.2 ^{13}C NMR of **26b**



2.41 3-(naphthalen-2-yl)benzoic acid, **27**:

2.41.1 ^{1}H NMR of **27**



2.41.2 ^{13}C NMR of **27**



2.42 3-(quinolin-7-yl)benzoic acid, **28**:

2.42.1 ^{1}H NMR of **28**



2.42.2 ^{13}C NMR of **28**



2.43 3-(6-aminopyridin-3-yl)benzoic acid, **29**:

2.43.1 ^{1}H NMR of **29**



2.43.2 ^{13}C NMR of **29**



2.44 3-(pyrimidin-5-yl)benzoic acid, **30**:

2.44.1 ^{1}H NMR of **30**



2.44.2 ^{13}C NMR of **30**



2.45 3-(2-aminopyrimidin-4-yl)benzoic acid, **31**:

2.45.1 ^{1}H NMR of **31**



2.45.2 ^{13}C NMR of **31**



2.46 3-(1-methyl-1H-pyrrol-2-yl)benzoic acid, **32**:

2.46.1 ^{1}H NMR of **32**



2.46.2 ^{13}C NMR of **32**



2.47 3-(thiazol-5-yl)benzoic acid, **33**:

2.47.1 ^{1}H NMR of **33**



2.47.2 ^{13}C NMR of **33**



2.48 3-(1H-indol-5-yl)benzoic acid, **34**:

2.48.1 ^{1}H NMR of **34**



2.48.2 ^{13}C NMR of **34**



2.49 3-(pyridin-2-yl)benzoic acid, 35:

2.49.1 1H NMR of **35**



2.49.2 13C NMR of **35**



2.50 symmetrical 3,5-disubstituted benzoic acid derivatives

2.51 3,5-Di(3-acetamidophenyl)benzoic acid 36:

2.51.1 1H NMR of **36**



2.51.2 13C NMR of **36**



2.52 3,5-di(4-acetamidophenyl)benzoic acid 37:

2.52.1 1H NMR of **37**



2.52.2 13C NMR of **37**



2.53 3,5-diquinolin-6-ylbenzoic acid **38**:

2.53.1 1H NMR of **38**



2.53.2 13C NMR of **38**



2.54 unsymmetrical 3,5-disubstituted benzoic acid derivatives

2.55 3-(3'-Acetamidophenyl)-5-pyridin-4-ylbenzoic acid 39:

2.55.1 1H NMR of 39



2.55.2 13C NMR of 39



2.56 3-Bromo-5-(quinolin-6-yl) benzoic acid int-40:

2.56.1 1H NMR of **int-40**



2.56.2 13C NMR of **int-40**



2.57 3-(3'-Acetamidophenyl)-5-quinolin-6-ylbenzoic acid **40**:

2.57.1 1H NMR of **40**



2.57.2 13C NMR of **40**



3 Biophysical, biochemical and structural analysis of OXA-48 with compound 3-40

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 3a







(a) K_D: 170 μM (b) pIC_{50} : 4.05 (c) 2D representation (d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 3b







(a) K_D: 300 μM (b) pIC_{50} : 3.78 (c) 2D representation (d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 4a



(a) K_D: 175 μM



(b) pIC_{50} : 4.30



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 4b



(a) K_D: 110 μM



(b) pIC_{50} : 3.97



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 4c



(a) K_D: 170 μM



(b) pIC_{50} : 3.33



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 5



(a) K_D: 230 μM



(b) pIC_{50} : 3.04



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 6a



(a) K_D: 123 μM



(b) pIC_{50} : 3.60



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 6b



(a) K_D: 226 μM



(b) pIC_{50} : 3.44



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 6c



(a) K_D: 250 μM



(b) pIC_{50} : 3.82



(c) 2D representation



(d) 3D representation

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 7



(a) K_D: 1000 μM



(b) pIC_{50} : 3.40

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 8a



(a) K_D: 170 μM (b) pIC_{50} : 3.89



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 8b



(a) K_D: 240 μM (b) pIC_{50} : 3.88



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 8c



(a) K_D: 312 μM



(b) pIC_{50} : 3.45



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 9a



(a) K_D: 200 μM



(b) pIC_{50} : 3.69



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 9b



(a) K_D: 144 μM



(b) pIC_{50} : 3.59



(c) 2D representation



(d) 3D representation

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 10



(a) K_D: 280 μM



(b) pIC_{50} : 3.42

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 11a



(a) K_D: 220 μM (b) pIC_{50} : 3.58

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 12a



(a) K_D: 150 μM (b) pIC_{50} : 3.91



(c) 2D representation



(d) 3D representation

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 12b



(a) K_D: 361 μM (b) pIC_{50} : 3.42

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 13



(a) K_D: 330 μM (b) pIC_{50} : 3.48



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 14



(a) K_D: 220 μM



(b) pIC_{50} : 3.41



(c) 2D representation



(d) 3D representation

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 15a



(a) K_D: 800 μM



(b) pIC_{50} : 3.22

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 15b



(a) K_D: 550 μM (b) pIC_{50} : 2.85

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 16a



(a) K_D: 300 μM (b) pIC_{50} : 3.95

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 16b



(a) K_D: 970 μM



(b) pIC_{50} : 2.98

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 11b



(a) K_D: 200 μM



(b) pIC_{50} : 3.73



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 17



(a) K_D: 100 μM



(b) pIC_{50} : 3.43



(c) 2D representation



(d) 3D representation

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 18



(a) K_D: 210 μM



(b) pIC_{50} : 4.25

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 19a



(a) K_D: 110 μM



(b) pIC$_{50}$: 3.96



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 19b



(a) K_D: 240 μM



(b) pIC$_{50}$: 3.35



(c) 2D representation



(d) 3D representation

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 20



(a) K_D: 200 μM (b) pIC_{50} : 3.43

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 21a



(a) K_D: 100 μM (b) pIC_{50} : 4.45



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 21b



(a) K_D: 290 μM



(b) pIC_{50} : 3.35



(c) 2D representation



(d) 3D representation

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 22



(a) K_D: 130 μM



(b) pIC_{50} : 3.89

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 23a



(a) K_D: 170 μM



(b) pIC_{50} : 3.64



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 23b



(a) K_D: 190 μM



(b) pIC_{50} : 3.28



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 24





(a) K_D: 181 μM



(b) pIC_{50} : 3.60



(c) 2D representation



(d) 3D representation

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 25





(a) K_D: 1160 μM



(b) pIC_{50} : 2.89

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 26a





(a) K_D: 70 μM



(b) pIC$_{50}$: 4.24



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 26b





(a) K_D: 70 μM



(b) pIC$_{50}$: 4.48



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 27



(a) K_D: 400 μM



(b) pIC_{50} : 3.98



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 28



(a) K_D: 160 μM



(b) pIC_{50} : 3.61



(c) 2D representation



(d) 3D representation

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 29



(a) K_D: 130 μM (b) pIC_{50} : 3.76

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 30



(a) K_D: 900 μM (b) pIC_{50} : 3.10

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 31



(a) K_D: 113 μM (b) pIC_{50} : 3.46

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 32



(a) K_D: 590 μM (b) pIC_{50} : 3.30



(c) 2D representation



(d) 3D representation

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 33



(a) K_D: 900 μM



(b) pIC_{50} : 3.09

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 34



(a) K_D: 400 μM



(b) pIC_{50} : 3.51



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 35



(a) K_D: 159 μM



(b) pIC_{50} : 4.46



(c) 2D representation



(d) 3D representation

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 36



(a) K_D: 30 μM



(b) pIC_{50} : 5.53



(c) 2D representation



(d) 3D representation

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 37



(a) K_D: 70 μM



(b) pIC_{50} : 4.32

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 38



(a) K_D: 70 μM



(b) pIC_{50} : 3.94



(c) 2D representation



(d) 3D representation

(A) Biophysical and (B) biochemical analysis of the interaction of OXA-48 with compound 39



(a) K_D: 70 μM (b) pIC_{50} : 3.99

(A) Biophysical, (B) biochemical and (C-D) structural analysis of the interaction of OXA-48 with compound 40



(a) K_D: 60 μM (b) pIC_{50} : 5.54



(c) 2D representation



(d) 3D representation

4 Data collection and processing statistics for X-ray crystallographic analysis

Compound – PDB-ID	Resolution range	Space group	Unit cell	Total reflections	Multiplicity	Completeness (%)	Mean I/sigma(I)	Wilson B-factor	R_{meas}	$CC_{1/2}$	R_{work}	R_{free}	RMS (bonds)	RMS (angles)	Ramachandran			Rotamer outliers	Ligand occupancy	Average B-factor			
															Favored	Allowed	Outliers			Overall	Enzyme	ligands	solvent
3a 5QA4	43.56 - 1.95 (2.02 - 1.95)	$P2_12_12_1$	89.10 108.94 124.91 90 90 90	405276 (41707)	4.60 (4.70)	99.57 (99.76)	8.72 (2.16)	19	0.14 (0.73)	1.00 (0.83)	0.17 (0.25)	0.20 (0.27)	0.007	0.8	97.9	2.1	0.0	0.0	0.88	25	23	37	38
3b 5QA5	43.62 - 1.95 (2.02 - 1.95)	$P2_12_12_1$	89.34 109.06 124.91 90 90 90	414161 (39847)	4.60 (4.50)	99.67 (99.80)	7.57 (1.93)	22	0.14 (0.84)	1.00 (0.80)	0.16 (0.23)	0.19 (0.27)	0.011	1.0	98.0	2.0	0.0	0.1	0.86	28	26	51	39
4a 5QA6	41.92 - 1.95 (2.02 - 1.95)	$P2_12_12_1$	89.01 108.99 124.79 90 90 90	421217 (40332)	4.70 (4.60)	99.60 (99.74)	9.12 (2.15)	19	0.14 (0.74)	1.00 (0.83)	0.17 (0.25)	0.20 (0.26)	0.007	0.8	98.1	1.9	0.0	0.0	0.86	25	23	45	37
4b 5QA7	41.86 - 1.82 (1.89 - 1.82)	$P2_12_12_1$	88.86 108.51 124.85 90 90 90	904398 (92981)	8.30 (8.70)	99.79 (99.81)	10.03 (2.07)	20	0.14 (1.04)	1.00 (0.79)	0.16 (0.25)	0.19 (0.29)	0.005	0.7	98.2	1.8	0.0	0.0	0.50	25	22	36	39
4c 5QA8	45.72 - 2.50 (2.59 - 2.50)	$P2_12_12_1$	125.01 88.34 106.88 90 90 90	190500 (17766)	4.80 (4.50)	95.63 (96.27)	7.96 (2.05)	43	0.12 (0.80)	1.00 (0.84)	0.21 (0.30)	0.26 (0.33)	0.003	0.6	97.7	2.2	0.1	0.9	0.87	54	54	73	46
5 5QA9	43.38 - 1.90 (1.97 - 1.90)	$P2_12_12_1$	88.98 108.45 124.14 90 90 90	413106 (41687)	4.40 (4.50)	98.90 (98.63)	8.63 (2.20)	18	0.15 (0.86)	1.00 (0.85)	0.19 (0.30)	0.23 (0.33)	0.003	0.6	97.7	2.3	0.0	0.2	1.00	27	26	28	36

6a 5QAA	43.66 - 1.95 (2.02 - 1.95)	$P2_12_12_1$	90.28 108.94 124.11 90 90 90	400305 (40597)	4.50 (4.60)	99.05 (98.65)	10.13 (2.32)	19	0.13 (0.73)	1.00 (0.89)	0.17 (0.26)	0.21 (0.30)	0.005	0.7	97.9	2.1	0.0	0.0	0.87	27	25	51	35
6b 5QAB	43.13 - 2.15 (2.23 - 2.15)	$P2_12_12_1$	88.51 107.48 125.34 90 90 90	485649 (49144)	7.40 (7.60)	99.71 (99.60)	10.66 (2.02)	38	0.11 (1.01)	1.00 (0.89)	0.19 (0.27)	0.22 (0.30)	0.003	0.6	98.2	1.7	0.1	0.1	0.95	49	49	79	48
6c 5QAC	49.10 - 2.00 (2.07 - 2.00)	$P2_12_12_1$	88.16 106.81 124.91 90 90 90	372992 (38213)	4.70 (4.80)	99.51 (99.65)	10.73 (2.28)	23	0.12 (0.72)	1.00 (0.82)	0.17 (0.25)	0.22 (0.31)	0.004	0.7	98.1	1.9	0.0	0.0	1.00	29	28	38	38
8a 5QAD	41.88 - 1.75 (1.81 - 1.75)	$P2_12_12_1$	88.92 108.89 124.89 90 90 90	693504 (70114)	5.70 (5.80)	99.81 (99.82)	10.53 (2.16)	18	0.11 (0.83)	1.00 (0.81)	0.16 (0.25)	0.18 (0.26)	0.003	0.6	98.0	2.0	0.0	0.0	0.85	24	21	37	37
8b 5QAE	46.81 - 2.10 (2.17 - 2.10)	$P2_12_12_1$	90.30 109.46 125.19 90 90 90	351403 (36305)	4.80 (5.00)	99.47 (99.75)	7.48 (2.03)	23	0.18 (0.85)	0.99 (0.76)	0.19 (0.27)	0.24 (0.33)	0.004	0.7	98.2	1.7	0.1	0.4	0.50	33	33	34	38
8c 5QAF	45.80 - 2.15 (2.23 - 2.15)	$P2_12_12_1$	88.41 107.09 124.88 90 90 90	475308 (48176)	7.30 (7.50)	99.56 (99.24)	9.41 (1.93)	34	0.14 (1.19)	1.00 (0.86)	0.19 (0.28)	0.23 (0.30)	0.003	0.6	98.7	1.3	0.0	0.0	0.87	43	42	68	46
9a 5QAG	24.96 - 2.30 (2.38 - 2.30)	$P2_12_12_1$	90.58 108.93 125 90 90 90	609069 (61717)	11.00 (11.30)	99.03 (99.05)	12.44 (3.68)	23	0.17 (0.78)	1.00 (0.98)	0.21 (0.26)	0.25 (0.32)	0.003	0.6	97.8	2.2	0.0	0.1	0.60	31	31	28	34
9b 5QAH	43.63 - 1.95 (2.02 - 1.95)	$P2_12_12_1$	89.91 108.89 124.81 90 90 90	399826 (40881)	4.50 (4.60)	99.51 (99.49)	11.23 (2.34)	20	0.11 (0.68)	1.00 (0.86)	0.17 (0.25)	0.20 (0.25)	0.004	0.6	98.1	1.9	0.0	0.0	0.85	27	24	49	40

11b 5QAL	45.68 - 1.95 (2.02 - 1.95)	$P2_12_12_1$	85.02 104.04 126.85 90 90 90	385310 (39564)	4.70 (4.90)	99.33 (99.77)	7.67 (2.10)	20	0.17 (0.86)	0.99 (0.73)	0.17 (0.23)	0.19 (0.27)	0.008	0.9	98.2	1.8	0.0	0.2	0.80	23	22	24	35
12a 5QAI	43.50 - 1.90 (1.97 - 1.90)	$P2_12_12_1$	89.25 108.77 124.26 90 90 90	825059 (83113)	8.60 (8.90)	99.67 (99.54)	9.37 (2.16)	21	0.17 (0.97)	1.00 (0.84)	0.16 (0.25)	0.20 (0.26)	0.008	0.8	98.3	1.7	0.0	0.1	0.85	27	25	37	38
13 5QAJ	29.32 - 2.00 (2.07 - 2.00)	$P2_12_12_1$	88.52 107.60 124.44 90 90 90	315723 (32023)	4.00 (4.00)	97.67 (99.29)	8.55 (2.14)	28	0.10 (0.62)	1.00 (0.87)	0.17 (0.28)	0.21 (0.31)	0.006	0.7	98.0	2.0	0.0	0.0	0.65	37	35	58	46
14 5QAK	43.28 - 1.90 (1.97 - 1.90)	$P2_12_12_1$	88.94 107.94 124.95 90 90 90	841589 (85712)	8.80 (9.10)	99.78 (99.78)	12.07 (2.40)	28	0.10 (0.89)	1.00 (0.90)	0.16 (0.25)	0.19 (0.28)	0.005	0.7	97.9	2.1	0.0	0.1	0.50	38	37	55	48
17 5QAM	43.74 - 1.87 (1.94 - 1.87)	$P2_12_12_1$	90.73 109.05 124.08 90 90 90	681035 (67846)	6.70 (6.80)	99.52 (99.39)	13.82 (2.37)	19	0.12 (0.94)	1.00 (0.90)	0.18 (0.30)	0.21 (0.32)	0.005	0.7	97.9	2.1	0.0	0.0	0.80	29	28	56	36
19a 5QAN	43.34 - 2.30 (2.38 - 2.30)	$P2_1$	44.94 125.24 107.70 90 98.42 90	104987 (9928)	2.20 (2.00)	93.28 (93.05)	7.54 (2.10)	37	0.09 (0.55)	1.00 (0.75)	0.19 (0.28)	0.23 (0.34)	0.002	0.5	98.1	1.9	0.0	0.1	0.48	43	43	37	42
19b 5QAO	62.66 - 2.00 (2.07 - 2.00)	$P2_12_12_1$	88.77 107.28 125.31 90 90 90	336824 (34116)	4.30 (4.30)	96.78 (98.70)	3.80 (1.64)	31	0.17 (0.67)	0.94 (0.91)	0.18 (0.26)	0.21 (0.31)	0.003	0.5	98.3	1.7	0.0	0.0	0.50	40	39	67	47
21a 5QAP	43.43 - 1.79 (1.85 - 1.79)	$P2_12_12_1$	88.77 108.63 124.63 90 90 90	434263 (41077)	3.80 (3.70)	99.17 (98.19)	7.95 (1.72)	19	0.12 (0.87)	1.00 (0.69)	0.17 (0.30)	0.20 (0.33)	0.007	0.8	98.1	1.9	0.0	0.0	0.38	24	22	30	36

21b 5QAQ	43.46 - 2.40 (2.49 - 2.40)	$P2_12_12_1$	89.41 108.44 124.71 90 90 90	348854 (34137)	7.30 (7.20)	99.68 (99.54)	15.20 (2.56)	39	0.10 (0.77)	1.00 (0.93)	0.19 (0.24)	0.23 (0.30)	0.003	0.6	98.2	1.8	0.0	0.1	0.63	47	47	49	46
23a 5QAR	49.54 - 2.10 (2.17 - 2.10)	$P2_12_12_1$	89.82 108.08 124.06 90 90 90	284938 (27813)	4.10 (4.00)	96.60 (98.85)	8.79 (2.41)	33	0.09 (0.53)	1.00 (0.91)	0.22 (0.30)	0.25 (0.31)	0.003	0.5	97.7	2.3	0.0	0.1	0.92	41	41	61	42
23b 5QAS	46.16 - 1.90 (1.97 - 1.90)	$P2_12_12_1$	88.78 108.08 124.38 90 90 90	564220 (53284)	6.00 (5.80)	99.10 (97.28)	7.70 (2.16)	24	0.14 (0.59)	0.99 (0.94)	0.19 (0.26)	0.23 (0.31)	0.004	0.7	98.1	1.9	0.0	0.2	0.87	32	30	59	38
24 5QAT	54 - 1.90 (1.97 - 1.90)	$P2_1$	45.14 125.26 107.81 90 98.54 90	383408 (38865)	4.10 (4.20)	99.19 (98.96)	6.74 (2.02)	25	0.12 (0.66)	0.96 (0.83)	0.17 (0.22)	0.20 (0.26)	0.005	0.7	98.2	1.8	0.0	0.1	0.50	33	32	41	43
26a 5QAU	40.90 - 1.75 (1.81 - 1.75)	$P2_12_12_1$	89.69 108.73 124.16 90 90 90	503198 (46442)	4.20 (3.90)	97.52 (97.70)	10.15 (1.60)	23	0.08 (0.89)	1.00 (0.78)	0.18 (0.32)	0.21 (0.36)	0.007	0.9	98.0	2.0	0.0	0.1	0.49	32	31	52	41
26b 5QAV	40.89 - 1.72 (1.78 - 1.72)	$P2_12_12_1$	90.07 108.42 124.56 90 90 90	550943 (50045)	4.30 (4.10)	98.31 (96.33)	11.27 (1.80)	24	0.07 (0.77)	1.00 (0.82)	0.18 (0.32)	0.21 (0.35)	0.005	0.7	97.9	2.1	0.0	0.2	0.78	33	32	52	44
27 5QAW	46.70 - 2.20 (2.28 - 2.20)	$P2_12_12_1$	90.50 109.05 124.64 90 90 90	278315 (26270)	4.40 (4.20)	99.36 (99.41)	9.13 (2.05)	28	0.12 (0.78)	1.00 (0.77)	0.20 (0.30)	0.24 (0.32)	0.003	0.6	97.5	2.5	0.0	0.0	0.50	38	38	28	39
28 5QAX	44.89 - 2.31 (2.40 - 2.31)	$P2_1$	64.20 107.85 85.15 90 103.82 90	221773 (18937)	4.60 (4.40)	97.87 (87.35)	9.47 (2.10)	32	0.13 (0.59)	0.99 (0.73)	0.17 (0.23)	0.21 (0.27)	0.003	0.6	98.2	1.7	0.1	0.0	1.00	42	42	60	39
32 5QAY	43.49 - 1.70 (1.76 - 1.70)	$P2_12_12_1$	89.72 108.40 124.87 90 90 90	720601 (74789)	5.40 (5.60)	99.08 (99.71)	7.70 (2.00)	23	0.12 (0.59)	0.99 (0.93)	0.19 (0.31)	0.24 (0.34)	0.01	1.0	98.3	1.7	0.0	0.0	0.50	35	34	44	43

34 5QAZ	24.17 - 2.20 (2.28 - 2.20)	$P2_12_12_1$	89.00 108.50 125.12 90 90 90	647016 (61070)	10.40 (10.00)	96.30 (97.46)	10.97 (4.40)	22	0.16 (0.45)	1.00 (0.96)	0.21 (0.25)	0.27 (0.31)	0.005	0.7	98.7	1.3	0.0	0.0	0.59	29	29	30	35
35 5QB0	41.23 - 1.95 (2.02 - 1.95)	$P2_12_12_1$	89.21 107.97 124.99 90 90 90	387835 (36662)	4.40 (4.20)	99.48 (99.75)	7.66 (1.85)	21	0.15 (0.79)	1.00 (0.80)	0.17 (0.26)	0.21 (0.32)	0.007	0.8	98.1	1.9	0.0	0.1	0.67	27	25	44	38
36 5QB1	40.87 - 1.80 (1.86 - 1.80)	$P2_1$	44.96 125.21 107.38 90 97.82 90	278122 (29312)	2.70 (2.80)	94.00 (97.89)	9.19 (2.04)	26	0.08 (0.56)	0.99 (0.80)	0.16 (0.25)	0.20 (0.28)	0.007	0.8	98.2	1.8	0.0	0.4	0.73	36	35	47	43
38 5QB2	42.32 - 1.75 (1.81 - 1.75)	$P2_12_12_1$	90.03 108.69 124.09 90 90 90	908717 (93019)	7.40 (7.60)	99.74 (99.76)	14.79 (2.04)	20	0.09 (1.08)	1.00 (0.89)	0.17 (0.28)	0.21 (0.30)	0.005	0.8	98.0	1.9	0.1	0.2	0.55	30	28	37	41
40 5QB3	43.42 - 2.00 (2.07 - 2.00)	$P2_12_12_1$	89.49 108.30 124.57 90 90 90	594076 (57425)	7.20 (7.10)	99.43 (99.56)	9.89 (2.01)	25	0.15 (0.97)	1.00 (0.92)	0.21 (0.30)	0.24 (0.29)	0.003	0.5	97.7	2.3	0.0	0.0	0.67	35	34	39	40
Imipenem 5QB4	43.13 - 1.95 (2.02 - 1.95)	$P2_12_12_1$	88.79 107.5 124.33 90 90 90	392383 (36743)	4.7 (4.5)	95.55 (93.89)	9.13 (2.24)	26	0.11 (0.71)	1.00 (0.90)	0.18 (0.27)	0.22 (0.29)	0.07	0.8	98.1	1.9	0.0	0.1	1.00	34	33	59	43
															Favored (%)	Allowed (%)	Outliers (%)			Overall	Enzyme	ligands	solvent
Compound	Resolution range	Space group	Unit cell	Total reflections	Multiplicity	Completeness (%)	Mean I/sigma(I)	Wilson B-factor	R_{meas}	$CC_{1/2}$	R_{work}	R_{free}	RMS (bonds)	RMS (angles)	Ramachandran			Rotamer outliers	Ligand occupancy	Average B-factor			

5 Inhibition and binding data for compounds 3-40 with standard errors

SMILES	Compound	pIC50	SE pIC50	Hill coefficient	K_d (µM)	SE K_d (µM)
[O-]C(C1=CC(C2=CC=CC=C2C)=CC=C1)=O	3a	4.05	0.03	0.9	170	10
[O-]C(C1=CC(C2=CC=CC(C)=C2)=CC=C1)=O	3b	3.78	0.01	1.1	300	10
[O-]C(C1=CC(C2=CC=CC=C2O)=CC=C1)=O	4a	4.30	0.01	1.1	175	5
[O-]C(C1=CC(C2=CC(O)=CC=C2)=CC=C1)=O	4b	3.97	0.03	0.9	110	30
OC(C=C1)=CC=C1C2=CC=CC(C([O-])=O)=C2	4c	3.33	0.02	1.8	170	60
[O-]C(C1=CC=CC(C2=CC=CC(CO)=C2)=C1)=O	5	3.04	0.09	1.5	230	20
[O-]C(C1=CC(C2=CC=CC=C2OC)=CC=C1)=O	6a	3.60	0.01	1.8	123	5
O=C([O-])c1cc(ccc1)-c2cc(OC)ccc2	6b	3.44	0.01	1.9	226	7
[O-]C(C1=CC(C2=CC=C(OC)C=C2)=CC=C1)=O	6c	3.82	0.02	1.1	250	30
O=C([O-])c1cc(ccc1)-c2ccc(cc2)SC	7	3.40	0.02	2.0	1000	100
[O-]C(C1=CC(C2=C(F)C=CC=C2)=CC=C1)=O	8a	3.89	0.02	1.1	170	30
[O-]C(C1=CC(C2=CC=CC(F)=C2)=CC=C1)=O	8b	3.88	0.02	0.9	240	30
O=C([O-])c1cc(ccc1)-c2ccc(F)cc2	8c	3.45	0.02	1.8	312	7
O=C(OC)C1=CC=CC=C1C2=CC(C([O-])=O)=CC=C2	9a	3.69	0.02	1.6	200	100
O=C([O-])C1=CC(C2=CC(C(OC)=O)=CC=C2)=CC=C1	9b	3.59	0.04	1.6	144	6
CC(=O)c1ccc(cc1)-c2cccc(c2)C(=O)[O-]	10	3.42	0.01	1.8	280	30
OC(C1=CC(C2=CC=CC(C(N)=O)=C2)=CC=C1)=O	11a	3.58	0.02	1.9	220	20
[O-]C(C1=CC(C2=CC(S(C)(=O)=O)=CC=C2)=CC=C1)=O	12a	3.91	0.02	1.0	150	40
O=C([O-])c1cc(ccc1)-c2ccc(cc2)S(=O)(=O)C	12b	3.42	0.02	1.6	361	5
NC1=CC=C(C2=CC(C([O-])=O)=CC=C2)C=C1	13	3.48	0.02	1.8	330	30
CN(C)C1=CC=CC(C2=CC(C([O-])=O)=CC=C2)=C1	14	3.41	0.03	1.5	220	60
NCC1=CC=CC(C2=CC=CC(C([O-])=O)=C2)=C1	15a	3.22	0.03	1.8	800	100
NCC(C=C1)=CC=C1C2=CC=CC(C(O)=O)=C2	15b	2.85	0.06	1.1	550	50
NCCC1=CC=CC(C2=CC=CC(C(O)=O)=C2)=C1	16a	3.95	0.05	1.1	300	200
NCCC(C=C1)=CC=C1C2=CC=CC(C(O)=O)=C2	16b	2.98	0.06	1.2	970	80
[O-]C(C1=CC(C2=CC=C(C(N)=O)C=C2)=CC=C1)=O	11b	3.73	0.01	1.0	200	40
CS(NC(C=C1)=CC=C1C2=CC=CC(C(O)=O)=C2)(=O)=O	17	3.43	0.02	1.7	100	40
O=S(NC1=CC=C(C2=CC=CC(C([O-])=O)=C2)C=C1)(C3=CC=CC=C3)=O	18	4.25	0.04	1.6	210	40

CS(NCC1=CC=CC(C2=CC=CC(C([O-])=O)=C2)=C1)(=O)=O	**19a**	3.96	0.03	1.0	110	30
O=C([O-])c1cc(ccc1)-c(cc2)ccc2CNS(=O)(=O)C	**19b**	3.35	0.04	1.4	240	80
CS(=O)(NCCC1=CC=CC(C2=CC=CC(C(O)=O)=C2)=C1)=O	**20a**	3.43	0.02	1.6	200	100
OC(C1=CC(C2=CC(NC(C)=O)=CC=C2)=CC=C1)=O	**21a**	4.45	0.03	1.0	100	20
CC(=O)Nc1ccc(cc1)-c2cccc(c2)C(=O)O	**21b**	3.35	0.02	1.6	290	8
CC(OCC1=CC=CC(C2=CC=CC(C([O-])=O)=C2)=C1)=O	**22**	3.89	0.05	0.9	130	20
CC(NCCC1=CC=CC(C2=CC=CC(C([O-])=O)=C2)=C1)=O	**23a**	3.64	0.06	1.1	170	90
CC(NCCC(C=C1)=CC=C1C2=CC=CC(C([O-])=O)=C2)=O	**23b**	3.28	0.02	1.4	190	80
CC(=O)OCc1cc(ccc1)-c(ccc2)cc2C(=O)[O-]	**24**	3.60	0.04	1.6	181	7
OC(C1=CC(C2=CN=C(N3C=CN=C3)N=C2)=CC=C1)=O	**25**	2.89	0.04	1.5	1160	30
[O-]C(C1=CC(C2=CC=CC(C3=NN=NN3)=C2)=CC=C1)=O	**26a**	4.24	0.05	0.9	70	20
[O-]C(C1=CC(C2=CC=C(C3=NN=NN3)C=C2)=CC=C1)=O	**26b**	4.48	0.03	1.1	70	30
O=C(C1=CC=CC(C2=CC3=CC=CC=C3C=C2)=C1)[O-]	**27**	3.98	0.03	1.2	400	100
O=C(C1=CC=CC(C2=CC=C(N=CC=C3)C3=C2)=C1)[O-]	**28**	3.61	0.02	1.8	160	30
NC(C=C1)=NC=C1C2=CC=CC(C(O)=O)=C2	**29**	3.76	0.08	0.9	130	30
O=C(C1=CC(C2=CN=CN=C2)=CC=C1)O	**30**	3.10	0.04	1.1	900	60
NC(N=C1C)=NC=C1C2=CC=CC(C(O)=O)=C2	**31**	3.46	0.02	1.4	113	8
CN1C(C2=CC=CC(C([O-1])=O)=C2)=CC=C1	**32**	3.30	0.06	1.0	590	70
O=C(C1=CC=CC(C2=CN=CS2)=C1)O	**33**	3.09	0.04	1.1	900	30
O=C(C1=CC=CC(C2=CC=C(NC=C3)C3=C2)=C1)[O-]	**34**	3.51	0.03	1.5	400	100
[O-]C(C1=CC(C2=CC=CC=N2)=CC=C1)=O	**35**	4.46	0.02	0.8	159	9
[O-]C(C1=CC(C2=CC=CC(NC(C)=O)=C2)=CC(C3=CC=CC(NC(C)=O)=C3)=C1)=O	**36**	5.53	0.04	1.0	20	4
[O-]C(C1=CC(C2=CC=C(NC(C)=O)C=C2)=CC(C3=CC=C(NC(C)=O)C=C3)=C1)=O	**37**	4.32	0.02	1.0	70	30
c1ccnc(c12)ccc(c2)-c(cc3C([O-])=O)cc(c3)-c(cc4)cc(c45)nccc5	**38**	3.94	0.04	1.0	70	50
O=C(O)C1=CC(C2=CC=NC=C2)=CC(C3=CC=CC(NC(C)=O)=C3)=C1	**39**	3.99	0.06	1.4	70	20
c1ccc(NC(=O)C)cc1-c(c2)cc(cc2C([O-])=O)-c(c3)ccc(c34)cccn4	**40**	5.54	0.03	1.0	60	10

General procedure for synthesis of compound 19 to 22 (Section 6.3.1)

Synthesis of compound 19

Solution of ethyl-2-(diethoxphosphonryl) acetate **5** (13.30 mmol, 3.00 g, 1 equiv) in DMF (0.3 mL/mmol of **5**) was stirred at 0°C. Potassium tert-butoxide (9.33 mmol, 1.11 g, 0.7 equiv) was added and solution was stirred at 0°C for 20 min. Propargyl bromide (9.33 mmol, 1.05 g, 0.7 equiv) was added dropwise to the reaction mixture, and ice bath was removed to allow the reaction mixture to reach room temperature. The reaction mixture was then heated at 60°C for 28 h. The reaction mixture was acidified with 10% citric acid. Lithium chloride solution (5%) was added to the mixture, and the product was extracted with diethyl ether (3 × 60 mL), washed with water (3 × 60 mL), brine (3 × 60 mL) and dried over Na_2SO_4. The product **19** was purified by flash chromatography using ethyl acetate and hexane (60:40) as eluent, to afford a yellow oil (mixture of mono and dialkylated products), (5.32 mmol, 2.45 g, 57%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 4.53 – 4.05 (m, 6H), 3.27 – 3.06 (m, 1H), 3.02 – 2.94 (m, 1H), 2.90 – 2.59 (m, 1H), 2.30 – 1.94 (m, 1H), 1.61 – 1.20 (m, 9H).^{13}C NMR (101 MHz, $CDCl_3$) δ 167.8 (d, *J* = 4.9 Hz), 80.6 (d, *J* = 20.6 Hz), 79.2 (d, *J* = 12.1 Hz), 71.3 (d, *J* = 1.5 Hz), 70.1 (d, *J* = 2.0 Hz), 63.4 (d, *J* = 7.0 Hz), 63.2 (d, *J* = 6.4 Hz), 62.9 (d, *J* = 6.8 Hz), 62.2, 61.8, 51.5, 50.1, 45.9, 44.6, 21.8 (d, *J* = 2.4 Hz), 17.2 (d, *J* = 3.1 Hz), 16.44 (m), 14.1 (d, *J* = 13.5 Hz). HRMS (ESI): Calcd. For $C_{11}H_{20}O_5P$ $[M+H]^+$ 263.1048; found: 263.1043. HRMS (ESI): Calcd. For $C_{14}H_{22}O_5P$ $[M+H]^+$ 301.1205; found: 301.1199.

Synthesis of compound 20

$LiBH_4$ (10.38 mmol, 226 mg, 2.5 equiv) was dissolved in THF (2 mL/mmol of **19**) at 0°C, and slowly added to the alkylated phosphonoacetate **19**, (4.15 mmol, 1.03 g, 1 equiv) at 0°C. The reaction mixture was stirred at room temperature for 30 min, and then irradiated at 80°C for 10 minutes under microwave irradiation. When the mixture reached room temperature, methanol was slowly added, while stirring, until access of $LiBH_4$ was neutralized. The reaction mixture was then acidified with 10% citric acid and the product was extracted with diethyl ether, washed with brine solution and dried over Na_2SO_4. The solvent was removed under vacuum. The product **20** (1.58 mmol, 346 mg, 38%) was purified as a colorless oil (mixture of mono and dialkylated products), on flash chromatography with ethyl acetate/acetone 90:10 as eluent. ^{1}H NMR (400 MHz, $CDCl_3$) δ 4.26 – 4.06 (m, 4H), 4.07 – 3.83 (m, 2H), 2.90 (t, *J* = 6.5 Hz, 1H), 2.66 – 2.41 (m, 2H), 2.26 – 2.10 (m, 1H), 1.39 – 1.29 (m, 6H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 80.7, 70.3 (d, *J* = 2.3 Hz), 62.2, 60.2 (d, *J* = 5.0 Hz), 39.2, 16.5, 16.4, 15.6 (d, *J* = 1.0 Hz). HRMS (ESI): Calcd. For $C_9H_{18}O_4P$ $[M+H]^+$ 221.0936; found: 221.0937. HRMS (ESI): Calcd. For $C_{12}H_{20}O_4P$ $[M+H]^+$ 259.1096; found: 259.1094.

Synthesis of compound 21

The compound **20**, (4.60 mmol, 1.01 g, 1 equiv) was dissolved in dichloromethane (10 mL/mmol of **20**). To the mixture was added trimethylamine (4.86 mmol, 492 mg, 1.05 equiv) and a catalytic amount of 4-dimethylaminopyridine (DMAP) (0.92 mmol, 112 mg, 20%). The reaction mixture was stirred for 5 minutes at room temperature. Methanesulfonylchloride (4.86 mmol, 557 mg, 1.05 equiv) was added to and the reaction mixture was stirred for overnight at room temperature. The crude was quenched with 50 mL aqueous NH_4Cl and extracted with diethyl ether (3 × 50 mL). The combined organic layers were dried over Na_2SO_4, filtered, and solvent was evaporated. The crude was dissolved in DMF (3 mL/mmol of crude). Potassium thioacetate (39.00 mmol, 4.45 g, 10 equiv) was dissolved in the reaction mixture and stirred overnight at room temperature. Solvent was removed under vacuum, and the brown suspension was quenched with 50 mL NH_4Cl, extracted with diethyl ether (2 × 100 mL) and washed with water (2 × 100 mL). Organic layers were dried over Na_2SO_4, filtered and solvent was evaporated. The product **21**, (1.66 mmol, 461 mg, 36%) was purified as an orange oil, by flash chromatography using ethyl acetate/acetone (95:05). ^{1}H NMR (400 MHz, $CDCl_3$) δ 4.25 – 4.03 (m, 4H), 3.43 (td, J = 13.5, 4.8 Hz, 1H), 3.22 – 3.08 (m, 1H), 2.78 – 2.65 (m, 1H), 2.59 (m, 1H), 2.33 (s, 3H), 2.28 – 2.02 (m, 2H), 1.34 (m, 6H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 195.0, 80.3 (d, J = 10.1 Hz), 70.9, 62.2, 42.0, 36.3, 30.5, 27.6 (d, J = 1.6 Hz), 21.6 (d, J = 1.7 Hz), 16.4. HRMS (ESI): Calcd. For $C_{11}H_{20}O_4PS$ $[M+H]^+$ 279.0817; found: 279.0814.

Synthesis of compound 22

Copper sulfate pentahydrate (0.18 mmol, 45 mg, 1 equiv) and sodium ascorbate (0.36 mmol, 71 mg, 2 equiv) were dissolved in 0.5 mL of water and added to a solution of **21** (0.18 mmol, 50 mg, 1 equiv) in 0.5 mL of *t*BuOH. To the reaction mixture, benzyl azide (0.27 mmol, 35 mg, 1.5 equiv) was added and the mixture was stirred for 48 h at room temperature. EDTA (0.18 mmol, 52 mg, 1 equiv) was added and mixture was stirred for 1 h. After 1 h the reaction mixture was diluted with water and 1M NaOH solution was added to adjust the pH to 10. The reaction mixture was then extracted with EtOAc (20 × 2 mL). Combined organic extract were dried over over Na_2SO_4, filtered and solvent was evaporated. The product was purified by repeated column chromatography to yield compound **22** (0.018 mmol, 7 mg, 10%). ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.51 – 7.10 (m, 6H), 5.49 (s, 2H), 4.14 (m, 1H), 4.07 – 3.92 (m, 4H), 3.33 (m, 1H), 3.15 (m, 1H), 2.97 (m, 2H), 2.28 (s, 3H), 1.24 (m, 6H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 195.2, 144.8, 134.8, 129.0, 128.6, 128.0, 122.4, 63.5 – 60.0 (m), 54.1, 37.3, 35.9, 30.5, 27.9, 24.2, 16.3 (d, *J* = 5.9 Hz). HRMS (ESI): Calcd. For $C_{18}H_{27}O_4N_3PS$ $[M+H]^+$ 412.1452; found: 412.1454.

General procedure for synthesis of compound 26 to 28 (Section 6.3.2)

General procedure for the synthesis of triazole

Synthesis of compound 26:

4-Iodo-N-((5-((4-(methylthio)phenylamino)methyl)-1H-1,2,3-triazol-4-yl)methyl)-benzenesulfonamide

N-(4-azidobut-2-ynyl)-4-iodobenzenesulfonamide **25** (see synthesis of **4e** in Paper 2) (100 mg, 0.26 mmol, 1.0 equiv) in CH_2Cl_2 (5 mL) and 4-(methylthio)aniline (108.0 mg, 0.78 mmol, 3 equiv) gave **26** (115 mg, 86%) as dark brown oil. ^{1}H NMR (400 MHz, CD_3OD): δ 7.82 – 7.75 (m, 2H), 7.49 – 7.43 (m, 2H), 7.17 – 7.09 (m, 2H), 6.62 – 6.53 (m, 2H), 4.29 (s, 2H), 4.17 (s, 2H), 2.33 (s, 3H). ^{13}C NMR (101 MHz, CD_3OD): δ 148.4, 141.4, 139.7, 139.6, 132.4, 129.7 129.6, 126.3, 115.1, 100.8, 39.4, 38.5, 19.2. HRMS (ESI): Calcd. for $C_{17}H_{19}O_2N_5S_2I$ $[M+H]^+$ 516.0012; found 516.0019.

Synthesis of compound 27

N-((5-((2-cyclohexylethylamino)methyl)-1H-1,2,3-triazol-4-yl)methyl)-4-iodobenzenesulfonamide

N-(4-azidobut-2-ynyl)-4-iodobenzenesulfonamide **25** (see synthesis of **4e** in Paper 2) (100 mg, 0.26 mmol, 1.0 equiv), 2-cyclohexylethanamine (110.0 mg, 0.78 mmol, 3 equiv) in CH_2Cl_2 (5 mL) gave **27** (80 mg, 61%) as colorless oil. ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.80 (t, J = 7.2 Hz, 2H), 7.56 (d, J = 8.0 Hz, 2H), 4.17 (s, 2H), 3.99 (s, 2H), 2.85 (t, J = 8.0 Hz, 2H), 1.62 – 1.67 (m, 5H), 1.50-1.51 (m, 1H), 1.25 – 1.07 (m, 5H), 0.86-0.92 (m, 3H). ^{13}C NMR (101 MHz, $CDCl_3$): δ 139.8 (triazole, determined from HMBC), 138.4, 138.1, 137.3 (triazole, very weak, determined from HMBC), 128.3, 99.7, 46.4, 42.0, 37.6, 35.3, 34.7, 32.8, 26.2, 25.9. HRMS (ESI): Calcd. for $C_{18}H_{25}O_2N_5IS$ $[M-H]^-$ 502.0771; found 502.0768.

Synthesis of compound 28

N-((5-((3-cyclohexylpropoxy)methyl)-1H-1,2,3-triazol-4-yl)methyl)-4-iodobenzenesulfonamide

N-(4-azidobut-2-ynyl)-4-iodobenzenesulfonamide **25** (see synthesis of **4e** in Paper 2) (100 mg, 0.26 mmol, 1.0 equiv), 3-cyclohexylpropan-1-ol (184.0 mg, 1.3 mmol, 5 equiv) in CH_2Cl_2 (5 mL) gave **28** (88 mg, 65%) as colorless oil. ^{1}H NMR (400 MHz, DMSO-d_6): δ 8.15 (t, J = 5.8 Hz, 1H), 7.95 (d, J = 8.1 Hz, 2H), 7.52 (d, J = 1.5 Hz, 2H), 4.41 (s, 2H), 4.04 (s, 2H), 3.29 (t, J = 6.6 Hz, 2H), 1.72 – 1.54 (m, 4H), 1.49 – 1.35 (m, 2H), 1.26 – 1.01 (m, 4H), 0.89 – 0.65 (m, 2H). ^{13}C NMR (101 MHz, DMSO-d_6): δ 142.5, 141.7, 140.4, 140.3, 138.4, 138.3, 128.7, 100.9, 70.5, 62.9, 37.4, 37.3, 33.8, 33.3, 26.9, 26.7, 26.3. HRMS (ESI): Calcd. for $C_{19}H_{26}O_3N_4IS$ $[M-H]^-$ 517.0770; found 517.0765.

^{1}H and ^{13}C NMR spectra

Compound 19

1HNMR of 19



13C-NMR of 19



Compound 20

1H-NMR of 20



13C-NMR 20



Compound 21


1HNMR of 21
OEt
OEt
P
O
CH
O
S
CH3
21
4.25
0.87
1.00
1.36
1.40
2.75
2.10
6.00
f1 (ppm)


13CNMR of 21
195.98
80.33
80.23
70.91
62.27
62.25
62.20
62.18
42.04
36.27
30.52
27.61
27.60
21.64
21.63
16.45
16.43
16.39
16.37
OEt
OEt
P
O
CH
O
S
CH3
21
f1 (ppm)

Compound 22


1HNMR of 22
7.41 7.37 7.37 7.36 7.35 7.34 7.34 7.33 7.28 7.28 7.26 cdcl3 7.26
5.49 4.16 4.16 4.15 4.14 4.14 4.13 4.12 4.11 4.06 4.05 4.05 4.04 4.04 4.03 4.02 4.01 4.00 4.00 4.00 3.99 3.99 3.98 3.97 3.96 3.96 3.96
3.33 3.33 3.32 3.30 3.28 3.16 3.15 3.14 3.11 3.10 3.03 3.02 3.01 3.00 2.99 2.99 2.97 2.96 2.96 2.95 2.94 2.93 2.34 2.28 1.43 1.42 1.27 1.25 1.24 1.22 1.20
OEt
O
P
OEt
SAc
N
N
N
Ph
22
5.92
2.08
1.32
4.00
0.98
1.34
2.10
2.98
6.02
f1 (ppm)


ABLE-1658 in CDCl3 1H NMR
195.23
144.82
134.79
129.03
128.64
128.03
122.39
77.32 cdcl3
77.00 cdcl3
76.69 cdcl3
62.05
61.97
61.90
54.08
37.28
35.90
30.50
27.90
24.18
16.37
16.31
OEt
O
P
OEt
SAc
N
N
N
Ph
22
f1 (ppm)

^{1}H and ^{13}C NMR spectra
Compound 26

ABSA-3-55



ABSA-3-55



Compound 27


7.82
7.80
7.78
7.57
7.55
7.26 CDCl3
4.17
3.99
2.87
2.85
2.83
1.67
1.65
1.65
1.64
1.62
1.51
1.50
1.25
1.19
1.16
1.14
1.13
1.10
0.92
0.90
0.87
0.86


2.33
2.51
2.38
2.00
1.84
5.53
1.38
5.48
2.31
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
f1 (ppm)


139.52
139.43
138.08
128.27
99.67
77.16 CDCl3
46.43
42.01
37.55
35.31
34.71
32.85
26.15
25.90
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
f1 (ppm)

Compound 28


8.16
8.15
8.13
7.96
7.95
7.94
7.53
7.52
7.52
4.41
4.04
3.34 HDO
3.30
3.29
3.27
2.51 DMSO
2.50 DMSO
2.50 DMSO
2.50 DMSO
2.49 DMSO
1.66
1.65
1.64
1.64
1.62
1.62
1.61
1.61
1.45
1.43
1.41
1.18
1.15
1.13
1.11
1.10
1.09
1.08
0.82
0.82
0.80
I
O
S
O
HN
O
N
N
H
0.76
1.99
2.00
1.84
2.26
2.19
4.42
2.31
6.52
2.16
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
f1 (ppm)


142.07
141.23
139.53
137.95
128.29
128.27
100.43
70.06
62.43
40.15 DMSO
39.94 DMSO
39.73 DMSO
39.52 DMSO
39.31 DMSO
39.10 DMSO
38.89 DMSO
36.95
33.35
32.82
26.42
26.20
25.86
I
O
S
O
HN
O
N
N
H
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
f1 (ppm)